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ABSTRACT 
The distribution of Langerhans dendritic cells in tobacco smoke related human 
lung cancer, tobacco smoke induced Langerhans cells changes during cutaneous 
and pulmonary carcinogenesis in mice were investigated. While dendritic cells 
were rare in normal lung, their density was marked in bronchioalveolar, well and 
moderately differentiated squamous cell carcinomas. Small cell lung cancer and 
poorly differentiated squamous cell carcinoma showed the lowest density. High 
density of dendritic cells in lung tumours was associated with marked tumour 
infiltrating lymphocytes and favourable survival. 
Exposure of mice to tobacco smoke increased the density of zinc-iodide-osmium 
positive pulmonary Langerhans cells. Pulmonary Langerhans cell granulomatosis 
and a proliferative alveolar and bronchial epithelial tumour-like lesions were 
observed. The density of pulmonary Langerhans cells returned to that of the 
control level after ceasing exposure to tobacco smoke and the interstitial 
granulomatous lesions disappeared, but the bronchial epithelial metaplasia did not 
reverse. The ultrastructure of the zinc-iodide-osmium positive cells was similar to 
that of pulmonary Langerhans cells. 
Tobacco smoke condensate increased the density, changed the morphology and 
impaired the function of epidermal Langerhans cells. This was associated with skin 
tumour development. 
While examining human lung lesions S100 positive DC were observed migrating 
into tumours. So these cells and their relation to LDC were further examined in 
blood. Metrizamide enriched dendritic cells isolated from human blood, were S100 
positive, co-expressed CD45 and were non-phagocytic. Their diameter was larger 
than that of CD3 positive T lymphocytes and smaller than CD14 positive 
monocytes. The ultrastructural features were consistent with that of blood 
dendritic cells. Their number slightly decreased with age, equal numbers were 
observed in both sexes and formed 0.09 ± 0.07 cells x 10 9 per litre of blood. 
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PREFACE 
The family of Langerhans dendritic cells (LDC) includes epidermal LDC, 
indeterminate cells in the upper dermis of the skin, veiled cells in the 
afferent lymph, interdigitating DC (IDC) in lymph nodes and spleen, 
interstitial DC in various organs and their precursors in the blood. 
Antigen presentation, migratory function and T cell activation are the three 
major functions of LDC. As antigen presenting cells, LDC strongly express 
all the class-II MHC molecules, (both Ia in mouse and HLA-DP, DQ, DR in 
human). They can capture antigen from the epithelial surface and present it 
to T-lymphocytes in the regional lymph nodes. 
The anti-cancer activity of bone marrow derived S100 positive LDC has been 
investigated for adenocarcinoma of the lung, nasopharyngeal carcinomas, 
gastric carcinomas, papillary thyroid tumours, colorectal carcinomas, 
oesophageal squamous cell carcinomas, laryngeal carcinoma, prostatic 
carcinoma, cervical squamous cell carcinoma and transitional cell carcinoma 
of the urinary bladder. All reports demonstrated an increased survival for 
patients associated with high density of LDC in these tumours. Their role in 
tobacco smoke related lung cancer had not been investigated conclusively 
prior to this study. 
Tobacco smoke remains a major cause of lung tumours and chronic 
pulmonary diseases not only in Australia, but world wide. The annual costs 
of medical care for smoking related illness for the US and Canada population 
was more than US$ 501 billion. In West Australia, 13,944 deaths were a result 
of tobacco smoking between 1981-1990. 
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The role of LDC in tobacco smoke induced pulmonary lesions is not clearly 
understood. Though the effect of tobacco smoke derived carcinogens, 
benzo(a)pyrene and catechols on LDC have been investigated previously 
during cutaneous carcinogenesis, crude tobacco smoke was not used before 
to investigate its effect on pulmonary antigen presenting LDC and to 
examine the relationship between the tobacco smoke induced LDC changes 
and tobacco smoke induced pulmonary lesions. The role of pulmonary 
LDC in the development of tobacco smoke induced pulmonary lesions is 
not clearly understood. 
This thesis was designed to examine the role of Langerhans dendritic cells 
in tobacco smoke related human lung tumours. Antigen presenting S100+ 
Langerhans dendritic cells were examined in normal trachiobronchial 
epithelium, lung, normal bronchial lymph nodes, lung tumours and in 
lymph nodes regional to these tumours. Their density, morphology, contact 
with tumour cells and TIL and relationship to patient survival was 
investigated in all varieties of lung cancer. 
Crude tobacco smoke was used for the first time in this study to investigate 
its effect on murine pulmonary antigen presenting LDC and to examine the 
relationship between the tobacco smoke induced LDC changes and tobacco 
smoke induced pulmonary lesions. The density of zinc-iodide-osmium 
positive pulmonary Langerhans dendritic cells was assessed in mice after 
passive exposure to tobacco smoke. After ceasing exposure to tobacco smoke 
the density of pulmonary Langerhans cells and their relationship to the 
pathological changes observed at that stage was studied. 
The relationship between the tobacco smoke condensate induced LDC 
changes and TSC induced skin lesions was also examined. 
Langerhans Dendritic Cells, Cigarette Smoke and Lung Tumours 	Page 5  
Characterisation of S100+ cells in human blood in this study arose from 
observing S100+ cells in blood vessels while examining the S100+ LDC in 
human lung tumours (Zeid and Muller, 1993). Although these S100+ cells 
were small, they were observed to increase in size and in the number of 
dendrites extending from their cell body during their migration through 
blood vessel wall. It was proposed that these S100+ cells found in the blood 
vessels were the precursors of the S100+ LDC investigated in lung tumours. 
Metrizamide enriched dendritic cells (DC) were isolated from human blood 
and examined for their cytoplasmic S100 protein, and surface markers. 
These cells were assesed by image analysis, eyepiece micrometer and their 
ultrastructure examined and compared with that of T lymphocytes and 
monocytes. 
In summary the aims of this thesis were: 
1. To investigate LDC in tobacco smoke related human lung cancer. 
2. To study the effect of passive tobacco smoke inhalation on pulmonary 
LDC in mice. 
3. To examine the effect of crude tobacco smoke condensate on murine 
epidermal LDC during cutaneous carcinogenesis. 
4. To study S100 positive cells in the peripheral blood. 
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CHAPTER 1 
LITERATURE REVIEW 
LANGERHANS DENDRITIC CELLS, RESPIRATORY SYSTEM 
AND TOBACCO CARCINOGENESIS 
1. Langerhans Dendritic Cell 
1.1 Introduction 
Paul Langerhans was a second year medical student in Berlin, Germany 
in 1868 when he published his discovery of non-pigmentary dendritic 
cells in the skin. He discovered this cell using a new gold chloride stain 
investigated by his teacher Cohnheim to demonstrate the peripheral 
nerve endings in the epidermis of human skin (Ebling, 1980). 
Langerhans considered these dendritic cells in the epidermis to be 
peripheral nerve endings because they stained with gold chloride. 
Masson, (1947) proposed that the Dopa negative high level clear 
epidermal cells, described by Langerhans, were aged melanocytes in the 
process of exfoliation. Billingham, (1948) supported the theory of 
Masson. Ferreira-Marques, (1951) considered Langerhans dendritic cells 
(LDC) as part of cutaneous innervation. The Langerhans dendritic 
cell/melanocyte hypothesis remained a controversial issue until 1961, 
when Birbeck and co-workers reported the discovery of a unique 
organelle, the Birbeck granule (BG) in the cytoplasm of LDC which was 
not observed in melanocytes or keratinocytes (Birbeck et al., 1961). 
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1.2 Origin of Langerhans dendritic cell 
The bone marrow was first demonstrated in 1979 as the site of origin of 
epidermal LDC by Frelinger et al., (1979) and Katz et al., (1979). Using 
bone marrow transplantation following X-ray irradiation, the Ia positive 
LDC in the recipient skin were found to be derived from the bone 
marrow of donor mice. 
Tamaki et al., (1980) also transplanted bone marrow to chimaeric mice 
confirming the bone marrow origin of LDC, while Pelletier et al., (1984) 
and Volc-Platzer et al., (1984) were the first to demonstrate the bone 
marrow origin of LDC in humans. After bone marrow transplantation 
from a donor male to a female recipient they found that LDC in the skin 
of a female recipient contained a Y chromosome indicating that these 
cells could only have been derived from the transplanted marrow. 
While bone marrow has been confirmed as the origin of LDC, the 
progenitor cell has yet to be identified. Clark and Kamen, (1987) proposed 
three possibilities for the progenitor of LDC. Firstly, the stem cell which 
generates the lymphoid lineage, secondly the stem cell which 
differentiates into monocytes and thirdly the stem cell of LDC may be a 
completely separate lineage. 
Because of a similarity in surface markers many reports have suggested 
the monocyte as the progenitor of LDC. LDC and monocytes have 
receptors for C3 and the Fc portion of IgG, and both have class II major 
histocompatibility antigens (Rowden et al., 1977; Stingl et al., 1977; 
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Barfoot et al., 1989). Against the monocytic origin of LDC, the latter are 
S100, CD1a and HLA-DQ positive while monocytes are S100, CD1a and 
HLA-DQ negative (Furukawa et al., 1984). Furthermore, LDC lack non-
specific esterase, lysozyme and the YI/82A marker of monocytes-
macrophages (Reid et al., 1990). Whether monocytes and LDC arise from 
a common stem cell in the bone marrow awaits clarification (Jaffe, 1993). 
1.3 Identification of Langerhans dendritic cells 
Gold chloride was first used to stain LDC in the skin (Langerhans, 1868; 
Breathnach, 1965). While LDC can not be observed in routine paraffin 
embedded, haematoxylin and eosin (H&E) stained sections, they can be 
identified by means of enzyme histochemistry, cell surface antigens, 
cytoplasmic reactions including S100 and zinc-iodide-osmium (ZIO) 
impregnation and conclusively by electron microscopy examination to 
demonstrate BG (Birbeck et al., 1961). 
1.3.1 Enzyme histochemistry 
The cytoplasm of LDC contains a variety of hydrolytic enzymes which 
can be utilised by enzyme-histochemical techniques to detect LDC (Wolff, 
1972). These hydrolytic enzymes include alkaline phosphatase 
(Kechijian, 1965), nucleosidephosphatase, such as adenosine 
triphosphatase (ATPase), which is found in the epidermal LDC of 
human, guinea pigs, mice and monkeys (Wolff, 1972), aminopeptidase, 
in LDC of guinea pigs (Wolff, 1964) and cholinesterase, found in the high 
level dendritic cells of the sheep epidermis (Lyne and Chase, 1966). Non- 
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specific esterase, are observed in LDC of rats and mice (Wolff, 1972), acid 
phosphatase in the Golgi apparatus and lysosomes of LDC, and 
endogenous peroxidase, in LDC of murine epidermis (Maruyama et al., 
1980). B-Glucuronidase is an excellent marker for LDC from mouse, 
human, monkey, guinea pig, rabbit and rat epidermis (Mackenzie et al., 
1982). 
1.3.2 Cell surface antigen markers 
LDC share some of the lymphoid cell surface markers, such as receptors 
for C3, Fc IgG (Stingl et al., 1977), OKT6 (CD1) and HLA-DR antigen (Ia in 
mouse and rat, Rowden et al., 1977). Various monoclonal antibodies 
react specifically with these surface markers which help to identify LDC 
in tissues. The best known surface markers of LDC commonly used to 
identify this cell are, HLA-DR antigen in human LDC, Ia antigen in mice 
(Rowden et al., 1977), OKT-6 (CD1) antigen in humans (Murphy et al., 
1981), receptors for C3 and the Fc portion of IgG in humans (Stingl et al., 
1977). 
Steinman, (1991) reported that LDC expressed the following surface 
markers: MHC class I and MHC class II, leucocyte common antigen 
(CD45), B cell marker (CD40), T cell markers (CD1, CD4, CD8), 132 
Integrins (CD11a, CD11b and CD11c), adhesion molecules (CD54, CD58), 
and other receptors such as receptor for IL-2 (CD25). LDC were also 
reported negative for NK cell markers (CD56, CD57). 
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Other surface markers also have been reported e.g. B7-1, B7-2 integrins 
CD80, CD86 (Inaba et al., 1994) and CD68 (Van Haarst et al., 1994). The 
expression of LDC for the leucocyte common antigen, some surface 
markers of both T and B cell may suggest that LDC originate from a 
multilineage rather than a single-lineage bone marrow stem cell (Furuta 
tai., 1993). 
1.3.3 Cytoplasmic markers 
The cytoplasm of human LDC contains S100 protein (Cocchia et al., 1981). 
This protein, called S100 because of its solubility in 100% ammonium 
sulphate, was discovered in 1965 in cells of the human nervous system 
(Moore, 1965). It was later found in other cell types including, 
chondrocytes, myoepithelial cells, melanoma cells and interdigitating 
dendritic cells in lymph nodes (Hammar et al., 1986). The S100 protein is 
an acidic, calcium-binding protein with molecular weight between 21,000 
and 24,000 Dalton. It consists of a single tryptophan, three tyrosine, three 
or four cysteines and a number of phenylalanine residues (Moore, 1965). 
Though the biological role of S100 protein is not fully known, it has been 
reported that S100 protein consisted of two subunits a and 13 (Isobe et al., 
1983). S100a protein and not sloop can inhibit the enzymatic activity of 
glycogen phosphorylase a in a calcium-independent manner (Zimmer 
and Dubuisson, 1993). 
LDC do not contain the lysozymes (Furukawa et al., 1984) which are 
classically seen in the cytoplasm of monocytes-macrophages. 
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The zinc-iodide-osmium (ZIO) procedure was originally reported by 
Champy, (1913) to visualise chromaffin granules of nerve cell synaptic 
vesicles. While Niebauer et al., (1969) utilised the ZIO procedure to detect 
epidermal LDC and reported the affinity of BG for the ZIO stain, Wolff, 
(1972) reported both LDC and histiocytosis X cells had the affinity for the 
ZIO stain. Rodriguez and Caorsi (1978) used the ZIO procedure to 
visualise LDC and its characteristic structural marker, the Birbeck 
granule. The internal structure of BG is selectively stained with this 
procedure. This has been used to proceed from light to electron 
microscopy examination of LDC in various tissues eg. to study LDC in 
human epidermis (Rodriguez and Caorsi, 1978) and uterine cervix 
(Caorsi and Figueroa, 1986). 
1.4 Ultrastructure of Langerhans dendritic cells 
The first electron microscopy description of the ultrastructure of LDC in 
human epidermis was in 1958 by Clark and Hibbs, (1958). Birbeck and his 
colleagues (1961), subsequently reported a unique cytoplasmic organelle 
in LDC but not other epidermal cells. Since then this cytoplasmic 
organelle, has been considered as the ultimate structural marker of LDC. 
Its major ultrastructural features are the rod and the disc forming the 
characteristic tennis racket shape organelle (Zelickson, 1965), with its 
trilaminar limiting membrane (Birbeck et al., 1961). 
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1.4.1 Morphology and size of Langerhans dendritic cell 
The morphology of the cell body of LDC has been described as triangular, 
oval or rounded in shape, 8-20 gm in diameter. Various numbers of 
dendrites extend from the plasma membrane giving the cell its 
characteristic dendritic nature (Rodriguez and Caorsi, 1978; Chu et al., 
1983). 
There are no desmosomal attachments between the plasma membrane 
of LDC and the adjacent epidermal cells (Birbeck et al., 1961; Younes et al. 
1968 and Wolff, 1972). This may reflect the migratory nature of these 
cells. 
The number, length and the branching nature of the dendrites vary from 
cell to cell. The length of these dendrites may reach up to 30 nm 
(Rodriguez and Caorsi, 1978). Figueroa and Caorsi, (1980) subdivided 
Langerhans cells into five types according to the number of dendrites: 
type I, one unbranched dendrite; type II, one branched dendrite; type III, 
two branched or unbranched dendrites; type IV, three dendrites and type 
V, more than three dendrites and with numerous branches. 
The cytoplasm of LDC is clear in the suprabasal layer of the epidermis of 
skin. This is due to the absence of keratin tonofilaments (Birbeck et al., 
1961). The clear cytoplasm of LDC has been confirmed by many 
investigators (Zelickson, 1965; Younes et al., 1968; Wolff, 1972; Hammar, 
1988). 
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The nucleus of LDC is large, indented, lobulated or convoluted with a 
prominent nucleolus (Hammar, 1988). LDC with rounded nuclei have 
been reported by Wolff, (1972). The nucleus is darker than that of the 
surrounding epidermal cells (Younes et al., 1968). Zelickson, (1965) 
reported the presence of holes in the nuclear membrane after electron 
microscopy examination and thought they represented a direct 
communication between the nucleus and the cytoplasm. 
1.4.2 Cytoplasmic organelles 
The cytoplasm contains many organelles found in biologically active 
cells. These include, mitochondria, Golgi apparatus, smooth and rough 
endoplasmic reticulum, centrioles and ribosomes. The unique 
ultrastructural marker, the Birbeck granule (Birbeck et al., 1961; Wolff, 
1972; Hammar, 1988) is also commonly identified in the cytoplasm. 
The mitochondria of the LDC are similar to those of most cells. The 
number of mitochondria in the cytoplasm has been reported as not 
numerous by Birbeck et al., (1961), while Wolff, (1972) and Hammar, 
(1988) reported the mitochondria as moderate in number. 
The LDC Golgi apparatus is well developed, frequently more than one 
and located on one side of the nucleus. It consists of many cysternae and 
multiple small vesicles. BG are commonly found in the region of Golgi 
complex. Some workers suggested that BG are secreted by the Golgi 
apparatus (Breathnach, 1964). 
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The cytoplasm of LDC contains centrioles in the region of Golgi complex 
and around the nucleus (Birbeck et al, 1961; Wolff, 1972). Thus LDC have 
the structural elements needed for cell division. Mitotic division of LDC 
remains a controversial hypothesis. Giacometti, (1969) studied skin 
during wound healing and reported LDC labelled with tritiated 
thymidine were found 2, 5, 6, 7, and 16 days after wounding. Giacometti, 
(1969) thought LDC may undergo cell division during the process of 
wound healing. Czernielewski and Demarchez, (1987) used anti-BrdU 
(bromodeoxyuridine) and found 6% of epidermal LDC in S-Phase. This 
suggests that the majority of epidermal LDC are not dividing locally in 
the skin. 
Fine and rough endoplasmic reticulum are organised in a parallel 
fashion in the cytoplasm of LDC (Hammar, 1988). Ribosomes are 
involved in the synthesis of the RNA and other cellular protein. Their 
number in the cytoplasm affect the LDC density in relation to the 
surrounding keratinocytes. Dark LDC with numerous ribosomes were 
reported by Ebner and Niebauer, (1967). 
In general the cytoplasm of LDC does not contain the large lysosomes or 
phagocytic vacuoles commonly found in macrophages (Hammar, 1988). 
Zelickson, (1965) described the ultrastructure of LDC lysosomes as dense, 
rounded bodies surrounded by a single membrane on the outside, but 
contain a series of concentric membranes. According to Zelickson, the 
lysosomes and the lipid droplets are more numerous in the superficially 
located LDC in the epidermis. He also observed that the plasma 
membrane of the superficially located LDC became more convoluted 
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giving the cell the pseudovacuolated appearance (Zelickson, 1965). The 
increase in the number of lysosomal and lipid droplets together with the 
changes in cell membrane of the superficially located LDC may represent 
exfoliation steps of these cells as they pass through the epidermis. 
1.4.3 Birbeck granules (BG) 
BC are the ultimate ultrastructural marker of LDC (Birbeck et al., 1961). 
The apparent size and shape of BC depends on the angle at which the 
LDC have been cut by the microtome. Reported as rod and disc in shape 
by Birbeck et al., (1961), Zelickson, (1965), described these granules as 
tennis racket in shape. The granules are about 40 nm in diameter 
(Hashimoto and Tarnowski, 1968). 
BC are composed of trilaminar membranes, the limiting membrane 
being about 60 A thick and lined from the inside by small particles 
arranged at regular spaces of 50-60 A (Wolff, 1967). In the middle between 
the two limiting membranes is a third dense line showing a regular 
periodic striation of 50-60 A (Zelickson, 1965). The centre of the disc 
portion of the granules is clear and lined with similar particles lining the 
rods (Wolff, 1967). 
BC are commonly found in the region of the Golgi complex (Wolff, 
1972), and less frequently related to the plasma membrane (Breathnach, 
1964). BC can be labelled specifically by the zinc-iodide-osmium (ZIO) 
procedure, (Niebauer et al., 1969; Wolf, 1972; Rodriguez and Caorsi, 1978). 
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The origin of BC and its function are unclear. There are two theOries 
proposed for the origin of BC in LDC. The first is known as the secretion 
theory and suggests that BC are secreted by the Golgi apparatus and then 
move to the cell membrane to release its contents to the extracellular 
space. The secretory theory was suggested by Breathnach, (1964), and 
supported by Zelickson, (1966); Wolf, (1967) and Niebauer et al., (1969). 
The latter used the ZIO procedure to fix and stain epidermal LDC and 
observed that the Golgi complex and the BC both took up the metal 
deposit suggesting that they were closely related. 
The second theory is known as the endocytosis theory. Various workers 
have reported that BC are formed by an infolding of the cell membrane 
(Hashimoto and Tarnowski, 1968). Using electron microscopy, to 
examine serial sections of human skin, Ishii et al., (1984) observed the 
steps of coated vesicle formation and invagination from the cell 
membrane of LDC to form BC. The endocytosis theory may implicate the 
involvement of BC in processing the antigen by LDC. This is supported 
by Senoo et al., (1993) , Solcia et al., (1993), and Reis e Sousa et al., (1993). 
1.5 Langerhans dendritic cells and other dendritic cells 
Thy-1 positive dendritic cells, follicular dendritic (FDC) and dendritic 
macrophages, all are dendritic cells, but are unrelated to LDC. 
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1.5.1 Thy-1 positive epidermal dendritic cells 
Thy-1 positive dendritic cells were reported in the skin for the first time 
in 1983 by Tschachler et al., (1983), and they are not related to LDC. They 
express the Ly5 mouse haematopoietic cell surface marker and are 
derived from bone marrow. Thy-1 positive DC also express the asialo-
GMI surface marker and share other cell markers belonging to natural 
killer cells (Hamilos, 1988). Unlike LDC they are negative for the plasma 
membrane Ia antigen (Bergstresser et al., 1985). Recently it was reported 
that 15% of the CD3 positive T cells in the peripheral blood are Thy-1+ 
(Hozumi et al, 1994). 
1.5.2 Follicular dendritic cells (FDO 
Humphrey, (1981) reported that FDC are Fc and C3 receptor positive but 
Ia negative. They are located in the follicular germinal centre of the 
spleen and lymph nodes, interact with B-lymphocytes and not T-
lymphocytes. As the FDC lack surface Ia antigen, are related to B and not 
to T-lymphocytes, Humphrey, (1981) suggested they do not belong to the 
Ia positive LDC. 
The bone marrow origin of the follicular dendritic cells and their 
relationship to the monocytic/macrophage lineage was suggested by 
Fliedner et al., (1990). They suspended the monoblastic cell line THP-1, 
the histiocytic cell line U-937 and peripheral blood mononuclear cells 
(PBMC) in different dilutions of RPMI 1640 culture media mixed with 
10% FCS. The FDC-specific antigen Ki-M4 was induced only in the 
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monoblastic cell line, THP-1. They concluded that follicular dendritic 
cells are related to the mononuclear-phagocytic cell line derived from 
the bone marrow. Recently, the latter was supported by Maclennan, 
(1994); Butch et al., (1994) and by Imazeld et al., (1994). 
1.5.3 Dendritic macrophages 
Barfoot and his colleagues (1989) described a population of DC isolated 
from the peripheral lymph of the skin, liver of sheep and from the 
intestinal lymphatics of rats. These DC express class II major 
histocompatibility antigen on their surfaces and can phagocytose latex 
beads and influenza virus. Barfoot et al., (1989) suggested dendritic 
macrophages are related to mononuclear-phagocytes. While LDC are 
S100 positive, dendritic macrophages are negative for this cytoplasmic 
protein (Zeid and Muller, 1993). As both the dendritic macrophages and 
the follicular DC (Fliender et al., 1990) are of monocytic lineage, the 
relationship of these two cells to each other needs to be clarified. 
1.6 Family of Langerhans dendritic cells 
LDC of the skin was the first known DC (Langerhans 1868). Steinman, 
(1991) used the term "the dendritic cell system" to describe all cells 
related to LDC in the skin, this included veiled cells in the afferent 
lymph, interdigitating DC (IDC) in lymph nodes and spleen, interstitial 
DC in various organs and their precursors in the blood. 
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1.6.1 Indeterminate cells 
These cells represent the migratory form of LDC, either leaving the 
epidermis via the afferent lymphatics or a new generation arriving in 
the epidermis from their precursors in blood (Macatonia et al., 1987). It is 
noteworthy that Jarrett, (1963) described some ATPase positive DC in the 
upper dermis of the skin but he did not investigate this cell further. 
While human epidermal LDC are OKT-6+ (CD1a) and HLA-DR, 
Czernielewski et al., (1983) reported that the indeterminate cells in the 
dermis are OKT-6- and HLA-DR+. LDC may change surface markers as 
they migrate. 
1.6.2 Veiled dendritic cells 
These cells are found in the afferent lymphatics of the skin and are 
believed to be LDC migrating to the regional lymph node after exposure 
to antigen (Balfour et al., 1981). Silberberg et al., (1976), were the first to 
report LDC in a dermal lymphatics of the skin. Drexhage et al., (1979) 
reported the resemblance of veiled cells isolated from the peripheral 
lymph of pigs to the epidermal LDC. Balfour et al., (1981) hypothesised 
that the epidermal LDC become veiled dendritic cells in the afferent 
lymphatics and in lymph nodes they differentiate into the interdigitating 
dendritic cells in the T-dependent area (paracortex). Pugh et al., (1983) 
isolated DC from the peripheral lymph of rats and supported the 
observation of Drexhage and co-workers, (1979) that these cells closely 
resemble the lymphoid DC isolated from mice by Steinman and Cohn, 
(1973). 
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1.6.3 Interdigitating dendritic cells 
Steinman and Cohn, (1973) described a new generation of non-
phagocytic DC in the spleen, lymph nodes and in the intestinal Peyer's 
patches. The surfaces of these cells closely interdigitate with T 
lymphocytes and have since been called interdigitating dendritic cells 
(IDC). IDC were described in the white pulp of the human spleen by 
Heusermann et al., (1974) and in the thymus by Toro and Olah, (1966) 
and confirmed by Kaiserling et al., (1974). In an experimental model 
Kripke et al., (1993), reported that these cells are Ia+, may contain BG and 
they are in the lymph nodes to initiate the immune response. In human 
they are S100+ (Zeid and Muller, 1993) and BG rarely observed in their 
cytoplasm (Steinman, 1991). 
1.6.4 Interstitial dendritic cells 
Hart and Fabre (1981) described the Ia+ dendritic cells found in the 
interstitial connective tissue of various organs such as heart, liver, lung 
and in the mouse intestine. These interstitial dendritic cells are similar 
to LDC. They are bone marrow derived, strongly MHC class II positive, 
poorly phagocytic, capable of stimulating resting T lymphocytes, 
involved in solid organ graft rejection and have cytochemical features 
similar to those of the LDC (Hart and McKenzie, 1990). 
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1.7 Anatomical distribution of Langerhans dendritic cells in human body 
While LDC were discovered in the human skin almost 127 years ago 
(Langerhans, 1868), their widespread distribution only became apparent 
during the 1980's (Hart and Fabre, 1981; Nakajima et al., 1982; Watanabe 
et al., 1983; Takahashi et al., 1984; Hammar et al., 1986). 
Chen and his colleagues (1985), studied the distribution of ATPase-
positive LDC in 117 specimens of normal human skin and mucosa taken 
from different areas of the body. They reported the highest density of 
LDC in the skin of the face and the neck (976 ± 30.93/mm 2 ). The lowest 
density was in the skin of the palm and sole (267 ± 56.14/mm 2 and 189 ± 
19.15 /mm2 respectively) while in trunk skin the density was 740 ± 
28.97/mm 2 , scalp (693 ± 69.56/mm 2 ) and arm or leg skin (640 ± 
40.95 /mm2). 
The density of epidermal LDC in experimental animals varies 
(Bergstresser et al., 1980). In guinea pig, hamster and mouse the LDC 
density ranged between 600 and 1500 cells/nun2 . While the density was 
the lowest in the mouse tail (110-269/mm2 ), it was the higher in the 
dorsal skin of these animals. Their density in ear skin and footpads was 
less than that in dorsal skin. 
As LDC are associated with the epithelia in the human body, many 
researchers have investigated LDC in the ocular epithelium. Rodrigues 
et al., (1981), reported LDC in the normal conjunctiva and in the 
periphery of the cornea. The centre of the cornea lack LDC (Chen et al., 
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1985). LDC have been reported in cases of allergic conjunctivitis (Tagawa 
et al., 1983; Takeuchi et al., 1985, 1986), where their pathophysiological 
role needs to be fully investigated. 
The density of LDC in the oral mucosa shows regional variation (Chen et 
al., 1985), where their density ranged from 420-802 cells/n=2 . 
There are few reports in the literature on LDC in the gastrointestinal 
tract. LDC have been identified in normal esophagus (Yassin et al., 1979) 
and in carcinoma of the esophagus (Morris et al., 1986 and Matsuda et al., 
1990). Tsujitani et al., (1987) investigated the density of S100+ LDC in 
gastric carcinomas, while Ambe et al., (1989) investigated their density in 
colorectal carcinomas. LDC were reported in the liver by Hart and Fabre, 
(1981), while Bock, (1983) identified LDC with BG in the epithelium of 
the main pancreatic duct of a cat. 
Younes and his colleagues (1968) were the first to identify the 
ultrastructure of LDC in normal human cervix and proposed that the 
number of LDC was higher in the cervical epithelium of patients with 
intra-epithelial neoplasia. Figueroa and Caorsi, (1980) investigated the 
morphology, density and ultrastructure of LDC in the normal cervix 
using the ZIO procedure. They reported an LDC density between 6.29- 
10.19 cells/mm2. 
Basset and colleagues (1974) described the ultrastructure of cells similar 
to LDC in the bronchioalveolar lavage fluid from patients with 
bronchioalveolar carcinoma of the lung. Sertl and colleagues (1986), 
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Holt and Schon-Hegrad, (1987) reported that Ia positive dendritic cells 
represent 1% of all epithelial cells of normal mice and human lungs. 
Richard et al., (1987) reported S100+ dendritic cells with BG in human 
bronchial epithelium and supported the above reports in regard to their 
density. 
Colver and colleagues, (1988), described T6+ dendritic cells in the human 
bladder and they questioned a possible relationship to cutaneous 
sensitization. 
1.8 Functions of Langerhans dendritic cell 
Three aspects of LDC functions will be discussed: antigen presentation; 
LDC migratory function and T cell activation. 
1.8.1 Antigen presentation 
As antigen presenting cells, LDC strongly express all class-II MHC 
molecules in mouse and HLA-DP, DQ, DR in human (Steinman, 1991). 
Macatonia et al., (1987) investigated the antigen presenting function of 
the epidermal LDC, 30 minutes after skin painting with the contact 
sensitizer fluorescein isothiocyanate (FITC). Using a fluorescent 
microscope, FITC was detected on the DC in the draining lymph nodes 
with the peak of fluorescence intensity at about 24 hours. They 
concluded that LDC captured the antigen from the skin and presented it 
to T-lymphocytes in the regional lymph nodes. Kripke et al., (1990), 
sensitized the skin with FITC and examined the FITC+ draining cells in 
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the regional lymph nodes by immunofluorescence and immunoelectron 
microscopy. All of the F1TC+ cells were reported Ia+ and some contained 
BG in their cytoplasm. Kripke and co-workers reported that Ia+, FITC+ 
cells in the regional lymph nodes are LDC, leaving the skin to initiate 
hypersensitivity response. Various cytokines can affect antigen 
presentation by LDC, Grabbe et al., (1992) reported that granulocyte-
macrophage/colony-stimulating factor (GM-CSF), Interleukin-1 alpha 
(IL-1 alpha), tumour necrosis factor-alpha (TNF alpha), transforming 
growth factor-8 (TGF beta) and interferon-gamma (IFN gamma) can up 
modulate the antigen presentation of LDC. 
1.8.2 Migratory function 
From the site of their origin in the bone marrow (Katz et al., 1979), the 
precursors of LDC migrate through the blood to various organs 
(interstitial dendritic cells) in the body (Steinman, 1991) including the 
skin. The migratory function of epidermal LDC was investigated by 
Bujdoso et al., (1989). After intradermal injection of antigen, veiled 
dendritic cells were recovered from the afferent lymphatics and found to 
be carrying antigen. When assessed these cells were capable of triggering 
antigen-specific T-lymphocytes. The veiled LDC have a high level of 
MHC class-II and have been isolated from the afferent lymphatics of 
lymph nodes in rabbit, pig, rat, mouse, sheep and human (Steinman, 
1991). When LDC reach lymph nodes, they are called interdigitating 
dendritic (IDC) cells and are found in the T-zone around the germinal 
follicles. It is not clear what happens to IDC after stimulating the resting 
T-lymphocytes in the lymph nodes. While there is no evidence for LDC 
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degeneration in lymph nodes, the cells may exfoliate through the 
epithelial surfaces in the body (Chen et al., 1985). Cumberbatch and 
Kimber, (1992), reported TNF-alpha can stimulate the migration of 
epidermal LDC to the regional lymph nodes to initiate a cutaneous 
immune response. 
1.8.3 T-lymphocyte activation 
The process of T-lymphocyte activation by Langerhans dendritic cells is 
not fully understood. Many workers have investigated this and reported 
different factors involved in this process. It is known that IL-1 is essential 
for T-lymphocyte activation, Steinman, (1991) and Sauder, et al., (1984) 
reported that LDC can produce IL-1. LDC form clusters with T-
lymphocytes during primary interaction (Landry et al., 1990), which is 
essential for the LDC to stimulate the resting T cells (Muller et al., 1994). 
Landry et al., (1990) reported that the adhesion molecules ICAM-1 and 
LFA-3 were expressed by the LDC which may be involved in clustering 
with T-lymphocytes. Steinman, (1991) has proposed that activating 1-
lymphocytes by LDC may be related to the various cytokines or by 
membrane binding between T-lymphocytes and LDC. Moulon et al., 
(1991) investigated the effect of anti-CD1a monoclonal antibody on T cell 
proliferation and proposed that the CD1a molecule of epidermal LDC 
may have an important role in T cell activation. While prostaglandins 
would inhibit T cell proliferation (Kumar and Das, 1994), it was reported 
by Demidem et al., (1991), that GM-CSF would enhance stimulation of T 
cell by LDC. Larsen et al., (1994), proposed that GM-CSF upregulated the 
expression of both B7-1 and B7-2 on LDC and this will stimulate T cells 
Chapter 1 Literature Review LDC, Respiratory System and Tobacco Carcinogenesis Page 32  
proliferation. Retinoic acid was also reported upregulate LDC antigen 
presentation and T cell activation by enhancing the surface expression of 
HLA-DR, CD11c and 132 integrin (Meunier et al., 1994). 
1.8.4 Activation of Langerhans dendritic cell function and viability 
Cytokines like GM-CSF can enhance the function and the viability of 
LDC (Larsen et al., 1994). Koch et al., (1990) reported cachectin-TNF to 
enhance the viability but not the function of LDC. In contrast Inaba et al., 
(1988) reported IL-1 enhances their function, but not the viability of these 
LDC in vitro culture. While Bagot et al., (1994), reported the 
immunosuppressive effects of vitamin D on epidermal LDC, Meunier et 
al., (1994) reported retinoic acid upregulation of LDC antigen 
presentation. 
1.8.5 Role of Langerhans dendritic cells in various human diseases 
LDC are involved in the following human diseases: 
1. Contact dermatitis, where LDC can take up and present antigen to T 
cells to generate an immunological response (Shelley and Juhlin, 
1976 & Silberberg-Sinalcin et al., 1980). If this function of LDC could 
be modified, this may help to counter this disorder. 
2. Hypersensitivity reactions- Fokkens et al., (1990) reported that LDC 
bear IgE surface molecules in allergic rhinitis and atopic dermatitis. 
The IgE positive LDC may capture the antigen and present it to T-
lymphocytes inducing an allergen-specific T cell response and IgE 
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synthesis. The role of IgE bearing LDC in allergic asthma, 
hypersensitivity pneumonitis and other allergic disorders of the 
gastrointestinal tract needs to be clarified. 
3. In AIDS, there is an increasing number of reports linking the HIV-1 
virus and LDC (Belsito et al., 1982; Niedecken et al., 1987). Human 
epidermal LDC express CD4, HLA-DR antigens together with Fc-IgG 
receptors, which are all involved in the receptor binding of the 
HIV1 virus (Stingl et al., 1990). LDC may be a target cell for the HIV-
1 virus. Stingl et al., (1990) reported a low density of epidermal LDC 
in patients suffering from AIDS. Damaging LDC by the virus will 
compromise their function to stimulate T-lymphocytes causing 
further immunodeficency. They also reported HIV-1-like particles 
on the surface of LDC and in the extracellular spaces. This was also 
supported by Zemelman et al., (1994) as they reported epidermal 
LDC bearing CD4 receptors, which make them targets for infection 
with HIV-1. As LDC can exfoliate through the epithelial surfaces, 
LDC infected with HIV in saliva, vaginal and rectal secretions may 
act as a vehicle to transmit the virus during sexual contact. 
4. With transplantation, LDC can stimulate allogeneic and syngeneic 
reactions (Hammar, 1988). Odling et al., (1987) investigated the 
survival of skin grafts on animals treated with the chemical 
carcinogen (DMBA) to deplete LDC from the epidermis. Odling and 
co-workers reported longer survival of skin grafted on animals with 
depleted LDC in their skin. This was also supported by McMinn et 
al., (1990), reporting similar findings. Hill et al., (1994), used UV-B 
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irradiation to decrease corneal LDC number and reported 
improvement in corneal graft survival in rabbit. It may be possible 
to control rejection against a transplanted organ by pharmacological 
agents which modify the function of these antigen presenting cells. 
5. Non-neoplastic diseases, LDC have been identified in about 60 
human diseases, most being related to skin disorders. The majority 
of these reports was concerned with the identification of LDC rather 
than investigating their immunological role. Table 1.1 shows a list 
of such reports on LDC and human diseases. 
1.9 Langerhans dendritic cells and human tumours 
Basset et al., (1974) were first to report LDC in human tumours. They 
identified LDC by ultrastructural examination of cells in the 
bronchioalveolar lavage fluid of patients with bronchioalveolar 
carcinoma of the lung. The widespread distribution of LDC in human 
tumours was shown by Hammar et al., (1986), using S100 protein as a 
cytoplasmic marker for LDC together with ultrastructural tissue 
examinations. LDC were found in the following tumours- pulmonary 
adenocarcinoma, nasopharyngeal carcinoma, ovarian adenocarcinoma, 
gastric carcinoma, renal cell carcinoma, breast carcinoma, pancreatic 
carcinoma, thymoma, basal cell carcinoma, melanoma and in skin 
appendage neoplasms. 
The density of LDC in actinic keratosis, Bowen's disease, 
keratoacanthoma, squamous cell carcinoma and basal cell carcinoma of 
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the skin was investigated by McArdle et al., (1986), who reported a high 
density of S100+ LDC in all skin lesions except actinic keratosis. The 
increase in density of LDC in basal cell and in squamous cell carcinomas 
was supported by Missner et al., (1986). 
Stene et al., (1988) investigated the density of Leu-6 (CD1a) positive LDC 
in various pigmented lesions of the skin and reported a decrease in the 
number of epidermal LDC in deeply invasive melanomas. They also 
reported normal LDC density in naevi, in early invasive melanomas and 
in metastatic cutaneous melanomas. Stene and co-workers, (1988) 
proposed that epidermal LDC may recognise a tumour associated antigen 
expressed by the neoplastic melanoma cells and presented to T-
lymphocytes in the tissue and regional lymph nodes. 
The density of LDC in human cervical intraepithelial neoplasia and wart 
viral infection was investigated by McArdle and Muller (1986). They 
observed a significant decrease in LDC number in cervical wart infection, 
possibly due to the effect of HPV on cervical LDC. They also found a 
marked increase of LDC density in cervical intra epithelial neoplasia 
(CIN). They proposed the decrease in the density of cervical LDC caused 
by HPV infection reduced the local cervical immunosurveillance and 
may promote the development of cervical cancer. Increase of LDC 
density in CIN has also been reported by Caorsi and Figueroa, (1986). 
Bonilla-Musoles et al., (1987) investigated LDC distribution and their 
relationship to cervical cancer. They reported an increase in the HLA-DR 
positive LDC in squamous cell carcinoma of the cervix but did not find 
Table 1.1 	Identification of Langerhans dendritic cells in human 
diseases 
Disease 	 Author/Year 
Vitiligo 
Psoriasis 
Urticaria pigmentosa 
Granulomatous skin diseases 
Keratoacanthoma 
Allergic conjunctivitis 
Hypersensitivity pneumonitis 
Pulmonary fibrosis 
Progressive systemic sclerosis 
Connective tissue diseases 
Sarcoidosis 
LDC granulomatosis 
(Histiocytosis X) 
Chronic liver diseases 
AIDS 
Cervical HPV 
Behcet's disease 
Fabry's disease 
Omen's diseases 
Birbeck et al.,(1961) 
Bos et al., (1986) 
Johansson, (1985) 
Aoki et al., (1987) 
McArdle and Muller, 
(1986) 
Takeuche et al., (1983) 
Hammar et al., (1986) 
Basset et al., (1976) 
Andrews et al., (1986) 
Goobar et al., (1986) 
Berman et al., (1986) 
Hance et al. (1988) 
Tobe et al., (1982) 
Stingl et _al, (1990) 
Vayrynen et al., (1984)) 
Kohn et al., (1984) 
Le-Charpentier et al. (1978) 
Ruco et al., (1985) 
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LDC in cervical adenocarcinoma. None of these studies correlated LDC 
density to the survival of patients. The association between high LDC 
number in SCC of the cervix and longer patients survival was also 
reported by Xie, (1990). Schenk, (1980) identified the ultrastructure of LDC 
in laryngeal carcinoma but no further investigations were reported. 
Using S100 protein to identify LDC, the correlation between LDC density 
in human tumours and patient survival has been reported for lung 
tumours (Furukawa et al., (1984); nasopharyngeal carcinomas (Nomori 
et al., 1986); gastric carcinomas (Tsujitani et al., 1987); papillary thyroid 
tumours (Schroder et al., 1988); colorectal carcinomas (Ambe et al., 1989); 
oesophageal squamous cell carcinomas (Matsuda et al., 1990); laryngeal 
carcinoma (Rucci, et al., 1991); prostatic carcinoma (Bigotti, et al., 1991); 
cervical squamous cell carcinoma (Xie, 1990) and transitional cell 
carcinoma of the urinary bladder (Inoue, et al., 1994). They all reported 
longer survival of patients associated with high density of LDC in their 
tumours. 
It is noteworthy that when Furukawa et al., (1985) investigated the 
distribution of S100+ LDC in 40 patients with stage Ia lung 
adenocarcinoma; they reported a longer survival of patients with a high 
density of LDC in their tumours, although they correlated the density of 
LDC with tumour differentiation, they did not classify adenocarcinoma 
according to the cellular subtypes- ciliated, Clara, mucous producing and 
bronchioalveolar nor investigated LDC in SCC of the lung (Herrera et 
al., 1983 and Kawai et al., 1988). 
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Other workers have identified LDC in other human tumours, in 
pleomorphic adenoma of salivary gland (David, 1980), in non-Hodgkin's 
lymphoma (Daniel et al., 1985 and Neuman et al., 1986), in Hodgkin's 
lymphoma (Flint et al., 1987) and in leukemia (Kaiserling et al., 1988). 
With regard to Hodgkin's lymphoma, Hsu and Hsu, (1990) identified an 
antigen, Mr70,000 (cell surface marker) expressed by both Reed-Sternberg 
cells of Hodgkin's lymphoma and the interdigitating reticulum cells of 
lymph nodes and spleen. The relationship between Hodgkin's 
lymphoma and LDC warrants further investigation. 
Primary LDC tumours were reported in the skin by Kaiserling and 
Horny (1988) and by Strickler et al., (1990) and in the lymph nodes by 
Weiss et al., (1990) and by Yamakawa et al., (1992). The neoplastic diseases 
of LDC in peripheral blood, lymphoid tissue and solid organs warrants 
further investigation. 
During 1993 many workers investigated the role of dendritic cells in 
tumours. Zeid and Muller, (1993), reported dendritic cells in human 
lung tumours are related to tumour type, cell differentiation and 
enhanced patients survival. Zeid and Muller, (1995) also reported the 
increase in dendritic cells in skin tumours in mice was associated with 
tumour regression. The anti-cancer activity of the bone marrow derived 
LDC has been investigated by Becker, (1993), Deutsch et al., (1993), 
Tsujitani, et al., (1993) and Austyn, (1993). While Becker (1993) reported 
high LDC density in primary human and experimental tumours was 
associated with tumour regression, Tsujitani, et al., (1993) demonstrated 
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that high density of LDC in regional lymph nodes to gastric carcinoma 
was associated with low incidence of nodal metastasis. 
1.10 Langerhans dendritic cells in tobacco smoke induced pulmonary 
disorders 
The role of antigen presenting LDC in lung pathology is incompletely 
understood. Nezelof et al., (1973) first reported LDC in the bronchio-
alveolar lavage fluid of patients with pulmonary histiocytosis. LDC were 
reported in pulmonary fibrosis (Hammar et al., 1986), hypersensitivity 
pneumonitis (Hammar et al., 1986; Kawanami et al., 1987) and 
pulmonary histiocytosis (Nezelof et al., 1973) 
The ultrastructural examination of Histiocytosis X cells in pulmonary 
histiocytosis showed that these cells contain the characteristic 
cytoplasmic marker of LDC, the BG. Since then pulmonary histiocytosis 
is called pulmonary Langerhans cell granulomatosis (Lieberman et al., 
1980; Hance et al., 1988). 
The effects of cigarette smoking on the bronchial epithelium and lung 
parenchyma have been documented in both human and animal models. 
Auerbach et al., (1957), investigated the bronchial epithelial tobacco 
smoke induced changes in the human lung and reported basal cell 
hyperplasia, stratification and squamous cell metaplasia of the bronchial 
epithelium as pre-cancerous changes in the lung. Wynder et al., (1961), 
applied tobacco condensate on the skin of various laboratory animals 
and reported skin papillomas and carcinomas after 8 to 12 months of 
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condensate application. Leuchtenberger et al., (1961), investigated the 
effect of tobacco smoke on the murine lung by exposing them for up to 
28 months. They reported bronchitis, peribronchitis, atypical bronchial 
epithelial proliferation and occasional lung adenomas. Harris et al., 
(1974), exposed mice to a smoke:air mixture throughout their lives and 
reported alveogenic, adenocarcinomas and keratinized tumours in their 
lungs. The effect of tobacco smoke on the defence mechanisms of the 
respiratory tract was investigated by other workers (Ehrlich, 1966; 
Zarkower and Morges, 1972; Miller and Zarkower, 1974; ). Holt et al., 
(1973), proposed that inhalation of tobacco smoke may damage local 
immunity and the immunosurveillance mechanisms of the respiratory 
tract causing recurrent respiratory infections and the development of 
some lung tumours. Thomas et al., (1978), investigated the effect of the 
vapour phase tobacco smoke on the phagocytic activity of macrophages 
and reported transient depression followed by enhancement of 
phagocytosis activity. 
Nezelof et al., (1973) were the first to report LDC in pulmonary 
histiocytosis X, while Basset et al., (1974) were first to identify the 
ultrastructure of LDC in bronchioalveolar carcinoma. The effect of 
tobacco smoke on pulmonary LDC is unclear. There are only two reports 
to date in the literature reporting findings in this regard. Casolaro, (1988), 
reported accumulation of LDC in the epithelium of the lower respiratory 
tract of smokers. Soler et al., (1989), reported an increase in LDC and 
other related DC in smokers lung. As antigen presenting cells are capable 
of stimulating resting T-lymphocytes, their relation to other cells 
(alveolar macrophages, eosinophils, smooth muscle, plasma and 
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endothelial cells) in the pathogenesis tobacco induced lesions in the lung 
is yet to be clarified. 
1.11 Analysis of tobacco smoke 
More than 4270 chemical compounds have been identified in cigarette 
smoke (Dube and Green, 1982; Bos and Henderson, 1984). These chemical 
compounds include water, nicotine, polycyclic aromatic hydrocarbons 
(PAHs), N-heterocycles, nitrosamines, pesticides, organic acids, keto 
compounds, phenols and metals (Fresenius, 1985). Table 1.2 is a list of 
these compounds. 
1.11.1 Carcinogens and co-carcinogens in tobacco smoke 
Seventy one chemical compounds have been identified as carcinogens 
and co-carcinogens in tobacco smoke (Bos and Henderson, 1984). 
Hoffmann and Wynder, (1971) reported the chemical analysis of a 
neutral fraction and subfractions B and B1 of tobacco smoke. The most 
common co-carcinogens in this fraction were polycyclic aromatic 
hydrocarbons, benzo(a)pyrenes and catechol from the phenol group 
(Brunnemann et al., 1977). N-nitrosonornicotine and 4- 
(methylnitrosamino)-1-(3-pyridy1)-1-butanone are the most powerful 
carcinogens formed by burning nicotine and other tobacco alkaloids 
nitrosamines (N-nitrosamines). Tobacco smoke condensate (TSC) was 
painted on the skin of mice, rats and Syrian golden hamsters to induce 
skin tumour formation (Hoffmann and Wynder, 1986). 
Table 1.2 	Chemical compounds found in tobacco (Fresenius, 1985) 
group 	chemical compounds 
Polycyclic aromatic hydrocarbons (PAHs): 
jig/cigarette 
Benzo(a)pyrene 0.04 
Methylchrysene 0,02 
Dibenz(a,h)anthracene 0.004 
Benzo(b)fluoranthene 0.003 
Benzo(j)fluoronthene 0,006 
N-Heterocucles: 
Indol 1.4 
Skatol 4.3 
Carbazole 0.7 
Methylcarbazole 0.15 
Harman 13,00 
Nrthharman 4,5 
Dibenzo(c,g)carbazole 0.07 
Nitrosamines: 
Dimethylnitrosamine (mainstream) 1.7-97 ng/cigarette 
Dimethylnitrosamine (sidestream) 680-1770 ng/cigarette 
Pesticides (Organic acids): 
Acetic acid 205-620 
Benzoic acid 25-258 
Butyric acid 15-46 
Propionic acid 17-61 
Keto compounds: 
Acetone 27-562 
acetaldehyde 4-856 
Acrolein 1-87 
Aldehyde 0.9 -1.2 
Formaldehyde 2-7 
Phenols: 
Phenols (mainstream) 228 
Phenols (sidestream) 603 
o-Cresol 22 
p-Cresol 18-40 
pyrocatechol 61 
hydroquinone 83 
Resorcinol 8 
Metals: 
43 metals including, aluminium, antimony, arsenic, barium, lead, 
cadmium, caesium, cerium, chromium, iron, europium, gold, hafnium, 
cobalt, copper, lanthanium, lithium, lutetium, magnesium, manganese, 
molybdenum, nickel, polonium, mercury, radium, rubidium, 
samarium, scandium, selenium, silver, strontium, terbium, thorium, 
titanium, uranium, vanadium, bismuth, ytterbium, zinc, tin and 
zirconium have been identified in tobacco smoke. 
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Ruby et al., (1989) investigated the effect of benzo[a]pyrene and catechol 
on the epidermal LDC of mice and reported that both of these tobacco-
derived carcinogens caused an increase in la+ LDC density in the skin. 
They also reported abnormal LDC morphology, LDC appeared smaller 
than normal and with shorter dendrites. Following 24 weeks of BP 
application to the dorsal skin, 35% of mice developed skin tumours, 58% 
were squamous papilloma and 42% were squamous cell carcinoma. The 
BP treated skin showed hyporesponsiveness to a contact sensitizing 
agent, dinitrofluorobenzene. The impaired function of epidermal LDC 
may compromise the skin anti-tumour immunosurveillance system 
and allow tumour development. 
1.11.2 Carcinogenesis of passive smoking 
The mainstream tobacco smoke is generated during puffing the cigarette, 
which may not allow complete burning of the tobacco. The 
concentration of the chemical compounds in the mainstream tobacco 
smoke including carcinogens will be less than that of the sidestream 
tobacco smoke. The latter is generated by slow burning of the tobacco and 
will contain higher concentrations of chemicals compounds and 
carcinogens than that of the mainstream. Hoegg, (1972) reported that 80- 
90% of air pollution in closed spaces is caused by side stream tobacco 
smoke. Hirayama, (1981) investigated 91,540 non-smoking married 
women for 14 years and reported that wives of heavy smokers have a 
higher risk of developing lung cancer than wives of non-smokers. Bos et 
al., (1984) reported higher urinary output of metabolites relating to the 
chemical compounds in the tobacco smoke in men exposed to passive 
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smoking compared with the values before exposure. Later it was 
confirmed that the concentration of chemical compounds in the side 
stream tobacco smoke was 50-100% higher than in the mainstream 
tobacco smoke (Hoffmann and Wynder, 1986). 
1.12 Summary 
The bone marrow derived LDC are the best known potent antigen 
presenting cells and are capable of stimulating naive T-lymphocytes in 
organ associated lymphoid tissue and in the regional lymph nodes to 
initiate a specific immune response. They include the epidermal LDC, 
dermal indeterminate dendritic cells, veiled dendritic cells in the 
• afferent lymphatics, interdigitating dendritic cells in lymph nodes and 
spleen, interstitial dendritic cells in the connective tissue of various body 
organs, and their precursors in the blood and in the bone marrow. 
To date the effect of tobacco smoke on the density and function of the 
pulmonary antigen presenting dendritic cells and their role in tobacco 
smoke induced lung lesions and lung tumours have not been fully 
investigated. 
The aims of this thesis were to study LDC in tobacco smoke related 
human lung cancer and to investigate the effect of passive tobacco smoke 
inhalation on murine pulmonary LDC. Further investigations e.g. the 
effect of crude tobacco smoke condensate on murine epidermal LDC 
during cutaneous carcinogenesis and investigating the S100+ cells in the 
peripheral blood arose during the course of the study. 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
2.1 Specimens for human lung tumour study 
Paraffin blocks of 130 lung tumours, 100 regional lymph nodes, 13 
normal lung, 7 normal bronchial lymph nodes were obtained from the 
files of the Department of Anatomical Pathology, Royal Hobart Hospital. 
Three 3-4 gm sections were cut from each block, one for S100 staining, 
one for antibody control and the third for haematoxylin and eosin 
staining. 
2.2 Clinical data 
All data related to patients involved in this study were obtained from the 
files of the Medical Records Department, Royal Hobart Hospital. 
2.3 Preparation of human tracheal and bronchial mucosal sheets 
Four segments, 2 X 1 cm each of unfixed trachea and major bronchus 
from two autopsies were incubated in ethylene diamine tetraacetic acid 
solution (0.38 g EDTA in 50 ml PBS, pH 7.2; Serva, 11282). The incubation 
time and temperature were modifications of those suggested by Scaletta 
and MacCallum (1972). The mucosal segments were incubated for 3 hours 
at 37°C and overnight at 4°C. The tracheal and bronchial segments were 
treated with 50% ethanol for 30 minutes. The mucosal sheets were 
separated gently from the underlying cartilage, flattened on filter paper 
and processed for routine paraffin embedding; mucosal segments were 
blocked in paraffin as a flat mucosal sheet. The whole tracheal and 
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bronchial mucosa was tangentially and serially sectioned at 3 micron. A 
total of 159 sections was prepared for S100 and routine H&E staining. 
2.4 Immunohistochemical staining of Langerhans dendritic cells in 
human materials 
Rabbit antibody to bovine S100 protein (Dakopatts, Denmark, Z 311) was 
used to identify the dendritic cells in paraffin sections. The paraffin wax 
of the sections was first melted at 56°C for two hours, dried overnight at 
37°C and then the paraffin wax was remelted at 56°C for 5 minutes before 
dewaxing in two changes of xylene, 5 minutes each. Sections were 
hydrated in descending concentrations of ethanol to water. Dewaxed 
sections were placed in prewarmed phosphate buffer saline (PBS), pH 7.4 
at 37°C for 5 minutes. Enzyme digestion was then carried out by placing 
the sections in prewarmed 360 ml PBS, pH 7.4 containing 0.02 g of 
protease (Sigma No. 8038) and incubated at 37°C for 6 minutes. After 
washing the sections in running water for 5 minutes they were rinsed in 
0.05 M Tris-HC1 saline, pH 7.6 for 5 minutes. After drying, S100 antibody 
diluted 1:400 in diluent (1% bovine serum albumin, Sigma A 7030; and 
human serum group AB; CSL 1121001) was applied to the sections and 
incubated for 90 minutes at room temperature. Sections were washed in 
0.05 Tris-HC1, pH 7.6 for 5 minutes. Sections were then incubated for 50 
minutes at room temperature with the secondary antibody (biotinylated 
anti-rabbit immunoglobulin, Biogenex HK 326-UR) diluted 1:500 as for 
S100 antibody. After washing sections in 0.05 M Tris-HC1 saline, they 
were incubated with alkaline phosphatase labelled streptavidin (Biogenex 
UK 321 UK) diluted 1:50 in Tris-HC1 0.05M pH 7.6. Sections were 
incubated at room temperature for 50 minutes. Sections were rinsed in 
0.1 M Tris-HC1 pH 8.2 after washing in 0.05 M Tris-HC1 pH 7.6. The 
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phosphate in Tris buffer) and the chromagen Fast Red, (fast red TR salt 
and levamisol, Biogenex, USA, HK 182-5K) were applied to the sections 
and incubated at room temperature for 20 minutes and then 
counterstained in Mayers haematoxylin for 3 minutes after washing in 
deionised water for 5 minutes. Following washing in deionised water 
sections were mounted in crystal/mount (Biomeda, USA, MO2), cleaned 
in xylene and finally mounted in Eukitt (Carl Zeiss, West Germany, 00 20 
02). 
2.5 Identification and counting of S100 positive Langerhans dendritic cells 
The S100+ Langerhans dendritic cells were identified by their red 
cytoplasm, indented nuclear membrane and prominent nucleolus. 
Chondrocytes of bronchial cartilage, myoepithelial cells of the serous 
glands in the lamina propria and nerve fibres are S100+ in lung sections, 
but these cells were readily distinguished from the S100+ dendritic cells. 
5100+ Langerhans dendritic cells (LDC) were counted in four high power 
fields (HPF, X 400) randomly selected for each section. These fields 
covered the tumour itself and zonal junction between the tumour and 
the surrounding lung parenchyma. The mean of the dendritic cell 
number in the four high power fields and the standard deviation were 
calculated for each case. 
The relationship between the S100+ LDC in each type of lung tumours 
and the density of tumour infiltrating lymphocytes (TIL) in and around 
tumours was recorded. The density of TIL was evaluated as mild, 
moderate and marked. Enumeration of S100+ DC in lymph nodes was 
performed following the same methodology applied to lung sections. 
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2.6 Animals for tobacco smoke inhalation 
BALB/c female mice 6-8 weeks old were obtained from the Central 
Animal House at the University of Tasmania after Ethics Committee 
approval. The 108 mice used for the tobacco smoke inhalation 
experiment were divided equally into two groups- experimental and 
controls. Control and experimental mice were maintained separately in 
groups of 6. 
2.7 Experimental design of tobacco smoke inhalation 
The experimental mice were exposed daily to the tobacco smoke of 8 
cigarettes. Each cigarette needed 2 minutes to burn completely thus mice 
were exposed for a maximum of 16 minutes per day. The smoke:air ratio 
used in this study was 1:12; other researchers have used ratios of 1:7 
(Leuchtenberg et al., 1960; Keast and Taylor; 1983; Wynder et al., 1985). 
The smoke:air ratio is vital to protect the mice from acute smoke toxicity 
and death. During the first week of the experiment, mice were exposed to 
the smoke of only one cigarette a day to acclimatise the mice to the much 
higher dose of 8 cigarettes during the second week. Six test and six control 
mice were killed by cervical dislocation at weeks 1 and 2 and then every 4 
weeks. One lung from each mouse was snap frozen in liquid nitrogen 
and stored at -80°C for ZIO and anti-Ia immunoperoxidase staining. The 
other lung, together with the trachea and the bronchi, were perfused 
overnight in 10% formalin in PBS (pH 7.3) and processed for histological 
examination. At 28 weeks, and when the histological examination of the 
lungs of the test group showed positive tobacco induced changes, the 
remaining mice ceased to be exposed to further tobacco smoke. They were 
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maintained for a further 6 weeks to study the reversibility of the tobacco 
induced changes in the lung. 
2.8 Tobacco smoke chamber 
The tobacco smoking chamber (Fig. 2.1) was designed by the author N. A. 
Zeid. It consisted of three units, a smoke generating unit, a smoke 
exposure tent and an air outflow unit. The smoke generating unit was a 
500 ml filter (Buchner flask, Selbys, Cat. No. 414644, FB500/3) connected 
by plastic tube to a central continuous source of air. The rate of air flow 
can be adjusted by a valve switch. A cigarette holder was fitted in the 
centre of the cover of the flask. The mouthpiece of the cigarette holder 
was connected by plastic tube to the smoke exposure tent. The central air 
flow was switched on before lighting the cigarette and firmly closing the 
flask. The air flow to the flask was adjusted to ensure the two minutes 
time needed for complete burning of the cigarette. The air in the flask 
together with the generated tobacco smoke flowed through the cigarette 
holder and plastic tube to the smoking tent. The amount of smoke 
generated from burning one untipped cigarette was about 350 ml (50 ml 
syringe was used to measure smoke from burning cigarette until 
completely burned). The smoke exposure tent was designed to provide 
the mice in the tent with environmental air similar to that of any 
endosed place in the human situation. It consisted of a plastic tent and 
mouse cage. The tent was constructed from transparent plastic and 
supported by a steel frame. The tent was not sealed at the lower margin in 
order to provide continuity and similarity between the tent and the room 
environmental air. The tent was provided with a smoke inlet and safety 
smoke outlet connected to a central adjustable air suction. A standard 
animal cage was used provided with 74 holes at all sides, each hole about 
Figure 2.1 Tobacco smoke chamber consisting of smoke generating unit with 
a cigarette holder (1) connected by plastic tube (2) to a central 
continuous source of air. This was connected by plastic tube (3) to 
the smoke exposure tent (4) which covered the mouse cage (5). 
The air outflow unit was composed of a safety smoke outlet (6) 
and adjustable central suction (7). 
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1 cm in diameter. The cage measured 50 X 33 X 13 cm. The air outflow 
unit consisted of a safety smoke outlet connecting the tent to the 
adjustable central suction. 
2.9 Tissue preparation of murine lung 
Representative sections from the mice lung, bronchi and bronchial 
lymph nodes were processed and vacuum embedded in wax. Four gm 
sections were cut and stained with haematoxylin and eosin for light 
microscopy examination. 
2.10 ZIO procedure to visualise Langerhans dendritic cells in mouse lungs 
A modified ZIO procedure (Champy, 1913 & Rodriguez and Caorsi, 1987) 
was developed because of the nature of the lung. The ideal size and 
thickness of the lung tissue was 5 X 5 X 2 mm to ensure complete 
penetration of the fixative and staining solution. The frozen lung 
sections were fixed in V-7.4-ZIO solution (veronal sodium-HC1 buffer 
solution-pH 7.4) at 4°C for 19 hours and then processed for routine 
paraffin embedding after washing in running tap water for 5 minutes. 
Five gm sections were cut, dewaxed in 2 changes of xylene, 5 minutes 
each and mounted directly in Euldtt mounting media. 
2.11 Preparation of V 7.4-ZIO solution 
A mixture of 2.4 g zinc powder (BDH Australia, 30596) and 1 g of iodine 
bisublimate (Ajax, Sydney-Melbourne, 70516) was added to 40 ml of 0.2 M 
7.4 veronal sodium-HC1 buffer. After shaking the mixture for ten 
minutes the solution was immediately filtered. The filtered solution was 
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mixed with 2% Osmium tetrwdde (0s04, BDH Australia, 29422) at a ratio 
of 3:1. This solution was prepared fresh for each experiment. 
2.12 Preparation of 0.2 M, 7.4 veronal sodium-HG buffer 
N/10 hydrochloric acid (HC1): 8.5 ml of concentrated HC1 per one litre of 
distilled water. 
Veronal acetate solution: Sodium acetate crystals, 19.4 g and 29.4 g of 
sodium diethyl barbiturate (Veronal) were dissolved in distilled water to 
make up to 1 litre. To prepare 0.2 M, 7.4 veronal sodium-HC1 buffer 
solution, 5 ml of N/10 HC1, 5 ml veronal acetate solution was added to 15 
ml of distilled water. 
2.13 V-7.4-ZIO staining of mouse lungs for electron microscopy 
Modifications of the procedure of Rodriguez and Caorsi, (1978) were used. 
Lung sections 25 gm thick, were cut from paraffin blocks of lung tissue 
which had already been incubated with V-7.4-ZIO solution. They were 
dehydrated in ascending concentrations of ethanol (30; 75; 90; 95; 100%), 
20 minutes each and embedded in Epon resin (Procrue 812, 11.7 g; 
Dodecenyl succinie, 3.3 g; Nadic methyl anhydride, 8.4 g; Tri-
dimethylaminoethyl phenol, 0.3 g). 
2.14 Immunoperoxidase staining to visualise Langerhans dendritic cells 
in mouse lungs 
Five gm acetone-fixed frozen sections of lung tissue were mounted on 
potassium-dichromate-gelatine coated slides, dried for 2 hours, incubated 
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with mouse monoclonal anti-Ia (MKD6, Kappler et al., 1981) for 90 
minutes at room temperature, washed 3 times in phosphate-buffered 
saline (PBS, pH 7.4) over 20 minutes, and incubated with peroxidase-
conjugated rabbit anti-mouse immunoglobulin (HRPO-anti-Ig, 1:80; 
Dakopatts, Denmark). Sections were washed in PBS, three times over 20 
minutes. The la+ cells were identified by incubating the sections with 
diaminobenzidine (DAB, Sigma- D5637, 0.5 mg/ml of PBS containing 
0.02% H202, pH 7.4) for ten minutes. Sections were washed with running 
water for 10 minutes and counterstained with Mayers haematoxylin. The 
washed sections were mounted in glycerol gelatin (Sigma, 86F-6098) for 
microscopic examination. 
2.15 Enumeration of ZIO positive LDC in lung sections 
The number of ZIO+ LDC in four HPF (X400) was calculated. The mean 
and the standard deviation were statistically analysed for groups of mice 
assessed. 
2.16 Animals for tobacco smoke condensate (TSC) cutaneous experiment 
Two hundred and four BALB/c female mice 6-8 weeks old were obtained 
from the Central Animal House at the University of Tasmania after 
Ethics Committee approval. One group of mice (48) was used to assess the 
function of LDC by inducing a contact hypersensitivity reaction, while the 
remaining 156 mice were divided into 2 groups of 78 mice each, 
experimental and control. Control mice were treated with olive oil and 
acetone, while the experimental mice were treated with TSC in acetone 
and olive oil. 
Figure 2.2 Unit used to prepare the tobacco smoke condensate. It consists of 
the following components: 
Cigarette burning unit 1; 2. 
Smoke condensation unit, 4; 5; 6. 
Cold trap unit, 3; 7; 8; 9. 
Suction unit, 10. 
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2.17 Preparation of tobacco smoke condensate 
The TSC was prepared (Fig. 2.2) by condensation of cigarette smoke by a 
cold trap (Bentley and Burgan, 1961). TSC was collected in jars and the 
water content evaporated by placing the jars, after gradual warming, in a 
water bath adjusted at 100°C. TSC was then dissolved in an equal volume 
of acetone. Each 550 cigarettes gave 55 g (35 ml) of condensate. After 
dilution with an equal volume of acetone, the total amount of diluted 
condensate was 70 ml. 
2.18 Experimental design of TSC cutaneous experiment 
After shaving the dorsal skin of control mice, this group was treated with 
200 p.1 of olive oil and acetone (1:1). The skin of the experimental mice 
was prepared as for the control, and treated with 100 IA of olive oil and 
100 1.1.1 of tobacco smoke condensate in acetone (1:1). The treatment was 
applied every second day including the weekends. At 35 weeks TSC 
treatment was stopped, and the mice were kept for further 10 weeks to 
observe changes in tumour size and relationship to LDC numbers. Six 
mice from both groups, control and test were killed by cervical dislocation 
at 3 days, 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 45 weeks. Skin sections were 
stained with haematoxylin and eosin and immunoperoxidase anti-Ia 
staining to visualise and count LDC in the prepared epidermal sheets. 
2.19 Preparation of epidermal sheets 
The method of Baker et al., (1983) was used to prepare epidermal sheets. 
The dorsal skin was shaved using electrical clippers and then depilated 
with a thioglycollate cream (Veet, Reckitt and Colman, UK). Adhesive 
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cellophane tape was then applied to the dry skin, the skin was removed 
and incubated at 37°C for 3 hours in tetra-sodium ethylenediamine 
tetraacetic acid solution (0.38 g EDTA in 50 ml PBS, pH 7.4; Serva, 11282). 
Using fine forceps the epidermis was separated from the dermis and 
stained with anti-Ia to demonstrate epidermal LDC. 
2.20 Inununoperoxidase anti-Ia staining of LDC in epidermal sheets 
Epidermal sheets were fixed in acetone at room temperature for 20-30 
minutes and then incubated overnight at 4°C with mouse monoclonal 
anti-Ia (MKD6). After washing the sheets in PBS for 20-30 minutes, they 
were incubated at room temperature for 2 hours with horse peroxidase-
conjugated rabbit anti-mouse immunoglobulin (HRPO-anti-Ig, 
Dakopatts, Denmark), diluted 1:80 in PBS, pH 7.4. Epidermal sheets were 
washed again in PBS for 30 minutes and incubated for 10 minutes with 
diaminobenzidine (DAB; Sigma; 0.5 mg/ml of PBS containing 0.02% 
H202, 7.4). The epidermal sheets were mounted in glycerol gelatin after 
washing in tap water. 
The Ia+ LDC were identified in the epidermal sheets as brown dendritic 
cells with various numbers of dendrites extending from the cell body. 
2.21 Immunoperoxidase anti-Ia staining of LDC in tumour sections 
Eight gm frozen sections of skin tumours were fixed in acetone for 20-30 
minutes, washed three times in PBS over 20-30 minutes, incubated with 
anti-Ia for 30 minutes at room temperature, washed in PBS as before and 
incubated with HRPO-anti-Ig for 30 minutes at room temperature. 
Sections were again washed in PBS before incubation with DAB at room 
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temperature (Ruby et al., 1989) for 10 minutes and counterstained in 
Mayers haematoxylin after washing in running tap water for 5 minutes. 
Finally section were mounted in glycerol gelatin. 
2.22 Enumeration of Ia positive LDC in epidermal sheets 
LDC were assessed as the number of Ia±  LDC/mm2 and the mean 
standard deviation was calculated per group of mice. 
2.23 Histology of murine skin 
Skin sections of mouse tumours and normal control skin were processed 
for routine haematoxylin & eosin staining. 
2.24 Contact hypersensitivity assessment 
The function of LDC was assessed by inducing a contact hypersensitivity 
reaction at the 2nd and the 6th weeks, after commencing treatment with 
TSC. This was performed by applying TSC in a 1:1 solution of 
acetone:olive oil and the control mice acetone:olive oil alone. The dorsal 
skin of the test mice was initially sensitised with 10 ill of a 1% solution of 
2,4,6-trinitrochlorobenzene (TNCP; Tokyo-Kasei, FCV61). The right ear of 
both control and test mice was challenged with 10 pi of a 1% TNCB 
solution 5 days after sensitisation. The thickness of the right and the left 
(unchallenged) ear was measured 24 and 48 hours later using an 
engineers spring loaded micrometer. The percent increase in ear 
swelling was calculated according to the following formula: 
General Materials and Methods 	 Page 54 Chapter 2 
thickness of right ear - thickness of left ear  °/0 increase 	 X100 
thickness of left ear 
The average percent increase and the standard deviation was calculated 
for each group of mice. 
2.25 Blood specimens 
Peripheral blood mononuclear cells (PBMC) were isolated from 20 ml of 
venous blood from each of 100 normal subjects. The heparinised blood was 
diluted 1:1 with PBS and layered over 9 ml of Histopaque-1077 (Sigma, 
USA) in a 30 ml centrifuge tube. After centrifugation at 2000 rpm (600g) for 
30 minutes, PBMC were harvested from the upper interface and washed 
for 10 minutes in PBS at 1500 rpm (350g) and then twice at 1000 rpm (150g). 
The mononuclear cells were resuspended in 1 ml of PBS and counted 
using a Neubauer improved haemocytometer. Cell viability was assessed 
on the bases of the ability of live cells to exclude eosin Y dye. 
2.26 Cytospins 
PBMC were diluted in PBS-FCS (PBS containing 10% fetal calf serum-
CSL, Melbourne) to a final concentration of 3 X 10 5 cells /ml. Two 
hundred Ill of the cell suspension was centrifuged at 1100 rpm (100g) for 2 
minutes. The cells on the slide were marked with a diamond pencil and 
dried overnight before staining. 
2.27 Buffy coats 
The anticoagulated blood was centrifuged at 1600 rpm (400g) for 15 
minutes in Westergren tubes. The buffy coat layer containing WBC was 
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harvested with a pasteur pipette. A drop of the cell suspension was 
smeared on slide with the edge of another slide. 
2.28 Metrizamide enrichment of LDC from the peripheral blood 
The method of Knight et al., (1986) was adopted to isolate dendritic cells 
from peripheral blood. Blood was diluted 1:1 with PBS and 30 ml layered 
over 20 ml Ficoll/Paque (Pharmacia, Code No. 17-0840-02) and 
centrifuged for 30 minutes at 750 g. Peripheral blood mononuclear cells 
(PBMC) were collected from the interface and washed with PBS for 5 
minutes. Thirty ml of PBS containing the PBMC was layered over 5-10 ml 
14.5% metrizamide (Nycomed, 2344) added to 100 ml RPM1 and then 
centrifuged for 30 minutes at 750 g. Dendritic cells were collected from the 
interface washed with PBS, and cytospins were prepared for 
immunocytochemical staining. 
2.29 Immunocytochemical staining of blood cells 
Buffy coats and cytospins of the PBMC and metrizamide enriched LDC 
were fixed for 90 seconds in a mixture of acetone (190 ml), methanol (190 
ml) and 40% formaldehyde (20 ml). Blood cells were stained using rabbit 
antibody to bovine S100 protein (Dakopatts, Denmark, Z 311) using the 
protocol previously described (Section 2.4). Monoclonal mouse anti-
human T-cell- CD3 (Pan T cell, Becton Dickinson, USA; Lot No. 437), CD4 
(helper/inducer T cell, combination of anti-Leu 3a + anti-Leu 3b, Becton 
Dickinson, USA; N0511), CD8 (suppressor/cytotoxic T cell, anti-Leu 2a, 
Becton Dickinson, USA; M1106), anti-human monocytes- CD14 
(monocytes, MY4, Coulter Immunobiology, USA, 6390124), anti-leucocyte 
common antigen, (HLe-1, CD45, Becton Dickinson, USA; NC048) and 
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CD1a (LDC and thymocytes, Becton Dickinson, USA; 437) were used to 
characterise blood cells. S100+ cells, lymphocytes and monocytes numbers 
were expressed as the number of cells x10 9 per litre of blood. 
2.30 Double immunocytochemical labelling of PBMC and DC 
Cytospins were fixed in acetone:methanol:formaldehyde for 90 seconds. 
To suppress endogenous peroxidase, the cytospins were incubated in 
0.05M Tris-HC1 containing 0.3% H202. Cytospins were then incubated 
with antibody to the S100 protein, followed by incubation with peroxidase 
conjugated swine anti-rabbit, and then with peroxidase anti-peroxidase. 
At this stage, cytospins were incubated with the diaminobenzidine (DAB, 
Sigma- D5637) substrate to localise the S100 protein. The second surface 
antigen was demonstrated using an indirect alkaline phosphatase 
technique. Cytospins were incubated with mouse anti-human surface 
antibody (CD1, CD3, CD4, CD8, CD14, CD45) and then incubated with 
alkaline phosphatase conjugated sheep anti-mouse antibody. The 
reaction colour for the second antigen was developed after incubating the 
cytospins with Fast Blue substrate solution (naphthol; N,N dimethyl 
formamide; Tris buffer; levamisol; Fast blue TR salt). Slides were covered 
with crystal mount and mounted in Eukitt. 
2.31 Phagocytic assay of the S100 positive cells in the peripheral blood 
Polystyrene latex beads (diameter 1.16 gm; Polysciences Inc., USA) were 
diluted, 2 drops in 10 ml PBS. Ten gl of the latex beads, 100 gl of PBMC at 
a concentration of 1 X 10 7 /m1 and 10 gl of foetal calf serum (FCS) were 
added to a small tube, vortexed gently and incubated at 37°C for 30 
minutes. This was centrifuged at 2000 rpm (600g) for 5 minutes and the 
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supernatant discarded. The cells were washed twice in PBS-azide (PBS 
containing 0.1% sodium azide, BDH, England) at 600g for 5 minutes. The 
cells were then resuspended at 3 X 105 /ml, cytospins were prepared and 
stained for S100 protein. 
2.32 Adherent and non-adherent PBMC 
Peripheral blood mononuclear cells (PBMC) were resuspended in RPMI 
(Flow Laboratories, Scotland) supplemented with 5% FCS solution 
(RPMI-5%), at a concentration of 2 X 107 cells/ml. One ml of this 
suspension was placed in a 35 mm petri dish and incubated for 1 hour at 
37°C in 5% CO2 in air in a humidified incubator. After 1 hour the dish 
was washed gently 5 times with pre-warmed (37°C) PBS to remove the 
non-adherent cell fraction. These cells were first washed gently from the 
dish using pre-warmed PBS, cells were counted and the prepared 
cytospins were stained for S100 protein. To collect the adherent cells, 2 ml 
of RPMI-10% FCS containing 0.67% EDTA was added to the petri dish and 
incubated at 4 °C for 10 minutes. The dish was washed by flushing RPMI-
10% FCS-0.67% EDTA over the surface with a pasteur pipette. The 
adherent cells were washed using PBS solution, cytospins were prepared 
and stained for S100 protein. 
2.33 Olympus CUE-2 image analysis system 
Using the image analysis system (Olympus CUE-2, versuion 4), the 
perimeter, volume, width and length of the S100+ cells (n=75 cells) in 
peripheral blood was recorded and compared with that of the CD3+ 
lymphocytes (n=55 cells) and CD14+ monocytes (n=12 cells). The 
measured standard deviations were calculated. 
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2.34 Micrometer eyepiece 
Using the micrometer eyepiece (Olympus OSM-D4), the perimeter, 
diameter and volume of S100+ cells (n= 200) in peripheral blood was 
recorded and compared with that of the CD3+ lymphocytes (n= 401 cells) 
and CD14+ monocytes (n= 399 cells). The means and standard 
deviations were calculated. 
2.35 Immunoelectron microscopy examination of PBMC S100÷ cells 
The method described by Takahashi et al., (1981) was used for the 
immunoelectron microscopy examination of the S100+ cells in blood. 
PBMC were fixed for 10 minutes in 2% paraformaldehyde containing 
0.25% glutaraldehyde (Serva, Germany) solution, then washed in PBS. 
The cells were incubated with rabbit anti-cow S100 (1/300) for 2 hours. 
After washing in PBS, cells were incubated with peroxidase conjugated 
swine anti-rabbit for 1 hour. After washing in PBS, cells were incubated 
for 30 minutes with DAB (20 mg in 100 ml Tris-HC1). Cells were washed 
and incubated for 6 minutes in DAB solution containing H202. The cells 
fixedin 1% 0s04 for 30 minutes and processed for routine electron 
microscopy. The negative control was treated as above except normal 
rabbit serum was substiuted for the primary anti-S100 antibody. 
2.36 Specimens of normal spleens and bone marrow 
Three 3-4 gm sections were cut (S100, control and H&E staining) from 
each paraffin blocks of 8 normal bone marrow and 10 normal spleen were 
obtained from the files of the Department of Anatomical Pathology, 
Royal Hobart Hospital. 
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2.37 Statistics 
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Statistics were performed using non-parametric Wilcoxon test, 
Bonferroni multiple-comparison test, Student's two-tailed, unpaired t-
test and Scheffe's test. Logarithmic values were used when the range of 
values was not normally distributed. 
Foot note 
Selection of immunohistochemical staining to identify Langerhans 
dendritic cells in human and murine material 
Selection of the type of immunohistochemical staining for specimens 
was based on the following:. 
1. For human material S100 was used to identify Langerhans cells since 
formalin fixed material can be examined by this technique. 
2. For murine experiments, as antibodies to S100 do not stain dendritic cells 
in this species, immunoperoxidase anti-Ia staining was used. 
3. For electron microscopy of murine DC, the ZIO procedure allowed 
visualisation of Langerhans dendritic cells in mouse lungs. Anti-Ia could 
not be used for this. 
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CHAPTER 3 
LANGERHANS DENDRITIC CELLS AND HUMAN LUNG TUMOURS 
3.1 INTRODUCTION 
Langerhans dendritic cells were first reported in human tumours (cervix) 
by Younes et al., (1968). Since then LDC have been reported in other 
tumours; bronchioalveolar tumour of lung (Basset et al., 1974), laryngeal 
carcinoma (Schenk, 1980; Rucci et al., 1991), pleomorphic adenoma of 
salivary gland (David and Buchner, 1980), skin tumours (Gatter et al., 
1983; McArdle et al. 1986), lung (Furukawa, et al., 1981, 1984; Fox et al., 
1989), breast and thymoma (Hammar et al., 1986), oesophageal (Matsuda 
et al., 1990), gastric tumours (Tsujitani et al., 1987), papillary thyroid 
carcinoma (Schroder et al., 1988), colorectal carcinoma (Ambe et al., 1989), 
nasopharyngeal carcinoma (Nomori et al., 1986), prostatic carcinoma 
(Bigotti, et al., 1991) and transitional cell carcinoma of the urinary bladder 
(Inoue et al., 1994). S100 protein was used as a marker for LDC in most of 
the above reports. Hammar et al, (1986) reported Birbeck granules in all 
the S100+ dendritic cells in lung bronchioalveolar carcinoma and 
adenocarcinoma, nasopharyngeal cancer, ovarian malignant tumours, 
breast carcinomas, thymoma and in malignant histiocytosis. 
Basset and colleagues (1974) first reported dendritic cells which were 
similar in ultrastructural features to LDC in the bronchioalveolar lavage 
fluid of patients with primary alveolar carcinoma of the lung. Since then 
Kawanami et al., (1981; 1987) and Richard etal., (1987) have described LDC 
with characteristic features in normal human lung. Sertl et al., (1986) and 
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Holt and Schon-Hegrad, (1988) have also reported MHC-class II positive 
dendritic cells in the bronchial epithelium and in the alveolar septum of 
normal lungs of mice, human and rats. 
In human lung tumours, there are conflicting reports on LDC and 
prognosis. While Furukawa et al. (1981; 1984) associated longer survival 
with marked infiltration of LDC in stage la adenocarcinomas of the lung, 
Fox et al., (1989) suggested that a high number of LDC in lung tumours 
was associated with a worse prognosis. Fox and co-workers (1989) reported 
the presence of CD1 positive LDC mainly in squamous cell carcinoma and 
adenocarcinoma of the lung, while Hammar et al., (1986) reported that 
only 17% of squamous cell carcinomas contain LDC. 
None of the above reports investigated the relationship between LDC, 
cellular subtype of tumour, tumour differentiation, tumour infiltrating 
lymphocytes (TIL) and patient survival. 
The aims of this study were to: 
1. Investigate LDC in normal mucosa of trachea, bronchi, bronchioles, 
lung and in normal trachio-bronchial lymph nodes regional to normal 
lung. 
2. Assess the density of pulmonary LDC in various cellular subtypes of 
human lung cancer and its relationship to tumour differentiation. 
3. Study the relationship between the density of LDC and tumour 
infiltrating lymphocytes. 
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4. Examine the relationship between the density of LDC in lymph nodes 
regional to lung tumours and the immunological activity of these nodes. 
5. Investigate the effect of LDC in lung tumours on the survival of 
patients. 
3.2 MATERIALS AND METHODS 
3.2.1 Specimens for human lung tumours 
130 lung tumours, 100 regional lymph nodes, 13 normal lung and 7 
normal bronchial lymph nodes were used in this study, as described in 
Section 2.1. 
3.2.2 Clinical data 
All clinical data were obtained from the files of the Medical Records 
Department, Royal Hobart Hospital (Section 2.2). 
3.2.3 Preparation of the human tracheal and bronchial mucosal sheets 
Four segments, 2 x 1 cm each of unfixed trachea and major bronchus from 
two autopsies were to prepare the mucosal sheets (Section 2.3). The whole 
tracheal and bronchial mucosa was tangentially and serially sectioned at 3 
micron. A total of 159 sections was prepared for S100 and routine H&E 
staining. 
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3.2.4 Immunohistochemical staining of Langerhans dendritic cells in human 
materials 
Rabbit antibody to bovine S100 protein (Dakopatts, Denmark, Z 311) was used 
to identify the Langerhans dendritic cells in paraffin sections as described in 
Section 2.4. 
3.2.5 Identification and counting of the S100 positive Langerhans dendritic cells 
S100+ Langerhans dendritic cells (LDC) were counted in four high power 
fields (HPF, X 400) randomly selected for each section and as previously 
desribed in Section 2.5. The density of TIL was evaluated as mild, moderate 
and marked. Enumeration of S100+ DC in lymph nodes was performed 
following the same methodology applied to lung sections. 
3.3 RESULTS 
3.3.1 Density of S100 positive dendritic cells in normal tracheal, bronchial 
mucosa and lung 
S100+ LDC showing red cytoplasm, indented nucleus and dendritic cell 
membrane (Fig. 3.1) were rarely found in the intra epithelial component 
of the bronchial tree (Fig. 3.2). They were commonly seen in the lamina 
propria of the tracheal and bronchial mucosa close to the perivascular 
lymphoid tissue. An average of two S100+ LDC were present in both 
tracheal and bronchial sections in every 3 HPF. LDC were observed in the 
alveolar septum of all sections of normal lung, but in various densities. 
Occasionally LDC were found in the alveolar spaces (Fig. 3.3). 
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Figure 3.1 S100 positive Langerhans dendritic cell (LDC) shows red 
cytoplasm and indented nucleus 
(S100 Immunohistochemical Technique X 400) 
Figure 3.2 S100 positive Langerhans dendriticells in the  bronchial epithelium 
and related lymphoid tissue 
(S100 Immunohistochemical Technique X 250) 
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The mean of S100+ LDC count in four HPF was 6 ± 4.9 cells in normal 
lung. 
3.3.2 Density of S100+ Langerhans dendritic cells in lung tumours 
S100+ LDC were found in direct contact with TIL and tumour cells in all 
varieties of lung tumours, but in various densities. Bronchioalveolar 
(Fig. 3.4), well and moderately differentiated squamous cell carcinomas 
(Fig. 3.5) showed the highest density of these cells within tumours. Small 
cell lung cancer, mucous producing adenocarcinomas and poorly 
differentiated squamous cell carcinomas contained the lowest number of 
5100+ LDC. The number of S100+ LDC related not only to tumour cell 
type, but also to tumour differentiation. While well and moderately 
differentiated squamous cell carcinomas contained 42.6 ± 21.2 LDC/HPF 
and 37.4 ± 10.8 LDC/HPF respectively, poorly differentiated squamous cell 
carcinoma contained only 13.2 ± 0.8 LDC/HPF. Table 3.1 summarises 
these results. 
3.3.3 Langerhans dendritic cell morphology in lung tumours 
The number of dendrites extending from LDC in relation to the 
histological variety of the lung tumours was examined. LDC were 
divided into two groups according to the number of dendrites extending 
from the cell body; LDC with more than 3 dendrites; LDC with less than 3 
dendrites. LDC with more than three dendrites were found in 77.8% of 
bronchioalveolar carcinomas, 67.4% of well and moderately differentiated 
squamous cell carcinomas, in 34.7% of all varieties of adenocarcinomas 
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Figure 3.3 S100 positive Langerhans dendritic cell in the alveolar spaces. 
Alveolar macrophages (arrow) are negative for S100 protein 
(S100 Immunohistochemical Technique X 400) 
Figure 3.4 S100 positive Langerhans dendritic cells in bronchioalveolar 
carcinoma (S100 Immunohistochemical Technique X 250) 
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Figure 3.5 S100 positive Langerhans cells in well differentiated squamous 
cell carcinoma (S100 Immunohistochemical Technique X 100) 
Figure 3.6 Direct contact between S100 positive Langerhans dendritic cells 
and adenocarcinoma tumour cells 
(S100 Irnmunohistochemical Technique X 400) 
Table 3.1 	S100+ LDC in various histological types of lung tumours 
Histology No. of cases Mean of S100+ LDC 
1. Bronchioalveolar 16 57.8 ± 26.5 
2. Well differentiated 
squamous cell 
carcinoma 
16 42.6 ± 21.2 
3. Moderately differentiated 
squamous cell carcinoma 
14 37.4 ± 10.8 
4. Poorly differentiated 
squamous cell carcinoma 
38 13.2 ± 0.8 
5. Nonciliated & Clara 
cell adenocarcinomas 
18 25.1 ± 11.4 
6. Ciliated & mucous 
producing adenocarcinomas 
14 12.4 ± 5.7 
7. Adenosquamous 4 24.25 ± 8.2 
8. Small cell lung cancer 10 4.7 ± 3.8 
Normal lung 13 6 ± 4.85 
Using the non-parametric, Wilcoxon test, 1 versus 4, 5, 6 and 8 was 
significantly different, P <0.0005. 2 versus 4, 5, 6 and 8 also significantly 
different, P <0.0001, 0.0125, 0.0001 and 0.0003 respectively. 
Langerhans dendriti cells and human lung tumors 	 Page 65 Chapter 3 
and in 32.6% of poorly differentiated squamous cell carcinomas. Dendritic 
cells with less than 3 dendrites were more commonly seen in the 
majority of small cell lung cancer and poorly differentiated squamous cell 
carcinoma. 
3.3.4 Contact between 8100+ Langerhans dendritic cells and lung tumour 
cells 
Direct contact between LDC and tumour cells (Fig. 3.6) was consistently 
present in all bronchioalveolar carcinomas, in all well and moderately 
differentiated squamous cell carcinomas and in 81.3% of all varieties of 
adenocarcinomas. Contact between LDC and tumour cells was rarely 
observed in poorly differentiated squamous cell carcinomas and. small 
cell lung cancers, although LDC were occasionally detected in these 
lesions. 
3.3.5 Contact between S100+ Langerhans dendritic cells and TIL in lung 
tumours 
Direct contact between LDC and TIL were found in all varieties of lung 
tumours (Fig. 3.7). In general there was a proportional relationship 
between the number of LDC and the density of TIL in and around various 
lung tumours. The density of TIL was marked in bronchioalveolar, and 
in both well and moderately differentiated squamous cell carcinomas. 
The density of TIL was moderate in other varieties of adenocarcinomas 
and mild in both poorly differentiated squamous cell and small cell lung 
cancer. 
Figure 3.7 Contact between S100 positive dendritic cells and TIL 
(S100 Immunohistochemical Technique X 400) 
Figure 3.8 S100 positive dendritic cells in the T-zone of lymph node with 
active germinal centre 
(S100 Immunohistochemical Technique X 250) 
Table 3.2 	S100+ LDC in normal regional lymph nodes 
Histology of LN No. Mean of S100+ LDC/HPF SD 
Lymphocytic predominance 27 69.3 28.9 (a) 
Active germinal centre 46 69.7 28.4 (a) 
With metastasis 16 69.9 43.9 (a) 
Unstimulated 33 24.8 13.4 (b) 
Normal lymph nodes 7 35.0 10.3 (b) 
Based on the Bonferroni multiple-comparison test, the number of S100+ 
LDC in lymph nodes with the same letter were not significantly different 
at the 5% level, while both groups (A) and (B) were significantly 
different. 
Table 3.3 	Lung tumours with the highest and lowest number of 
S100+ LDC 
Highest No. of LDC 
1. No. of cases 	27 
2. 5100+ LDC/HPF 	69.8 ± 19.4 
Lowest No. of LDC 
41 
6.55 ± 3.5 
3. Density of TIL Marked Scanty 
4. Average tumours 3.5 ± 1.4* 4.7 ± 3.3* 
size (cm) 
5. LN Metastasis 33.3 % 34.3 `)/0 
6. M:F Ratio 3:1 3:1 
7. Cigarettes/day 28.7 ± 15.4 27.6 ± 17.2 
8. Smoking years 37.2 ± 10.3 36.3 ± 13.3 
9. No. of Dead 8 (29.6%) 28 (68.6 %) 
10. Survival (Months) 68.5 ± 32.9 8.3 ± 7.7 
since diagnosis 
11. Histological DSCC 59.3 % PDSCC 55.2 ()/0 
typing BA 	33.3 l'/0 ADENO 31.0 % 
ADENO 7.4 % SCLC 13.8 % 
DSCC = well and moderately differentiated squamous cell carcinoma 
PDSCC = poorly differentiated squamous cell carcinoma 
BA = bronchioalveolar carcinoma 
ADENO = adenocarcinoma 
SCLC = small cell lung carcinoma 
* Maximum diameter of tumour 
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3.3.6 Central tumour necrosis, S100+ Langerhans dendritic cell number 
and TIL density in lung tumours 
Central tumour necrosis was observed in lung tumours with a high 
number of LDC and marked density of TIL. Marked central tumour 
necrosis was found in 70% of well and moderately differentiated 
squamous cell carcinomas as well as in 30% of the bronchioalveolar 
carcinomas. 
3.3.7 Density of S100+ Langerhans dendritic cells in lymph nodes regional 
to lung tumours 
Based on the histological evidence of immunological activity (Kitaichi et 
1981), lymph nodes regional to lung tumours examined in this study 
were divided into three groups. Firstly lymph nodes with lymphocytic 
predominance, secondly lymph nodes with active germinal centre and 
thirdly unstimulated lymph nodes. S100+ LDC were found in the 
paracortical T lymphocyte area (Fig. 3.8). The density of S100+ LDC in 
various groups of lymph nodes are shown in Table 3.2. 
The density of S100+ LDC was high in lymph nodes showing lymphocytic 
predominance and in lymph nodes with active germinal centres. The 
unstimulated lymph nodes showed the lowest density of these LDC. The 
density of the S100+ LDC in bronchial lymph nodes regional to normal 
lung was higher than that of the unstimulated lymph nodes. 
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The dendritic nature of LDC recorded in all varieties of lymph nodes was 
examined. 93% of LDC in lymph nodes with lymphocytic predominance 
(n= 25/27) showed more than three dendrites, compared to 89% in lymph 
nodes with active germinal centres (n= 41/46) and to less than 50% in 
unstimulated lymph nodes (n= 16/33). The number of dendrites reflected 
the state of immunological activity of these lymph nodes. 
3.3.8 S100+ Langerhans dendritic cells and patients survival with lung 
cancer 
When patients were divided into those with the highest number of 
S100+ LDC and a second group with the lowest number of LDC (Table 
3.3), a number of comparisons was noted. The density of TIL was marked 
in tumours with the highest number of LDC and was scanty in tumours 
with the lowest number of LDC. The overall survival of patients in the 
former group was almost 8 fold that of the second group. 92.6% of the 
cases in the better surviving group were bronchioalveolar, well and 
moderately differentiated squamous cell carcinomas, while small cell 
lung cancer, poorly differentiated squamous cell and other varieties of 
adenocarcinomas formed all cases in the second group. 
The male:female ratio in the two groups was 3:1, patients in both groups 
smoked an average of 28 cigarettes a day for an average of 37 years. 
Neither the number of cigarettes a day nor the number of years the 
patients smoked was related to the tumour type nor to the density of LDC 
in these tumours. There was no difference in tumour size or in the 
incidence of lymph node metastases in both groups. 
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3.4 Discussion 
This study demonstrates that in lung tumours the density of antigen 
presenting S100+ dendritic cells varies according to cellular subtype and 
differentiation of lung carcinomas. Bronchioalveolar, well and 
moderately differentiated squamous cell carcinomas contain the highest 
number of dendritic cells. The density of TIL is in direct proportional 
relationship with the number of S100+ dendritic cells. Patients with high 
number of dendritic cells in their lung tumours e.g. bronchioalveolar, 
well and moderately differentiated squamous cell carcinomas survived 
longer than patients with a low number of dendritic cells e.g. poorly 
differentiated squamous and small cell lung cancer, i.e. 68.5 ± 32.9 months 
compared to 8.3 ± 7.7 months. 
Si 00+ LDC with more than 3 dendrites were the majority in 
bronchioalveolar, well, and moderately differentiated squamous cell 
carcinomas of the lung and in lymph nodes with lymphocytic 
predominance and active germinal centres. These findings favour the 
hypothesis that the increase in number of LDC dendrites in certain 
tumours may reflect an active immunological state, as it was observed, 
the increase in the number of fully dendritic LDC in lung 
bronchioalveolar, well and moderately differentiated squamous cell 
carcinomas was associated with marked TIL and tumour necrosis and this 
enhanced patients survival. 
Contact between S100+ LDC, tumours cells and T-lymphocytes was 
investigated in the varieties of lung tumours and in lymph nodes. Direct 
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contact between these antigen presenting cells and tumour cells was 
observed in all bronchioalveolar, well differentiated, moderately 
differentiated carcinomas and in the majority of adenocarcinomas. Direct 
contact was also observed between T-lymphocytes and LDC in lung 
tumours and in the T-zone of lymph nodes. This contact may reflect the 
immune interaction between LDC, tumour cells and T-lymphocytes. This 
has also been reported in human skin tumours (Gatter et al., 1983). 
Central tumour necrosis in the investigated lung neoplasms was related 
to high density of S100+ LDC and marked infiltration of TIL. This was 
observed in well, moderately differentiated squamous cell and in 
bronchioalveolar carcinomas. This may result from the effect of 
sensitized T-lymphocytes acting specifically against the target tumour 
cells (Stingl et al., 1987; Hart and McKenzie, 1990). 
The current study shows the density of dendritic cells in lymph nodes 
regional to lung tumours is directly related to the immunohistological 
activity of these lymph nodes. Lymph nodes showing active germinal 
centres or lymphocytic predominance contained higher numbers of 
S100+ dendritic cells than the unstimulated nodes. 
Kitaichi et al., (1981) reported that the 3 years survival of patients in stage 
2 and 3 of lung cancer in which the regional lymph nodes showed 
lymphocytic predominance or active germinal centres was better than 
patients with unstimulated lymph nodes. 
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Furukawa et al., (1981; 1984) also reported that patients with a marked 
number of S100+ LDC in and around their lung adenocarcinomas 
survived longer than patients without or with minimal infiltration of 
these cells. Temeck, et al., (1984) found 65.3% of patients with carcinomas 
of the lung alive for 10 years after diagnosis and treatment had 
epidermoid carcinomas. Patients with adenocarcinoma represented 33%, 
while there was only one patient with small cell lung cancer and one 
patient with large cell lung cancer alive. A similar study by Kern et al., 
(1986) reported 46.4% of patients with carcinomas of the lung who 
survived an average of 15.5 years after diagnosis and treatment had 
epidermoid carcinomas, 25.5% adenocarcinomas and 11.8% 
bronchioalveolar carcinomas. In a recent study of 9090 patients with 
carcinomas of the lung, Watkin et al. (1981) reported a longer survival for 
squamous cell carcinomas than small cell lung cancer._ A relationship 
between the increased density of dendritic cells in other human tumours 
and longer patient survival has been reported during the last thirteen 
years e.g. nasopharyngeal tumours (Nomori et al., 1986), gastric tumours 
(Tsujitani et al., 1987), papillary thyroid carcinomas (Schroder et al., 1988), 
colorectal adenocarcinomas (Ambe et al., 1989), squamous cell carcinomas 
of the esophagus (Matsuda, 1990), cervical carcinoma (Xie, 1990), prostatic 
carcinoma (Bigotti et al., 1991), laryngeal carcinoma (Rucci et al., 1991) and 
transitional cell carcinoma of the urinary bladder (Inoue et al., 1994). 
This study also demonstrated S100+ Langerhans dendritic cells are 
present in normal trachea, bronchus, normal lung parenchyma and 
normal bronchial lymph nodes. These dendritic cells were more 
commonly observed in the alveolar septum of normal lung but 
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occasionally were seen in the normal tracheal or bronchial mucosa. These 
observations are in agreement with Sertl et al., (1986), Richard et al., 
(1987) and Holt and Schon-Hegrad, (1987). 
The primary function of Langerhans dendritic cells is the presentation of 
antigen to T-lymphocytes in the regional lymph nodes (Silberberg et al., 
1976; Stingl et al., 1987). The selective increase in the number of LDC in 
bronchioalveolar, well and moderately differentiated squamous cell 
carcinomas may be related to specific tumour associated antigen (Sertl et 
al., 1986; Hart and McKenzie, 1990). Alternatively tumours may release 
factors which are chemotactic for dendritic cells, hence drawing them into 
the tumour environment (Halliday et al., 1992). 
In conclusion this study has clearly demonstrated that the density of 
S100+ LDC in lung tumours was related to cellular subtype and 
differentiation of tumour cells. Bronchioalveolar, well and moderately 
differentiated squamous cell carcinomas attracted the highest number of 
LDC, and this was associated with marked density of TIL and better 
survival. The mechanism by which the increased number of antigen 
presenting cells in tumours warrants detailed investigation. 
3.5 SUMMARY 
Antigen presenting S100+ Langerhans dendritic cells were quantified in 
normal trachea, lung, bronchial lymph nodes, 130 lung tumours and in 
100 lymph nodes regional to tumour. Dendritic cells were rarely seen as 
intraepithelial components of the normal bronchial mucosa, but more 
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commonly observed in the perivascular lymphoid tissue of the submucosa 
and in the alveolar septum of normal lung parenchyma (6 ± 4.85 cells/HPF). 
The density of these dendritic cells was marked in histologically normal 
bronchial lymph nodes. Bronchioalveolar, well and moderately differentiated 
squamous cell carcinomas contained the highest density of S100+ dendritic 
cells, while small cell lung cancer and poorly differentiated squamous cell 
carcinoma showed the lowest density. Regional lymph nodes to lung 
tumours with lymphocytic predominance and active germinal centres 
showed the highest density of dendritic cells, while unstimulated lymph 
nodes contained the lowest number of S100+ dendritic cells. Tumour 
infiltrating lymphocytes were marked in and around lung tumours with the 
higher density of dendritic cells. Survival of patients whose tumours contain 
high density of S100+ dendritic cells was more favourable compared to 
tumours with low density of these cells. It is concluded that the density of the 
antigen presenting S100+ dendritic cells in lung tumours was related to 
subtype and tumour differentiation. High dendritic cell densities was 
associated with longer patient survival. 
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CHAPTER 4 
TOBACCO SMOKE INHALATION, LANGERHANS DENDRITIC CELLS, 
AND LUNG LESIONS 
4.1 INTRODUCTION 
Histopathological changes in the lungs induced by cigarette smoking 
have been documented in humans (The Health Consequences of 
Smoking, Cancer, Report of the Surgeon General, 1982, U.S. Department 
of Health and Human Services; Auerbach et al., 1957) and experimental 
animals (Leuchtenberger et al., 1961; Wynder et al., 1961). Auerbach et al., 
(1957) reported the tobacco smoke induced histologic changes in human 
trachiobronchial epithelium. These included basal cell hyperplasia, 
stratification and squamous cell metaplasia of the bronchial epithelium. 
The epithelial changes were more frequent in patients with lung cancer 
than in cancer free smokers. 
The carcinogenic effects of the tobacco smoke on the lungs of laboratory 
animals have been investigated by many workers (Wynder, 1961 and 
Leuchtenberger, 1961). These studies have concentrated on tobacco smoke 
induced precancerous changes and tumour development. In mice, the 
tobacco smoke induced pulmonary changes described include bronchitis, 
atypical bronchial epithelial proliferation and occasional adenomatous 
lung tumours (Leuchtenberger, 1961). 
In humans, Basset and Turiaf, (1965) together with Nezelof et al., (1973) 
identified the ultrastructure of cells consistent with that of LDC isolated 
from bronchioalveolar lavage fluid of patients with pulmonary 
histiocytosis X. 
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Casolaro, (1988), reported an increase in the number of CD1+ dendritic 
cells in the bronchioalveolar lavage fluid of smokers, while Soler et al., 
(1989), described an increase in both T6+ LDC and M241+ dendritic cells 
in smokers lung. 
A relationship between tobacco smoke inhalation and pulmonary 
interstitial granulomas has been reported in humans- 90% of patients 
with pulmonary histiocytosis X were smokers (Hance et al., 1988). An 
excellent review of LDC granulomatosis (histiocytosis X) was published 
by Hance et al., (1988). The three clinical syndromes, Letterer-Siwe 
disease, Hand-Schuller-Christian syndrome and eosinophilic granuloma 
were grouped and called histiocytosis X, based on the similarities of the 
lesions (Faber, 1941; Lichtenstein, 1953). Pulmonary Langerhans cell 
granulomatosis (pulmonary histiocytosis X) is slightly different from the 
other varieties of histiocytosis X. The former is commonly seen in young 
male adults (Smith et al., 1974), but not in children as are the other forms 
of histiocytosis X. 
Katzenstein and Askin, (1990) described detailed histologic features of 
pulmonary eosinophilic granuloma which included bronchiocentric, 
patchy and nodular lesions due to interstitial infiltration with a mixture 
of histiocyte-like cells and variable number of eosinophils, plasma cells 
and lymphocytes. The nodular interstitial lesions may appear star-shaped 
due to infiltration and fibrosis along the alveolar septum. A DIP-like 
reaction (desquamative interstitial pneumonia), with accumulation of 
alveolar macrophages in the surrounding alveolar spaces may be seen 
but is not specific for pulmonary LDC granulomatosis. Bronchiolitis is 
frequently observed and spontaneous healing of pulmonary LDC 
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granulomatosis may take place leaving a starfish-shaped scar, 
(Katzenstein and Askin, 1990). 
The diagnostic cell in this lesion is the LDC or histiocytosis-X cell. It is 
large cell with an ill-defined border, abundant eosinophilic cytoplasm, 
and a folded or indented nucleus with an inconspicuous nucleolus. 
There are many of these cells in active lesions, but become rare in older 
lesions with fibrosis (Katzenstein and Askin, 1990). Birbeck granules in 
both epidermal LDC and histiocytosis X cells show the same affinity for 
zinc-iodide-osmium (ZIO) staining (Wolf, 1972), both cells are S100 
protein positive (Flint et al., 1986, 1987) and OKT6 positive (Soler et al., 
1989). The ultrastructural features of histiocytosis X cell are consistent 
with that of LDC (Wolf K., 1972 and Flint, et al., 1986 & 1987). However 
the BG in the histiocytosis X cell appear to be more often attached to the 
cell membrane than those in epidermal LDC. 
The aim of this study was to investigate experimentally the effect of 
tobacco smoke on pulmonary LDC in mice. The associated pulmonary 
lesions which developed are also described. 
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
BALB/c female mice 6-8 weeks old were obtained from the central 
Animal House at the University of Tasmania. The 108 mice used for the 
tobacco smoke inhalation experiments were divided into two groups, 
experimental and controls, each of 54 mice. Control mice were kept in 
groups of 12, while the experimental mice were kept in groups of 6 Mice. 
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4.2.2 Experimental design 
The details of this experiment are outlined in Section 2.7 
4.2.3 Procedure to visualise Langerhans dendritic cells 
A modified ZIO procedure of Champy, 1913; Rodriguez and Caorsi, 1978 
was developed because of the nature the lung. The details of this 
procedure are listed in Chapter 2. The number of ZIO+ LDC in four high 
power fields (HPF X400) was calculated. The mean and the standard 
deviation were statistically analysed for groups of mice assessed. 
4.3 Results 
4.3.1 Tobacco smoke induced pulmonary changes 
Bronchial epithelial hyperplasia, focal alveolar cell hyperplasia, 
mononuclear and eosinophil infiltration of the alveolar septum, 
together with alveolar macrophages in the alveolar spaces were 
increasingly observed in lungs of mice after 4 weeks of exposure to 
tobacco smoke. By the end of week 8, multifocal interstitial lung lesions 
were present composed of monocytes and lymphocytes (Fig. 4.1). This was 
observed in the lungs of all six mice examined. 
After 12 weeks of tobacco smoke exposure, interstitial granulomas 
without central necrosis or cavitation were observed in lungs of 3 of 6 
mice. Cholesterol-like crystals (Fig. 4.2) were present between the cells 
forming these granulomas; histiocyte-like cells, foamy macrophages, 
lymphocytes, plasma cells and eosinophils. The alveolar spaces around 
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Figure 4.1 An increase in thickness of the alveolar septum due to increased 
numbers of mononuclear cells. ( H&E X 100) 
Figure 4.2 Interstitial granuloma showing cholesterol crystals, mononuclear 
cells and foamy alveolar macrophages. ( H&E X 200) 
Chapter 4 	 Tobacco Smoke Inhalation, LDC and Lung Lesions 	 Page 77 
the granulomas showed alveolar epithelial hyperplasia with marked 
accumulation of macrophages. 
By 16 weeks, bronchial epithelial hyperplasia and occasional focal 
bronchial squamous metaplasia were observed (5 of 6 mice). The lung of 
one mouse at this stage showed a complex of histopathological changes. 
The basic lesion was peribronchial chronic inflammation (Fig. 4.3) some 
with granulomas and a central cavity (Fig. 4.4). The cavity resulted from 
deformed bronchioles by the peribronchial inflammatory infiltration as 
some ciliated columnar epithelium was still identifiable. The cellular 
infiltrate of the granuloma extended in the adjacent alveolar septum 
forming a star-shaped lesion (Fig. 4.5). The cells forming the granuloma 
included clusters of large histiocyte-like cells and macrophages 
containing PAS positive material and haemosiderin. The histiocyte-like 
cells (Fig. 4.6) were large with an irregular and indented nucleus with 
occasional prominent nucleoli. The cytoplasm appeared pale acidophilic 
with ill-defined short dendrites extending from the cell membrane. 
Some bronchioles adjacent to the inflammatory lesions were filled with 
acute inflammatory exudate (Fig. 4.4) and the alveolar spaces contained a 
marked number of alveolar macrophages (DIP-like reaction, Fig. 4.7). The 
alveolar epithelium was hyperplastic and the subpleural airspaces 
showed focal emphysematous changes. 
By the end of 20 weeks, 2 of 6 mice showed marked bronchial epithelial 
hyperplasia together with squamous metaplasia with occasional atypical 
epithelium. Multifocal interstitial granulomatous lesions were observed 
in the lungs of 2 of 6 mice similar to that found after 16 weeks. Older 
interstitial lesions demonstrated typical satellite or star-shaped fibrosis. 
sr 
Figure 4.3 Multiple peribronchial interstitial granulomatous inflammation. 
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Figure 4.4 Interstitial pulmonary granuloma with a central  cavity. 
Polymorphs present in bronchial lumen. ( H&E  X 200) 
Figure 4.5 Starfish-like lesion of the interstitial pulmonary granuloma. 
(Gomori's reticulum stain X 400) 
Figure 4.6 Langerhans dendritic cells (arrow) in peribronchial interstitial 
granuloma. (H&E X 400) 
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Neoplastic-like lesions were found in the lungs of two mice. One lesion 
consisted of proliferating alveolar epithelial cells bounded by chronic 
inflammation (Fig. 4.8). These histopathologic features are similar to so 
called alveogenic lung tumours (Shimkin and Stoner, 1975), although 
the nature of these lesions are in-question i.e. reactive or neoplastic. 
The lesion in the lung of the second mouse was a single microscopic 
lesion consisting of multiple papillary structures (Fig. 4.9), filling what 
appeared to be a bronchiolar lumen. The cells of this lesion were cuboidal 
to columnar in shape and the nuclei hyperchromatic, rounded and 
eccentrically located. There were no cilia extending from the free borders 
of these cells. The histologic features of this lesion were consistent with a 
Clara cell bronchial adenoma. 
At week 20, tobacco smoke exposure ceased and the remaining mice (6) 
were kept for a further 6 weeks. The alveolar epithelial hyperplasia, the 
interstitial cellular accumulation, interstitial granulomas, features of 
bronchiolitis, DIP and the emphysematous changes resolved in 75% of 
the mice (5/6). A mild degree of these changes was observed in the 
remaining mouse. Only bronchial epithelial metaplasia persisted. 
4.3.2 Pulmonary ZIO+ Langerhans dendritic cells 
The ZIO+ dendritic cells were smaller than alveolar macrophages and 
most were oval or triangular in shape. Black granules (Fig. 4.10) were 
observed scattered in the cytoplasm. The dendritic nature of these cells 
was demonstrated on serial sectioning. The nuclear:cytoplasmic ratio was 
always low around 1:2; the nucleus appeared irregular. Most of the ZIO+ 
LDC were found in the alveolar septum, infrequently in alveolar spaces 
••• 
# • 
• )5• V$ • ow I 	Jr 	• . ap 
irs 	-I( • 4. jk, • • 
ar 	* ego 4•1 1 .% 
• •• 	 . 4.100.4 3=1, r1./Peti t44: 	sibp • 
--•F•21 A • 
to* 	-; 
• sew  
tr 
'1 
0.1 • 	4 4  
hr •••- 
• I `• "it 
- 
ifitti:411P 1.4, • •■• 
• 
t • 
# 611* 
-.• 
fovzsii.oir-*%-at -• 3 ez 	4 sbk . ettV"if=4 
el-. tare  - 41 
"I t11041 .0)1P. 	
Aestilu, ilk 
• 4 ONO, '41 	fjp 
•• .•.`'IVO. 6 d 4-11.11114W  
40. 
r. • 
±07/6747J7i i.C.41ir. 
1."14* 64 •
40: 
lo 	.000 Jr it 4.? 
41‘111111 	• 
4I•* % 
• 411 • 
• -te g" 	• sit 
• • & a' 	r 
A • • 
•4, 04 - 	1•• 
• r • *0 
• 
• #60 e• .141F11 %v.!. 
Figure 4.7 Desquamative interstitial pneumonia (DIP) in the lung 
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Figure 4.8 Alveolar proliferative cells bounded by inflammatory reaction. 
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Figure 4.9 Papillary Clara cell adenoma. ( H&E X 400) 
Figure 4.10  ZIO positive dendritic cells in lung granulomatous inflammation 
after exposure to tobacco smoke. (ZIO staining X 200) 
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Figure 4.11 Pulmonary murine LDC after exposure to tobacco smoke 
—.— LC Test 
Analysis of variance between test and control group showed a statistically 
significant difference in LDC number (p<0.0001) between 4-20 weeks 
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and rarely in the bronchial epithelium. The mean number of ZIO+ LDC 
in normal lung was 1.3 LDC ± 0.4/HPF. 
There was a steady increase in the number of ZIO+ LDC mainly in the 
thickened alveolar septum of the tobacco smoke exposed mice (Fig. 4.11) 
starting from the end of the first week (test = 2.3 ± 1.0; control = 0.8± 0.3). 
After eight weeks of tobacco smoke exposure, the number of pulmonary 
LDC peaked (test = 16.5 ± 3.6; control = 0.7 ± 0.4, p < 0.0001) and remained 
high with continuos exposure to tobacco smoke (test = 14.3 ± 4.3; control = 
0.5 ± 0.2, p <0.0001). When exposure to tobacco smoke ceased at the end 
of the 20 weeks, the number of ZIO+ LDC in the lungs of the remaining 
mice decreased to the level of the control group, (test = 0.5 ± 0.3; control = 
0.7 ± 0.6) after a further six weeks. 
On ultrastructure, the pulmonary dendritic cells with positive ZIO 
staining showed all the ultrastructural features of LDC; the indented large 
irregular nucleus and black BG were easily identifiable (Figs. 4.12 and 
4.13). Some branched BC were observed near the nuclear membrane. 
Many tubular structures were identified in the cytoplasm and the 
mitochondria were numerous. 
4.3.3 Ia positive pulmonary LDC 
The morphology and size of the Ia+ dendritic cells were consistent with 
that of ZIO+ LDC. Ia+ cells were mainly found in the alveolar septum 
and were occasionally seen with a few dendrites. Their numbers were 
similar to that of the Z10+ LDC. 
Figure 4.12 ZIO positive pulmonary dendritic cell showing labelled (arrow) 
Birbeck's granules. ( V-7.4-ZIO staining X 34,000) 
Figure 4.13 ZIO positive pulmonary dendritic cell showing branched and 
unbranched labelled (arrow) Birbeck's granules. 
(V-7.4-ZIO staining X 34,000) 
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44 Discussion 
The number of dendritic LDC in the lungs of mice exposed to tobacco 
smoke for twenty weeks increased approximately 25 fold. Although the 
increase in the pulmonary LDC was observed within one week, the 
highest level was obtained after 8 weeks and remained elevated until 
smoke inhalation treatment ceased at 20 weeks. This is in agreement 
with Casolaro et al., (1988), and Soler, (1989), who reported an increase in 
LDC in smokers lungs in human. 
In this study ZIO+ pulmonary LDC were always observed in control 
lungs in the alveolar septum and rarely in the bronchial epithelium. The 
mean of ZIO+ pulmonary LDC in normal murine lung was 0.9 ± 0.4 
cells/HPF. This parallels the previous finding of low density of 
pulmonary LDC in normal human lung (Chapter 3). 
The increase in the ZIO+ pulmonary LDC after tobacco smoke exposure 
was associated with the development of interstitial granulomas and 
inflammation. The alveolar spaces around the granulomas showed 
alveolar epithelial hyperplasia with marked accumulation of alveolar 
macrophages. By 16 weeks, the basic lesion was the interstitial granuloma 
with a central cavity together with inflammatory reaction of the lung 
parenchyma around the granuloma. The cellular infiltrate of the 
granuloma extended into the adjacent alveolar septum forming star-
shaped lesions. 
The histiocyte-like cells on cytological features were consistent with those 
of the histiocytosis-X cell (Katzenstein and Askin, 1990). They were 
irregular, with an indented or lobulated nucleus, pale acidophilic 
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cytoplasm with many ill-defined short dendrites extending from the cell 
membrane. While there were many of these cells in active lesions, they 
become rare in older lesions with fibrosis. 
In this study, on ultrastructural examination of the ZIO+ pulmonary 
dendritic cells, BG were observed in the cytoplasm (Figs. 4.12 and 4.13). 
This confirmed the lineage relationship between histiocytosis X cell and 
LDC. 
The bronchioles associated with the granulomas were filled with acute 
inflammatory exudate and the alveolar spaces contained a marked 
number of alveolar macrophages (DIP-like reaction). The alveolar 
epithelium was hyperplastic. By the end of 20 weeks, some older 
interstitial granulomas progressed into typical fibrotic satellite or star-
shaped lesions. These histopathological features are consistent with the 
tobacco smoke related human clinical syndrome, pulmonary histiocytosis 
X (Hance et al., 1988 & Katzenstein and Asldn, 1990), as called pulmonary 
LDC granulomatosis (Lieberman, 1980). 
Although the pathogensis of pulmonary LDC granulomatosis is not clear, 
90% of patients are smokers (Hoffman and Hect, 1985; Hance et al., 1988). 
Carcinogens of the tobacco smoke e.g. benzo[a]pyrene and catechols may 
cause alveolar epithelial damage leading to proliferative, hyperplastic 
and neoplastic alveolar epithelial cells (Favara et al., 1983; Hoffman and 
Hect, 1985; Hance et al., 1988). The damaged alveolar epithelium may 
express neoantigens which triggered the LDC response and T- lymphocyte 
activation leading to necrosis of the target cells. Activated macrophages 
secreting collagenase, elastase, prostaglandins and other factors are also 
central to granuloma formation (Favara et al., 1983; Hance etal., 1988). 
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Benzo(a)pyrene (BP) while increasing the number of pulmonary LDC, 
may alter cellular immunity via prostaglandins (Ruby et al., 1989; 
Andrews et al., 1991). Ruby et al., (1989), and Andrews et al., (1991), 
reported BP and co-carcinogen catechols increased the number of la+ 
LDC, changed their morphology and impaired their function. This was 
associated with the development of skin tumours after 24 weeks of 
treatment. Andrews and colleagues (1991), implanted the prostaglandin 
synthetase inhibitor, indomethacin beneath mouse skin before treatment 
with BP. This restored contact hypersensitivity; delayed the onset and 
reduced the size of skin tumours induced by BP. Tobacco smoke 
condensate (TSC) induced cutaneous carcinogenesis and changes in 
epidermal LDC. TSC increased the LDC density, altered their morphology 
and impaired their function. This was associated with skin tumour 
development (Chapter 5). 
Studies on the carcinogenic effects of tobacco smoke on the lungs of 
laboratory animals have concentrated on precancerous changes and 
tumour development (Wynder, 1961; Leuchtenberger, 1961; Mostofi and 
Larsen, 1951). Interstitial granulomas have been observed only in one 
previous study by Mostofi and Larsen (1951). They were investigating the 
histopathogenesis of urethane induced pulmonary tumours in mice 
where they observed the formation of interstitial granulomas between 3- 
12 weeks prior to tumour development. They also observed large 
acidophilic cells in these granulomas. While Mostofi and Larsen, (1951), 
did not investigate their observation further, their description of the 
interstitial granuloma is consistent with that of pulmonary LDC 
granulomatosis (histiocytosis X). The large acidophilic cells are atypical 
LDC (Lieberman, 1980 and Shimkin and Stoner, 1975). 
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In this study, the development of tumour-like lesions followed the 
formation of the interstitial granuloma after 20 weeks exposure to the 
tobacco smoke was observed. The histopathologic features of these 
lesions were consistent with bronchial Clara cell adenoma and so called 
alveogenic tumours. This was associated with a high density of ZIO+ 
pulmonary LDC. Shimldn and Stoner (1975), both reported 95% of lung 
tumours in mice originate from the alveolar epithelium. High density of 
S100+ LDC in tobacco smoke related human bronchioalveolar carcinoma 
and well differentiated squamous cell carcinoma was described in 
Chapter 3. Consequently, a strong relationship between tumour type and 
the density of tumour infiltrating LDC is confirmed. 
While tobacco smoke increased the ZIO+ pulmonary LDC density, the 
impaired function of these cells induced by benzo(a)pyrene in the 
inhaled tobacco smoke may have resulted in disordered alveolar 
epithelial growth in a setting of compromised immunological function. 
After tobacco smoke exposure ceased the histopathological changes 
resolved and the density of pulmonary LDC returned to that of control 
levels. Only the bronchial epithelial metaplasia did not show reversible 
change. Bronchial epithelial metaplasia may require a longer time to 
resolve. 
In conclusion this study has demonstrated that tobacco smoke increased 
the density of ZIO+ pulmonary dendritic cells and this was associated 
with the development of bronchial squamous metaplasia, interstitial 
granulomatous lesions (pulmonary LDC granulomatosis) and alveolar 
cell proliferation. The density of pulmonary LDC returned to that of the 
control level after ceasing tobacco smoke exposure and the interstitial 
granulomatous lesions, but not the metaplasia resolved. The mechanism 
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by which tobacco smoke increased the density of pulmonary LDC may be 
related to benzo(a)pyrene, while functional changes in these antigen 
presenting cells may have a role both in chronic granulomatous 
inflammation and tumour development. 
4.5 Summary 
The density of ZIO+ pulmonary Langerhans dendritic cells was increased 
approximately twenty fold in mice after passive exposure to tobacco 
smoke. This was associated with pulmonary changes consistent with the 
cigarette smoking related clinical syndrome in humans, pulmonary 
Langerhans cell granulomatosis. The major feature was an interstitial 
peribronchial granuloma. The cellular infiltrate of the granuloma 
(lymphocytes, plasma cells, eosinophils, clusters of large histiocyte-like 
cells and macrophages) extended into the adjacent alveolar septum 
forming a star-shaped lesion. The histiocyte-like cells were large with 
pale acidophilic cytoplasm and many ill-defined short dendrites 
extending from the cell membrane. Bronchial epithelial metaplasia also 
developed. The interstitial changes were followed by the development of 
proliferative alveolar and bronchial lesions in two mice. 
The ZIO+ cells were consistent with la+ pulmonary dendritic cells and 
their ultrastructure was similar to that of pulmonary Langerhans cells. 
After ceasing exposure to tobacco smoke the density of pulmonary 
Langerhans cells returned to that of the control level; interstitial 
granulomatous lesions disappeared, but the bronchial epithelial 
metaplasia did not reverse. Tobacco smoke exposure of mice produces 
interstitial granulomatous inflammation similar to Langerhans cell 
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granulomatosis in humans. The elevated level of pulmonary 
Langerhans cells implicate these cells in the pathogenesis of these lesions. 
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CHAPTER 5 
TOBACCO SMOKE CONDENSATE, LANGERHANS DENDRITIC CELLS 
AND SKIN TUMOURS 
5.1 Introduction 
Benzo[a]pyrene and catechols are the most important of the 71 
carcinogens in tobacco smoke condensate (TSC; Dube and Green, 1982). 
Skin papillomas and squamous cell carcinomas of the skin have been 
reported in various animals e.g. guinea pigs, Swiss mice, C57 black mice, 
after treatment with TSC (VVynder et al., 1953, 1961; Drukrey, 1961; Day, 
1966). 
Ruby et al., (1989) and Andrews et al., (1991) studied the effect of the 
tobacco derived benzo[a]pyrene (BP) and co-carcinogen catechols on the 
number, morphology and function of epidermal Langerhans cells (LDC). 
They reported a significant increase in number of the Ia+ LDC, changes in 
their morphology and impairment of their function. This was associated 
with the development of skin tumours after 24 weeks of treatment (58% 
were squamous cell papilloma and 42% squamous cell carcinoma). 
The various reports on the density of LDC in squamous cell carcinomas 
of human skin are conflicting. Gatter et al., (1984) used NA1/34 
monoclonal antibody to identify LDC in human skin tumours and 
reported changes in LDC morphology and depletion in their number in 
squamous cell carcinomas. Smolle et al., (1986) used OKT-6 to study LDC 
in human skin tumours and reported a low density of LDC in squamous 
cell carcinomas compared to normal skin. McArdle and co-workers, 
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(1986) used an antibody to S100 protein to study LDC in various skin 
lesions and reported a high LDC density in keratoacanthoma, squamous 
cell carcinomas and basal cell carcinomas compared to the normal 
epidermis. Korenberg and his colleagues (1987) also used an antibody to 
S100 protein to study LDC and supported McArdle et al., (1986) in regard 
to the high density of LDC in keratoacanthoma but found a low density of 
S100+ LDC in squamous cell carcinomas. Alcalay et al., (1989) used 
adenosine triphosphatase to study LDC and reported changes in LDC 
morphology but no increase in LDC number in squamous cell 
carcinomas. 
Analysis of LDC in cervical intraepithelial neoplasia likewise are 
conflicting. The majority of reports indicate high LDC number in cervical 
intraepithelial neoplasia (Morris et al., 1983; Caorsi and Figueroa, 1984, 
1986; McArdle and Muller, 1986; Bonilla-Musoles et al., 1987 and Xie, 
1990), but Tay et al., (1987) reported low LDC numbers in these lesions. 
The variation in the number of LDC in squamous cell carcinoma in these 
reports may reflect the different methods used including counting 
techniques. 
The present investigation arose out of the previous study (chapter 3) 
where an increase in LDC density in well and moderately differentiated 
human lung squamous cell carcinomas was demonstrated and this was 
associated with increased patient survival (Chapter 3). As tobacco smoke 
is linked to the cause of these tumours (Auerbach et al., 1957), the present 
investigation was designed to examine the effect of TSC on LDC during 
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carcinogenesis in murine skin, a well established model to analyse the 
sequential development of squamous tumours. 
5.2 Materials and Methods 
5.2.1 Animals 
Two hundred and four BALB/c female mice 6-8 weeks old were obtained 
from the Central Animal House at the University of Tasmania after 
ethical approval. Forty eight mice were used to assess the function of 
LDC. To assess the effects of TSC on cutaneous LDC, 2 groups of 78 mice 
each, experimental and control were used (Section 2.16). 
5.2.2 Experimental design 
TSC was applied every second day including the weekends. At 35 weeks 
TSC treatment was stopped, and mice were kept for a further 10 weeks to 
observe the changes in tumour size and the relationship to LDC numbers 
(Details are given in Section 2.18). 
5.2.3 Identification and enumeration of Ia positive LDC in epidermal 
sheets 
The la+ LDC were identified in the epidermal sheets as brown dendritic 
cells with various numbers of dendrites extending from the cell body. 
Figure 5. 1 Skin lesions and changes in LDC number induced by TSC 
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(a) Epidermal hyperplasia. 
(b) Dysplastic changes. 
(c) Skin papilloma. 
(d) Early invasive squamous cell carcinoma. 
(e) Treatment with TSC stopped. 
(f) Ten weeks after stopping TSC treatment. 
Difference in LDC number in both test and control groups is significant 
(p <0.0001). 
The increase in LDC number in the test mice, ten weeks after stopping 
TSC treatment (2) is significant compared with LDC number at 36 weeks 
(1), p <0.0001. 
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5.2.4 Contact sensitivity assessment 
The function of LDC was assessed by inducing a contact hypersensitivity 
reaction at the 2nd and the 6th weeks, after treatment with TSC in a 1:1 
solution of acetone:olive oil or in the control mice, acetone:olive oil 
alone. Details are listed in Section 2.24. 
5.3 RESULTS 
5.3.1 Skin Pathology induced by tobacco smoke condensate (TS0 
The histopathological changes induced by the TSC in the skin of the 
treated mice are summarised in Fig. 5.1. Epidermal hyperplasia was 
observed two weeks after treatment; the epidermis was composed of 6-8 
cell layers compared to 2-3 layers of control epidermis. 
Dysplastic changes in the hyperplastic epidermis were observed in 25% of 
mice after 10 weeks of TSC treatment. The cells had enlarged 
hyperchromatic nuclei, a high nuclear:cytoplasmic ratio and involved 
various thickness of the epidermis. By 18 weeks about one third of the 
treated mice developed macroscopic skin tumours: small wart-like 
papillomas, up to 2 mm in diameter. 
After 26 weeks of treatment, the skin of all remaining mice showed skin 
tumours of various sizes, between 1-6 mm in diameter. The histology of 
the largest skin tumour showed early invasive squamous cell carcinoma. 
By 35 weeks, the size of the skin tumours of all treated mice was between 
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0.2-1.3 cm in diameter and one third of mice had developed multiple 
tumours (Fig. 5.2a). The histology of skin tumours of the six mice killed 
at this stage showed invasive squamous cell carcinoma (Fig. 5.3). 
Application of TSC was stopped by 35 weeks and 48 mice were kept 
under observation for a further 10 weeks. Macroscopically, 23% of 
tumours spontaneously disappeared, the remaining tumours showed 
about 50% reduction in their size (Fig. 5.2b). Histopathologic examination 
of these lesions revealed invasive squamous cell carcinomas of the skin 
in 50% of lesions with varying degrees of tumour necrosis and 
lymphocytic infiltration (Fig. 5.4). Skin papillomas were observed in 27% 
of skin lesions; the remaining 23% mice showed various degrees of 
hyperplasia and dysplasia. 
5.3.2 Epidermal LDC numeration in tobacco smoke condensate (TSC) 
treated skin 
During the first two weeks there was an increase in the density of the Ia 
positive LDC in the skin of mice treated with TSC and the highest LDC 
level was achieved 28 weeks after treatment. The number of LDC in the 
epidermal sheets of the treated mice during this period was significantly 
higher (1793 LDC/mm2) than that of the control group (946 LDC/mm2 ), p 
<0.0001 (Fig. 5.1). 
At 45 weeks, almost 10 weeks after stopping the treatment with TSC, the 
number of LDC in the skin tumours (Fig. 5.5) and around lesions (Table 
5.1) had not decreased, but in general remained elevated (Fig. 5.1). The 
Figure 5.2a Multiple skin tumours after 35 weeks of TSC treatment 
(Scale in mm) 
Figure 5.2b Skin tumours at 45 weeks, 10 weeks after stopping TSC treatment 
(Scale in mm) 
Figure 5.3 Invasive squamous cell carcinoma with mixed  cellular reaction 
around tumour, 35 weeks after TSC treatment (H&E X 200) 
Figure 5.4 Necrotic squamous cell carcinoma of skin tumours at 45 weeks 10 
weeks after stopping TSC treatment.(H&E X200) 
Figure 5.5 la positive LC in frozen section of skin tumour 
(Immunoperoxidase anti-Ia staining X 200) 
Table 5.1 	LDC around skin lesions 10 weeks after stopping TSC 
treatment 
Skin lesion No Mean of LDC/mm2 SD 
1. Skin papilloma 13 2274 14.1 
2. Invasive SCC 13 2088 183.0 
3. SCC with necrosis 11 1960 61.3 
4.Hyperplasia & dysplasia 11 1650 153.5 
Using Scheffe's test at the 0.05 level, 2 versus (vs) 1, 3 vs 1, 1 vs 2 and 1 vs 
3 no significant difference, While 4 vs 1, 2, &3 all significant. 
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exceptions were hyperplastic and dysplastic lesions. The difference in LDC 
number before and after stopping TSC treatment was significant (p < 
0.0001). 
5.3.3 LDC morphology in tobacco smoke treated skin 
After 2 weeks of TSC treatment 25% of LDC in epidermal sheets became 
smaller in size and the dendrites were blunt and short compared with 
normal LDC (Fig. 5.6a). By 6 weeks many of the LDC cells were rounded 
or oval in shape (Fig. 5.6b). When TSC ceased at 35 weeks, the 
morphological changes reversed, the LDC became more dendritic and 
with more than 3 branched dendrites (Fig. 5.7). 
5.3.4 Contact sensitivity response after TSC skin treatment 
Table. 5.2 summarises the percent increase in ear thickness of both TSC 
treated and control mice at 2 and 6 weeks following sensitization and 
challenge with TNCB. 
The percent increase in thickness of the right ear of the TSC treated mice 
when challenged after sensitization with TNCB was significantly less 
than that of the control group (p <0.0001), at both 24 and 48 hours. This 
suggests an impairment in contact sensitivity response in the TSC treated 
mice and indicates a compromised function of the morphologically 
altered LDC. 
Figure 5.6a Normal fully dendritic LC in epidermal sheet of control mice 
(Immunoperoxidase anti-Ia staining X 1000) 
Figure 5.6b Rounded Langerhans Cells after TSC treatment 
(Immunoperoxidase anti-Ia staining X 400) 
Figure 5.7 Langerhans Cells returned to their dendritic morphology, with 
more than 3 branched dendrites 10 weeks after stopping TSC 
treatment, some LC still abnormal in shape 
(Immunoperoxidaseanti-la staining X 400) 
Table 5.2 	Cutaneous contact sensitivity response to TNCB of mice 
treated with TSC 
After 2 weeks 
Group No Time Mean of % increase in ear thickness 
Control 6 24 HR 110 ± 19.96 
TSC 6 24 HR 54 ± 9.95 
Control 6 48 HR 81 + 6.96 
TSC 6 48 HR 42 + 8.06 
After 6 weeks 
Control 6 24 HR 105 ± 6.59 
TSC 6 24 HR 54 ± 9.95 
Control 6 48 HR 76 + 7.07 
TSC 6 48 HR 50 + 7.0 
Differences between the % increase in ear thickness of test and control 
group is significant (p <0.0001) at all times (Student's two-tailed, 
unpaired t-test). 
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TSC increased the density of the epidermal LDC in epidermal sheets; with 
highest level 28 weeks after treatment (Fig. 5-1). At this stage the density 
of the epidermal LDC in the treated skin was double the control value 
and the high level of the epidermal LDC around lesions remained 
elevated even after stopping the TSC treatment. The morphology of 
epidermal LDC in the treated skin was also altered, as the cells were 
smaller and the dendrites became shorter and blunt. This was reflected in 
their function which was impaired as assessed by the contact sensitivity 
response. The initial increase in epidermal LDC number, the 
morphological changes and the impairment in their function observed 
during TSC treatment were also associated with tumour development. 
These findings support similar observations reported by Ruby et al., 
(1989) and Andrews et al., (1991) when they investigated the effects of 
benzo(a)pyrene on murine epidermal LDC. Andrews et al., (1991) 
demonstrated that implantation of the prostaglandin synthetase inhibitor 
indomethacin, beneath mouse skin before treatment with the tobacco 
derived carcinogen, benzo(a)pyrene delayed the onset of tumour 
development and reduced tumour size. Andrews and Co-workers, (1991) 
proposed that the cutaneous carcinogenesis of benzo(a)pyrene may be 
related to the suppression of the cellular cutaneous immunity induced by 
prostaglandins. 
It is of interest that while the density of epidermal LDC decreased (1650 ± 
154 cells/mm2 ) in the skin of mice with hyperplastic and dysplastic 
lesions ten weeks after stopping the treatment with TSC, the density 
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increased, in both squamous cell papillomas (2273 ± cells/mm 2 ) and 
squamous cell carcinoma (2088 ± cells/mm 2). These LDC appeared fully 
dendritic and this increase was associated with spontaneous regression of 
23% of skin tumours and 50% reduction in tumour size of remaining 
lesions. The high density of the fully dendritic epidermal LDC after 
stopping TSC application was accompanied by an increased LDC number 
in frozen sections of skin tumours. This was associated with marked 
lymphocytic infiltration and necrosis of these lesions. 
Muller et al. 1985 also reported skin tumour regression after cessation of 
further application of the chemical carcinogen, 7,12-dimethylbenz (a) 
anthracene (DMBA). DMBA depleted epidermal LDC this was associated 
with impaired skin immune function and skin tumour development 
(Muller et al., 1992). Repopulation of epidermal LDC was associated with 
tumour regression (Muller et al., 1985). 
The increase in LDC density in epidermal sheets around tobacco smoke 
induced squamous cell carcinomas (Table. 5.1) of the skin is consistent 
with the previous observations described in Chapter 3 that demonstrated 
an increase in S100+ LDC in squamous cell carcinomas of the lung 
(Chapter 3). This is also in agreement with the results of previous 
workers including McArdle et al., (1986) and Korenberg et al., (1988) who 
reported an increase in LDC density in squamous cell carcinomas of the 
skin. Caorsi and Figueroa together with Bonilla-Musoles et al. (1987) 
found a similar LDC elevation in cervical squamous cell carcinoma as 
did Matsuda et al., (1990) who investigated squamous cell carcinoma of 
the oesophagus. 
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Langerhans dendritic cells are the best known antigen presenting cells 
and consequently their increase in certain tumours may follow a 
recognition by the LDC of a specific antigen expressed by tumour cells. 
Kato et al., (1977, 1979) reported a serum tumour antigen (Ta-4) in 
patients with cervical squamous cell carcinoma and suggested the serum 
level of the antigen was correlated with the disease progress. Yagi et al., 
(1987) also reported squamous cell carcinoma (SCC)-related antigen (SCC-
RAG) in the serum of patients with cutaneous SCC. The titers of SCC-
RAG was correlated tumour behaviours and with the development of 
metastasis. Grabbe et al., (1991; 1992) reported Ia+ LDC are capable of 
presenting tumour associated antigen derived from a murine spindle cell 
tumour inducing an anti-tumour immune response manifested by 
tumour rejection and induction of delayed-type hypersensitivity in 
immunised animals. 
While the extent of LDC infiltration of cutaneous and other tumours 
may be linked to tumour antigens, how LDC arrive in the skin lesions 
remains unclear. One possibility is that skin tumour derived cytokines 
attract LDC into the skin lesions (Halliday et al., 1992). Once functionally 
normal LDC are in lesions, they could trigger an immune response 
leading to tumour regression as in the present experiment. 
It was concluded that TSC increased LDC number, altered their 
morphology, impaired their function; this was associated with tumour 
development. These events may be related to suppression of the cellular 
cutaneous immunity by prostaglandins as related to the effects of 
benzo(a)pyrene already described. The further increase in epidermal LDC 
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number after stopping TSC treatment was associated with reversible 
changes in LDC morphology, the cells became fully dendritic. These 
changes correlated with lymphocytic infiltration, tumour necrosis, 
reduction in tumour size and/or tumour regression presumably due to 
effective anti-tumour response. 
5.5 Summary 
Tobacco smoke condensate was painted on the skin of BALB/c mice. It 
increased the density and changed the morphology of Langerhans 
dendritic cells (LDC). LDC number in epidermal sheets of treated mice 
was significantly higher (1793 LDC/mm 2) than that of the control (946 
LDC/mm 2) group, p <0.0001 and remained elevated for 35 weeks. LDC 
became less dendritic, smaller in size or even rounded in shape. The 
function of the morphologically altered LDC was impaired when assessed 
by the contact hypersensitivity response. These changes were associated 
with skin tumour development in all treated mice. 
Ten weeks after stopping the TSC treatment, LDC number in skin 
tumours and in skin around these lesions had not decreased, but 
significantly increased (p <0.0001). During this period tumour regression 
occurred in 23% of tumours; the remaining tumours showed a 50% 
reduction in size. At 45 weeks, the LDC number in epidermal sheets 
around skin papillomas was 2273 ± 14.1/mm2 and in invasive squamous 
cell carcinomas was 2088 ± 183/mm2 . This was associated with reversible 
changes in LDC morphology, where cells became fully dendritic. This also 
correlated with lymphocytic infiltration into tumours, tumour necrosis, 
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reduction in tumour size and/or tumour regression. It is concluded that 
the influx of normal LDC into the skin tumours allowed the 
development of an immune response with tumour regression. 
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CHAPTER 6 
PRECURSOR OF LANGERHANS DENDRITIC CELLS 
6.1 Introduction 
While the bone marrow origin of LDC has been confirmed in animals 
(Frelinger et al.„ 1979; Katz et al., 1979) and in humans (Pelletier et al., 
1984; Volc-Platzer et al., 1984), its stem cell is unknown and their lineage 
relationship to monocytes and lymphocytes is disputed. 
6.1.1 Langerhans dendritic cells in bone marrow 
Goordyal and Isaacson, (1985) identified a small number of CD1a and 
S100+ cells in cultured human bone marrow cells. Gothelf and 
coworkers, (1986) fractioned bone marrow mononuclear cells on the basis 
of peanut agglutinin positivity and reported 20% of the PNA+ cells co-
expressed CD1a (cortical thymocytes and LDC marker), CD11 (mature 
monocytes), CD14 (myelomonocytes), and possessed both Fc and C3 
receptors. The co-expression of the monocytes markers with the LDC 
CD1a marker led Gothelf's group, (1986) to regard monocytes as the 
precursors of LDC. Fraissinette and co-workers, (1988) examined cultured 
CD1a+ cells from human bone marrow and reported the co-expression of 
CD14, CD33, CD4, HLA-DR, HLA-DP but no specific T-lymphocyte 
markers. On ultrastructural examination, these cells did n6t contain BG 
in their cytoplasm. Fraissinette and co-workers, (1988) considered that 
these cells promonocytes and on the bases of CD1a expression they 
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proposed that these cells may represent the bone marrow precursors of 
LDC. 
After long term bone marrow culture, Luksch and colleagues, (1989) 
reported a small fraction of the cultured cells co-expressed CD1a, CD1c, 
CD4, CD1lb and CD11c. Reid and co-workers (1990) reported two groups of 
cells in the cultured bone marrow cells. One group co-expressed HLA-DQ 
and CD1a and the second group co-expressed HLA-DR and CD4. They 
suggested a common progenitor for both LDC and monocytes-
macrophages. All the above reports proposed monocytes as the bone 
marrow precursor cells for the LDC. 
6.1.2 Langerhans dendritic cells in the peripheral blood 
The CD1a+ LDC represent less than 1% of human peripheral blood 
mononuclear cells (Van-Voorhis et al, 1982). Similar findings were also 
reported by Dezutter-Dambyant and colleagues, (1984) when they 
investigated the LDC isolated from the cord blood of the newborn. These 
cells were CD1a and HLA-DR positive, adhere to plastic and following 
exposure to CD1a, BG-like structures were observed in their cytoplasm 
when examined by electron microscopy. Therefor the ability to induce 
and observe BG-like structures provided strong evidence to LDC nature 
of those cells. 
Other reports have suggested that LDC precursor in the peripheral 
blood may express both T and monocyte surface markers, since they 
expressed CD11 (mature monocytes), CD14 (myelomonocytes), CD4 (T 
cells subsets) and CD3 (T cells) receptors, (Fraissinette et al., 1988; 
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Luksch et al., 1989; Reid et al., 1990; Steinman, 1991). Identification the 
bone marrow stem cell of LDC and their lineage relation to T-
lymphocytes and monocytes awaits further clarification (Jaffe, 1993). 
6.1.3 S100 protein and Langerhans dendritic cells 
There are two subunits of the S100 protein a and b (Isobe et al, 1983). The 
commercially available antibody to 5100 protein used in the present study 
reacts with both the a and b subunits but is predominantly anti-13S100 
protein. 
The cytoplasm of both epidermal LDC and interdigitating dendritic cells 
(IDC) in the T-zone of lymph nodes contain S100 protein (Kahn et al., 
1983). Small S100+ lymphocyte-like cells can be found in lymph nodes 
and spleen (Watanabe et al., 1983), these cells have been proposed to be 
the precursors of LDC. Further investigation of LDC, and S100+ IDC by 
Tanaka, (1986) revealed that both cells were HLA-DR+ and CD1a+. Uccini 
and colleagues, (1987) investigated the S100+ cells in lymph nodes, 
thymus, spleen and peripheral blood. Consequently they reported two 
types of S100+ cells; large and small lymphocyte-like cells, but in the 
blood only small S100+ lymphocyte-like cells were found. This group was 
unable to characterise the small S100+ lymphocyte-like cells but they 
agreed with Watanabe and co-workers, (1983) that the S100+ small 
lymphocyte-like cells in lymph nodes are the precursors of LDC. 
The distribution of S100 protein (a and 13) in the lymphoreticular system 
and in the blood was investigated by Takahashi and colleagues (1984, 
1985, 1987) and reported S10013+ cells in the blood co-expressed CD3 and 
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CD8, and consequently considered these S100 cells as lymphocytes. 
Sansoni et al., (1987) reported S10013+ cells in the peripheral blood co-
expressed both CD8 and CD11b surface markers, but were negative for the 
T cell subset surface marker, 9.3. They considered these cells a subset of T 
suppressor lymphocytes. It is noteworthy that the ultrastructural 
description of the S10013+ cells in the blood which have been reported as 
lymphocytes by Takahashi and colleagues -(1984, 1985, 1987), was 
consistent with that of lymphoid dendritic cells reported by Steinman 
and Cohn, (1973); Von Voorhis et al., (1982); Dezutter-Dambuyant et al., 
(1984, 1988); Schuler and Steinman, (1985); Gothelf et al., (1987) and 
Romani et al., (1989). 
6.1.4 Ultrastructure of Langerhans dendritic cells 
The first ultrastructural studies of the isolated LDC from the lymphoid 
organs was performed by Steinman and Cohn, (1973) who reported the 
electron lucent cytoplasm contains large mitochondria with well-
developed cristae, smooth surfaced vesicles, multivesicular bodies, long 
microtubules but no obvious BG were observed. Von Voorhis et al., 
(1982); Dezutter-Dambuyant et al., (1984, 1988) Schuler and Steinman, 
(1985); Gothelf et al., (1987) and Romani et al., (1989) supported the 
ultrastructure description of LDC by Steinman and Cohn, (1973) and 
added additional details on the irregularity of the nuclei and indentation 
of the nuclear membrane. The cytoplasm of these LDC did not contain 
the azurophilic granules found in monocytes (Zucker-Franklin D., 1975), 
and was not granular as in lymphocytes and granulocytes (Zicca et al., 
1981; Monahan et al. 1981). 
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While studying human lung tumours S100+ cells were observed in the 
lumen of small blood vessels (Chapter 3). This phenomena was most 
commonly observed in lung tumours rich in S100+ LDC 
(bronchioalveolar, well and moderately differentiated squamous cell 
carcinoma). These S100+ cells were attached to the endothelium, between 
the endothelial cells, and in blood vessel walls. 
The aim of this investigation was to examine the nature of these S100+ 
cells found in the blood and to investigate their lineage relationship to 
lymphocytes, monocytes and to the S100+ tumour infiltrating LDC 
6.2 Materials and methods 
6.2.1 Blood specimens 
See Section 2.25. 
6.2.2 Metrizamide enrichment of LDC from the peripheral blood 
Mononuclear cells of PBMC and DC fractions were collected from human 
blood and cytospins were prepared for immunocytochemical staining. 
Further details are listed in Section 2.28. 
6.2.3 Immunocytochemical staining of blood cells 
Buffy coats and the cytospins of the PBMC and metrizamide enriched 
LDC were fixed in a mixture of acetone:methanol:formaldehyde. Blood 
cells were stained using rabbit antibody to bovine S100 protein using the 
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protocol previously described in Sections 2.26, 2.27, 2.28, 2.29. Monoclonal 
mouse anti-human T-cell- CD3; CD4; CD8; CD14 and CD45 were used to 
characterise blood cells. S100+ cells, lymphocytes and monocytes 
numbers were expressed as % of total PBMC. 
6.2.4 Double immtmocytochemical labelling of PBMC and LDC 
Cytospins were fixed in a mixture of acetone:methanol:formaldehyde. 
After suppression of the endogenous peroxidase, cytospins were 
incubated with antibody to the S100 protein, and then with the 
diaminobenzidine (DAB) substrate to localise the S100 protein. The 
second surface antigen was demonstrated using an indirect alkaline 
phosphatase technique. Cytospins were incubated with mouse anti-
human surface antibody (CD3, CD4, CD8, CD14, CD45). The reaction 
colour for the second antigen was developed after incubating the 
cytospins with Fast Blue substrate solution. Further details are listed in 
Section 2.30. 
6.2.5 Phagocytosis assay of S100+ cells in the peripheral blood 
PBMC were incubated in small tubes with polystyrene latex beads at 37 °C 
for 30 minutes. The supernatant was discarded, cells were washed and 
cytospins were prepared and stained for S100 protein. Further details are 
given in Section 2.31. 
Precursor of Langerhans Dendritic Cells 	 Page 103 Chapter 6 
6.2.6 Adherent and non-adherent PBMC 
PBMC were suspended in RPMI-FCS solution and incubated in Petri dish. 
Cytospins were prepared from both non-adherent and adherent cell 
fractions and stained for S100 protein. Details are listed in Section 2.32 
6.2.7 Olympus CUE-2 image analysis system 
Using the image analysis system, the perimeter and volume of the S100+ 
cells (n= 75 cells) in peripheral blood were recorded and compared with 
that of the CD3+ lymphocytes (n= 55 cells) and CD14+ monocytes (n=12 
cells). The means and the standard deviations were calculated (Section 
2.33). 
6.2.8 Micrometer eyepiece analysis 
Using the micrometer eyepiece (Olympus OSM-D4), the perimeter, 
diameter and volume of S100+ cells (n= 200) in peripheral blood were 
recorded and compared with that of the CD3+ lymphocytes (n= 401 cells) 
and CD14+ monocytes (n= 399 cells). The means, medians and the 
standard deviations were calculated (Section 2.34). 
6.2.9 Immunoelectron microscopy examination of PBMC S100+ cells 
Modification of the methodology described by Takahashi et al., (1981) was 
used for the immunoelectron microscopy examination of the S100+ cells 
in PBMC (Section 2.35). 
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6.2.10 Specimens for normal spleens and bone marrow 
Three, 3-4 gm sections were cut (S100, control and H&E staining) from 
each paraffin blocks of 7 normal bronchial lymph nodes, 8 normal bone 
marrows and 10 normal spleens were obtained from the files of the 
Department of Anatomical Pathology, Royal Hobart Hospital (Section 
2.36). 
6.3 Results 
6.3.1 S100+ cells in blood of normal subjects 
In blood samples of 100 normal subjects investigated in this study, S100+ 
cells (Fig. 6.1) formed only 0.09 ± 0.07 cells x 109 per litre of blood, while 
lymphocytes represented 2.0 ± 0.6 and monocytes 0.26 ± 0.1. Their 
number in the blood of males and females was not significantly different, 
but there was a slight decrease in the number of S100+ cells in the blood 
of individuals above 55 year. This was demonstrated using a scatter plot 
and computer generated line-of-best-fit (Fig. 6.2). In contrast to the effect 
of age, lymphocytes and monocytes did not change with age while the 
total white cell count increased marginally. 
6.3.2 Characterisation of the S100+ cells in the peripheral blood 
Phagocytosis: The S100+ cells did not phagocytose latex beads (Fig. 6.3), 
while monocytes were clearly observed to take up the beads. In a previous 
study (Chapter 3), when S100+ dendritic cells in human lung tumours 
were investigated, alveolar pulmonary macrophages were S100 negative. 
Figure 6.1 S100 positive dendritic cell in the buffy coats of PBMC 
(S100 Immunocytochemical Technique X 1000) 
Figure 6.3 S100 positive dendritic cell were non-phagocytic (red cell), while 
monocytes phagocytosed latex beads (arrow) 
(S100 Immunocytochemical Technique after incubation with latex 
beads X 1000) 
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Figure 6.2  Effect of age on the number of S100+ cells per litre of blood 
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Adherence to plastic: When mononuclear cells were incubated in plastic 
petri dishes, 97.5% of S100+ cells were found within the non-adherent 
fraction and only 2.5% within the adherent fraction. 
Double immunolabelling: The S100+ cells were assessed using 
monoclonal anti-bodies to CD45, CD4, CD3, and CD14. The co-expression 
of the cytoplasmic S100 protein and the surface antigens were difficult to 
determine as the surface antigen staining was always weak compared to 
the cytoplasmic S100 protein reaction. Only 1 ± 1% of the S100+ cells in 
the blood co-expressed CD4, while 2.5 ± 1.40% co-expressed CD3 and 95 ± 
5% co-expressed CD45. None of the S100+ cells co-expressed CD14. 
6.3.3 Metrizamide enriched Langerhans dendritic cells 
The low density dendritic cells from the Ficoll-separated PBMC of human 
blood were collected and separated on metrizamide. The majority of 
metrizamide enriched dendritic cells isolated from human blood, were 
positive for S100 protein and CD45 surface antigen and did not express 
CD3, CD8 and CD14 (Fig. 6.4). Whereas the remaining cells collected from 
the pellet were CD3+ with few S100+ cells and there was no obvious co-
expression of CD3 and S100 protein in any of the cells examined (Fig. 6.5). 
6.3.4 Olympus CUE -2 image analysis system 
The perimeter, volume, width and length of S100+ cells, CD3+ T 
lymphocytes and CD14+ monocytes were analysed using the image 
analysis system. These parameters showed clear differences between the 
S100+ cells, CD3+ lymphocytes and CD14+ monocytes (p<0.001). These 
Figure 6.4 Metrizamide enriched DC are S100 positive 
(S100 Immunocytochemical Technique X 1000) 
Figure 6.5 Double immunostaining of the mononuclear cell fraction after 
DC isolation. Majority of cells are CD3 + (black) and only one cell 
S100 positive (red). No obvious co-expression of CD3 and S100 
(Double Immunocytochemical staining X 400) 
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results are listed in Table 6.1. The S100+ cells are significantly larger than 
lymphocytes and smaller than monocytes. 
6.3.5 Micrometer eyepiece analysis 
The perimeter, diameter and volume of S100+ cells, CD3+ T lymphocytes 
and CD14+ monocytes were analysed using the micrometer eyepiece. 
These parameters showed clear differences between the S100+ cells, CD3+ 
lymphocytes and CD14+ monocytes (p<0.001). These results are listed in 
Table 6.2. The S100+ cells are significantly larger than lymphocytes and 
smaller than monocytes. 
6.3.6 Immunoelectron microscopy of the S100+ cells in the peripheral 
blood 
The peripheral blood S100+ cells were identified with granular S100 
protein scattered through the cytoplasm and around the nuclear 
membrane of these cells (Fig. 6.6a&b). Short dendrites extending from the 
cell membrane of these cells were demonstrated and were much shorter 
than those of epidermal Langerhans cells. The nuclei were large, 
frequently irregular and occasionally showed indentation of the nuclear 
membrane. A prominent rim of heterochroma tin was consistently 
observed around the nucleus. 
Although the cytoplasmic organelles were few, the mitochondria were 
numerous and large with prominent cisternae. No BC were found, but 
tubular structures, small single vesicles or multivesicular bodies with 
smooth limiting membranes were observed in the cytoplasm. The 
Table 6.1 Image analysis of blood S100+ cells, CD3 lymphocytes and CD14 
monocytes 
S100+ cells CD3 lymphocytes CD14 Monocytes 
Number 
Perimeter 
75 
26.3 ± 3.2 
55 
16.4 ± 1.7 
12 
33.1±3.4 (p< 0.001) 
Length 8.7 ± 1.1 5.6 ± 0.61 11.3 ± 1.7 (p<0.001) 
Width 7.1 ± 1.2 4.7 ± 0.61 7.3 ± 1.7 (*) 
Volume 240.8 ± 64.5 61.6 ±? 402.7 ± 63.43 (p<0.001) 
The perimeter, length and volume were significantly different between 
S100+ cells, lymphocytes and monocytes (p<0.0001-0.001). While the 
difference in width between S100+ cells and lymphocytes was also 
significant (p<0.001), it was less significant between S100+ cells and 
monocytes. (Measurements are in gm) 
Table 6.2 	Micrometer eyepiece measurements of blood S100+ cells, CD3 
lymphocytes and CD14 monocytes 
Number 
S100+ cell 
200 
CD3 T lymphocytes 	CD14 Monocytes 
401 	 399 
Perimeter 31.37 ± 1.99 24.44 ± 3.43 41.24 ± 5.94 (p=0.0001) 
Diameter 7.84 ± 0.5 6.1± 0.86 10.31 ± 1.49 (p=0.0001) 
Volume 255.7 ± 49.49 126.75 ± 57.2 609.57 ± 258.57 (p<o.001) 
The perimeter, diameter and volume were significantly different between 
S100+ cells, lymphocytes and monocytes (p<0.0001-0.001). 
(Measurements are in i.tm) 
Figure 6.6a Micrograph of the S100 positive cell in blood: S100 reaction 
product in the cytoplasm and surrounds the nuclear membrane 
(Immunoelectron microscopy using immunoperoxidase 
Techniaue X 15000) 
Figure 6.6b DC in blood from control, Control preparation not stained with 
anti-S100 antibody. The electrolucent cytoplasm contain 
numerous large mitochondria, tubular and vesicular structures 
(X 35000) 
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azurophilic granules of monocytes, lymphocytes and granulocytes were 
not observed in the cytoplasm of the S100+ cells. 
6.3.7 S100+ cells in bone marrow of normal subjects 
The S100+ cells were identified in all sections but with variable density, 
the mean of S100+ cells number was 3 ± 2 cells/2 HPF. The size and 
morphology of these cells varied, from small, oval or rounded cells. 
Some were without obvious dendrites on their surfaces while others 
were fully dendritic (Fig. 6.7). 
6.3.8 S100+ cells in normal spleen 
The S100+ cells were observed in the T-zone, mainly around the 
periarterial lymphoid sheaths (Fig. 6.8). Cells varied in size and 
morphology, small, intermediate and fully dendritic cells were observed. 
The mean of the S100+ cells number was 36.67 ± 17.67 cells/HPF. The 
density of S100+ DC and the range of their morphology in the spleen was 
almost similar to that in normal human lymph nodes (Fig. 6.9) 
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Figure 6.9 S100 positive DC, small, intermediate and fully dendritic in the T-
zone of normal lymph node 
(S100 Immunohistochemical Technique X 200) 
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6.4 Discussion 
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The bone marrow origin of LDC has been well established (Frelinger et al., 
1979; Katz et al., 1979; Pelletier et al., 1984; Volc-Platzer et al., 1984), however 
the progenitor cell has yet to be confirmed as its lineage relationship to 
either monocytes or lymphocytes remains disputed (Jaffe, 1993). The  
cytoplasmic S100 protein is a strong and well accepted marker for both 
epidermal LDC and the interdigitating dendritic cells (IDC) found in the T-
zone of lymph nodes (Kahn et al., 1983; Watanabe et al., 1983; Goordyal and 
Isaacson, 1985; Tanaka, 1986). 
During the course of this study, 5100+ cells were identified in normal 
bone marrow, normal spleen and in normal lymph nodes. The size and 
morphology of these cells varied, some had obvious dendrites on their 
surfaces, whereas others were more rounded and have only short and 
blunt dendrites. However, in the peripheral blood, the S100+ cells were 
always small and without prominent dendrites extending from their cell 
membrane. Such variation in size and morphology of LDC in tissues is 
consistent with the previous observations of the S100+ LDC in various 
lung tumours (Zeid and Muller, 1993, Chapter 3) and in agreement with 
similar observations reported by both Watanabe et al., (1983) and Uccini et 
al., (1987). 
The S100+ cells in the blood, and the isolated metrizamide enriched 
dendritic cells, were found to be identical in both size and morphology as 
determined by image and micrometer eyepiece analysis. These cells, even 
though classified as small, were significantly larger than the CD3+ 
lymphocytes (p<0.001) but smaller than the CD14+ monocytes. Uccini and 
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colleagues (1987) investigated the S100+ LDC in lymph nodes, thymus, 
spleen and peripheral blood and described them either large dendritic or 
small lymphocyte-like cells. The detection of S100+ LDC in lymph nodes, 
thymus and spleen indicates a wide distribution of these cells and is 
consistent with the notion that LDC originate in the bone marrow and 
migrate through the blood to reach the target organs or tissues including 
the skin. 
Only 0.09 ± 0.07 cells x 109 per litre of blood were S100+ compared to the 
majority of metrizamide enriched dendritic cells isolated from normal 
human blood. These S100+ cells were non-adherent to plastic, co-
expressed CD45, did not phagocytose latex beads and did not express the 
monocyte surface marker, CD14. A small number of S100+ cells in the 
peripheral blood (2.5 ± 1.4%) co-expressed weak CD3. The majority of cells 
in the mononuclear cell fraction remaining after isolating the 
metrizamide enriched DC, were CD3+ with few S100+ cells and there was 
no obvious co-expression of both markers by any of the cells examined 
(Fig. 6.5). From these observations it is apparent that by purifying for 
dendritic cells you are enriching for S100+ cells, whereas purifying for T 
cells you are depleting S100+ cells. There is clear segregation of these cell 
types. 
The ultrastructural examination of S100+ cells in the blood (Fig. 6.6) 
supports the concept that these S100+ cells are LDC but different from 
lymphocytes and monocytes. S100+ cells in the blood had a few short 
dendrites extending from the cell membrane, S100+ protein granules 
could be seen in the cytoplasm and around the nuclear membrane which 
was often seen with indentation. The translucent cytoplasm contained 
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numerous and large mitochondria, tubular cytoplasmic structures, single 
or multivesicular bodies, but no classical BG were seen. This description 
is totally consistent with the ultrastructure of LDC previously described 
(Von Voorhis et al., 1982; Dezutter-Dambuyant et al., 1984, 1988; Schuler 
and Steinman, 1985; Gothelf et al., 1987; Romani et al., 1989) and are 
clearly different from T lymphocytes (Zucker-Franklin, 1975; Zicca et al., 
1981; Monahan et al. 1981). 
Steinman and Cohn (1973) reported the ultrastructure of the isolated LDC 
from the lymphoid organs. They described these cells with electron lucent 
cytoplasm containing large mitochondria with well-developed cristae, 
smooth surfaced vesicles, multivesicular bodies, long microtubules but 
no obvious BG were observed. Irregularity of the nuclei and indentation 
of the nuclear membrane was also a common feature of these cells. This 
ultrastructural description has been repeatedly maintained by many 
workers (Von Voorhis et al., 1982; Dezutter-Dambuyant et al., 1984, 1988; 
Schuler and Steinman, 1985; Gothelf et al., 1987; Romani et al., 1989). The 
cytoplasm of these LDC did not contain the azurophilic granules found in 
monocytes (Zucker-Franklin, 1975) and was not granular as in 
lymphocytes and granulocytes (Zicca et al., 1981; Monahan etal., 1981). 
Based on these observations it is proposed that these S100+ cells in the 
blood represent the precursor of LDC found in human skin, spleen and 
lymphoid tissue. The findings in this study support the observations of 
Watanabe et al., ( 1984) and Uccini et al., (1987) as they reported a lineage 
relationship between the S100+ LDC and S100+ lymphocyte-like cells in 
the blood, lymph nodes and spleen. 
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In contrast Takahashi and co-workers (1984, 1985, 1987); De Panfilis et al., 
(1988); Sansoni et al., (1987); Ferari et al., (1988) who reported that S100+ 
cells in blood as T lymphocytes, did not undertake image analysis of these 
cells and did not compare their parameters with T lymphocytes or 
monocytes. Their findings were based on the results of double 
immunostaining of S100+ cells in the blood. They claimed that a small 
fraction of CD3+, CD8+ and CD11b+ lymphocytes in the blood co-
expressed the cytoplasmic S100g protein. In a subsequent report these 
workers appear to have contradicted themselves by, in the first instance, 
describing T cells on the basis of CD11 expression, and then describing 
LDC as expressing CD11b (De Panfilis et al., 1988). This antigen is not 
unique to T cells and in fact De Panfilis et al., (1988) described epidermal 
LDC on the bases of their expression of CD11b and CD11c in combination 
with CD18 and SION and therefore the CD11b expressing cells from the 
earlier reports could have been either T cells or LDC. Double 
immunostaining of surface and cytoplasmic antigens is not always 
conclusive, because of the need of various fixatives to demonstrate the 
surface antigen and the cytoplasmic S100 protein. The difference in 
colours of the reaction products between the strong cytoplasmic S100 
protein and the weak surface antigen is difficult to distinguish. Uccini et 
al., (1987) reported difficulty when they tried to double immunostain the 
S100+ small cells they observed in blood, spleen and lymph nodes with T 
or monocyte surface markers. From the work described in this study only 
a small number (2.5 ± 1.4%) of S100+ cells in the peripheral blood 
coexpressed weak CD3 antigens. The majority of cells in the mononuclear 
cell fraction remaining after isolating the metrizamide enriched LDC, 
were CD3+ with only few remaining S100+ cells and there was no 
obvious co-expression of both markers by any of the cells examined. 
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The ultrastructural description of the S10013 positive cells in the blood 
(Takahashi et al., 1985, 1987; Sansoni et al., 1987; De Panfilis et al., 1988; 
Ferari et al., 1988) is actually consistent with that of blood and lymphoid 
dendritic cells (Von Voorhis et al., 1982; Dezutter-Dambuyant et al., 1984, 
1988; Schuler and Steinman, 1985; Gothelf et al., 1987; Romani et al., 
1989). Based on the evidence presented in this study, it is likely that the 
S100+ lymphocytes described in the blood are more likely to be S100+ 
dendritic cells than T lymphocytes. 
Since 1989, only one report has appeared describing S100+ T cells (Hanson 
et al., 1991). This group described 4 cases of chronic lymphoproliferative 
disease of an uncommon S100+ T cell. Close analysis of the above report 
revealed many contradictory results. While Hanson et al., (1991) reported 
that the leukemic cells in the blood were CD3+ and therefore considered 
them as T cells, they failed to clarify if these leukemic cells express the 
cytoplasmic S100 protein. It was also unclear in this report if the CD3+ 
cells coexpressed S100 as double labelling experiments were not 
performed. Furthermore, at no time did the author present data on the 
percent of S100+ cells and therefore there is no clear evidence whether 
the TCR DNA and RNA gene studies of the leukemic cells were carried 
out on the S100+ cells, or in fact the CD3+ cells. Hanson et al., reported 
that the leukemic cells had no cytoplasmic granules, but subsequently 
contradicted themselves when they described them with occasional 
electron-dense cytoplasmic granules following ultrastructural 
examination. It was not clear from the ultrastructural description of the 
leukemic cells, whether they examined the CD3+ cells, or the S100+ cells. 
The best evidence for T cell origin is TCR gene rearrangement. This was 
performed on the leukemic cells, but again, on further analysis, there was 
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no evidence that these cells were S100+. It is most likely that these 
workers detected some S100+ cells but there is no evidence that these cells 
were the described leukemic cells. It is most likely that their description 
was of the leukemic cells which were possibly NK cells as they killed K562 
cell and expressed CD56 and CD16. 
It is noteworthy to observe that when other workers investigated the 
S100+ LDC and other lymphoid cells in various human tissues, there has 
not been a single report describing T lymphocytes coexpressing S100 
protein in their cytoplasm (Timens, et al., 1988; Temenia et al., 1990; 
Huang, 1990; Gallo et al., 1991; Cribier, 1992; Shin and Co-workers, 1992, 
Yamaguchi et al., 1992; Gaillard et al., 1993; Colasante et al., 1993; Paschke 
et al., 1993; Chaux's group, 1993; Hart and Co-workers, 1993). Though, 
dendritic and other blood cells may share the same bone marrow stem 
cell, they differentiate as a separate cell line. LDC may originate from a 
multilineage haematopoietic stem cells in the bone marrow (Fleming et 
al., 1993; Furuta et al., 1993) and express CD45 and some T cell surface 
markers at various stages of maturation. The fact that these antigen 
presenting LDC specifically stimulate T lymphocytes, the expression of 
some T lymphocytes surface antigens may be required in the process of 
recognition and stimulation of the resting T lymphocytes in the 
lymphoid tissue. Shedding some of the cell surface molecules by the 
activated T lymphocytes has been reported (Dooley et al., 1993), such 
molecules may be picked up by LDC during the immunological 
interaction between the antigen presenting LDC and T cells. Subsequently 
these LDC may appear to express some of the T cells surface molecules 
such as CD3. 
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Based on the evidences presented in this study and supported by the 
findings of various workers mentioned above, it is concluded that the 
small S100+ cells found in the peripheral blood, represent the precursors 
of LDC found in human skin, bone marrow, spleen, lymph nodes and 
some pathological conditions such as tumours. While they co-express the 
common leukocyte surface marker CD45 and occasionally weak T cell 
surface markers, there is no obvious lineage relationship with either T 
lymphocytes or monocytes. 
6.5 Summary 
Metrizamide enriched Langerhans dendritic cells (LDC) isolated from 
human blood, were S100+, CD45+, CD3 -, CD8-, CD14- and did not 
phagocytose latex beads. The perimeter, diameter, width, length and 
volume of these S100+ cells was larger than that of CD3+ T lymphocytes 
and smaller than that of CD14+ monocytes. Their ultrastructural features 
were consistent with that of Langerhans dendritic cells from the skin as 
the nuclei were large, indented with a prominent rim of 
heterochromatin around the nuclei and the mitochondria were 
numerous and large. While no Birbeck granules (BG) were observed, 
tubular structures, single vesicles and multivesicular bodies were present. 
Although lymphocytes represented 2.0 ± 0.6 and monocytes 0.26 ± 0.1, 
S100+ dendritic cells represented only 0.09 ± 0.07 cells x 10 9 per litre of 
blood. Equal numbers of blood S100+ cells were observed in males and 
females, but their number slightly decreased with age. It was concluded 
that S100+ blood mononuclear cells are of a lineage relationship with 
other S100+ Langerhans dendritic cells found in human bone marrow, 
skin, spleen, lymphoid tissue and in human tumours. Although these 
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cells co-express the common leukocyte surface marker CD45, there was no 
obvious lineage relationship with T lymphocytes or monocytes. 
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CHAPTER 7 
GENERAL DISCUSSION 
7.1 Introduction 
Tobacco smoke remains a major cause of lung tumours and chronic 
pulmonary diseases. By early 1980 more than half a million people in 
the USA were dying each year from diseases that were directly related 
to smoking (A Report of the Surgeon General, 1982). The annual cost 
of medical care for smoking related illnesses in Canada and USA is in 
excess of US $ 501 billion (A 1992 report of the Surgeon General). In 
West Australia, 13,944 deaths were a result of tobacco smoking 
between 1981-1990 (Deaths from tobacco smoking in Western 
Australia: 1981-1990, WA Drug Data Collection Unit, 1992). 
Tobacco smoke contains seventy one carcinogens and co-carcinogens 
(Bos and Henderson, 1984), the concentration of these in sidestream 
tobacco smoke is higher than in the mainstream tobacco smoke 
(Hoegg, 1972). This highlights the dangers of passive exposure to 
tobacco smoke as not only are the smokers at risk of lung cancer but 
individuals passively exposed to tobacco smoke may also be affected. 
This was confirmed when Hirayama, (1981) investigated 91,540 non-
smoking married women for 14 years and reported that wives of 
heavy smokers have a higher risk of developing lung cancer than 
wives of non-smokers. Previously Casolaro, (1988) and Soler et al., 
(1989) reported that tobacco smoke increases the density of pulmonary 
LDC, but to date the effects of tobacco smoke on the density and 
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function of the pulmonary antigen presenting LDC and their role in 
tobacco smoke induced lung lesions and lung tumours have not been 
fully investigated. 
The first part of this study (Chapter 3) investigated the density of LDC 
infiltrating tobacco smoke related human lung cancer and in the 
draining lymph nodes to determine if there was a relationship 
between LDC density and prognosis. Furthermore an analysis of 
tumour infiltrating lymphocytes was undertaken to ascertain the 
interaction of LDC and TIL with patient survival and prognosis. The 
observations from the human lung study led to the conclusion that 
there was a correlation between tumour type, LDC and TIL density 
which was a direct consequence of exposure to tobacco smoke and its 
carcinogens. This led to next phase of the project which included the 
establishment of an animal model to examine more directly the effect 
of tobacco smoke and its condensate on LDC. The effect of passive 
tobacco smoke inhalation on murine pulmonary LDC investigated in 
Chapter 4, and furthermore the effect of tobacco smoke condensate on 
murine epidermal LDC during cutaneous carcinogenesis was 
examined in Chapter 5. 
During the analysis of LDC in human lung tumours, cells stained for 
S100 were observed within the blood vessels. Upon further analysis these 
S100+ cells were detected extravasating from the blood vessels into the 
perivascular lymphoid tissue. This raised the important question 
regarding the lineage relationship between these S100+ cells found in the 
blood vessel lumen and the S100+ tumour infiltrating LDC. In Chapter 6 
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the nature of the S100+ cells in the blood was investigated and their 
lineage relationship to lymphocytes, monocytes and LDC analysed. 
7.2 Langerhans dendritic cells and tobacco smoke related human lung 
tumours 
Immunohistochemical analysis of human lung tumours clearly 
demonstrated that fully dendritic S100+ LDC were often in direct contact 
with tumour cells and T lymphocytes. A direct relationship between the 
number of LDC and the density of TIL was observed in specific tumour 
types including bronchioalveolar, well and moderately differentiated 
squamous cell carcinomas. This was associated with central tumour 
necrosis and increased patient survival. Such observations were not as 
marked in the human lung tumours where the number of tumour 
infiltrating LDC was low and patient survival less favourable e.g. poorly 
differentiated squamous cell carcinoma and SCLC. Consequently the 
increased number of fully dendritic tumour infiltrating LDC and the 
associated TIL was associated with tumour necrosis and longer patient 
survival. This is indicative of an active immunological interaction 
between certain tumours, LDC and TIL. This is supported by the 
observations of Caorsi & Figueroa, (1984) and Moons et al., (1983). They 
also reported an increase in the number of fully dendritic LDC in 
squamous cell carcinoma of the cervix and this was associated with 
marked TIL. They proposed that this might indicate a specific immune 
response against the neoplastic cells. Such a condition is also supported by 
Xie, (1990) who reported an increased density of S100+ Langerhans 
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dendritic cells in cervical carcinoma and this was associated with longer 
patient survival. 
Why bronchioalveolar, well and moderately differentiated squamous cell 
carcinomas were infiltrated with a greater number of LDC than other 
tumours e.g. SCLC and poorly differentiated squamous cell carcinoma is 
an important question. One possible explanation is that the LDC are 
attracted to the tumour due to the presence of a tumour antigen. 
Evidence for such antigens has been reported for bronchioalveolar, well 
and moderately differentiated squamous carcinoma (Faber, 1941; Kato et 
al., 1977; 1979; Dairaku et al., 1983; Yagi et al., 1987; Katyal and Kawai et 
al., 1988; Hance, et al., 1988). These antigens could be recognised by the 
LDC which could be transiently retained in the tumour and attract 
further LDC through the elaboration of cytokines which further increased 
their number and TIL density in these tumours. The ability of LDC to 
present tumour associated antigen has been investigated by Grabbe et al., 
(1991 & 1992) who found that LDC can present tumour associated antigen 
derived from a murine spindle cell tumour. This resulted in the 
induction of an anti-tumour immune response manifested by tumour 
rejection and induction of delayed-type hypersensitivity in immunised 
animals. 
The collective evidence presented in this thesis supports the possibility 
that bronchioalveolar, well and moderately differentiated squamous cell 
carcinoma express a tumour associated antigen which the LDC could 
present to T lymphocyte resulting in their activation which leads to 
tumour necrosis and a more favourable prognosis. Such an antigen could 
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be absent or at least poorly expressed, in SCLC and poorly differentiated 
squamous cell carcinoma (Broers and Ramaekers, 1994) as these tumours 
do not appear to induce LDC infiltration. 
7.3 Langerhans dendritic cells and tobacco smoke induced lung lesions 
Exposure of mice to tobacco smoke in the absence of any other 
confounding factors such as environmental exposure to other 
carcinogens resulted in the development of pulmonary Langerhans cell 
granulomatosis, squamous metaplasia of the bronchial epithelium, 
alveolar and bronchial lesions (Chapter 4). This was associated with an 
increase in the number of pulmonary LDC. This is the first dearly defined 
experimental observation that directly links tobacco smoke exposure, LDC 
and the development of such a lesion. This relationship therefore 
implicates pulmonary Langerhans dendritic cells directly in the 
pathogenesis of pulmonary Langerhans cell granulomatosis. 
The increase in the density of pulmonary LDC induced by tobacco smoke 
is supported by Casolaro, (1988) and Soler et al., (1989) who analysed and 
show their accumulation in smokers' lungs. The mechanism by which 
tobacco smoke increases the density of pulmonary LDC is not clearly 
understood. One possibility is that the LDC recognised some of the 
chemical compounds, including the 71 carcinogens (Dube and Green, 
1982; Bos and Henderson, 1984) in tobacco smoke as an antigen (Woods et 
1993; Ragg et al., 1994). Alternatively the damaged alveolar and 
bronchial epithelium induced by the tobacco smoke which may have 
expressed neoantigens (Faber, 1941; Kato et al., 1977; 1979; Singh, 1979; 
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Dairaku et al., 1983; Yagi et al., 1987; Katyal and Kawai et al., 1988; Hance, 
et al., 1988) which triggered the increase in LDC density as described in 
Chapter 4. It was also reported that benzo(a)pyrene and catechols of 
tobacco smoke increase the number and impair the LDC function by 
prostaglandin release (Muller et al., 1985; Odling et al., 1987; Ruby et al., 
1989; McMinn et al., 1990, 1991; Andrews et al., 1991). This increase in the 
pulmonary LDC number could lead to T-lymphocyte activation (De 
Panfilis et al., 1989; Muller et al., 1994) and these sensitised T-lymphocytes 
would interact with the antigen bearing target cells, bronchial and 
alveolar epithelium, leading to their necrosis and inflammatory reaction 
and eventually interstitial granuloma formation. 
When further exposure to tobacco smoke ceased for six weeks, the 
pulmonary LDC number in the lungs of the remaining mice was simillar 
to that of the control level. Furthermore, neither interstitial granulomas 
nor alveolar or bronchial hyperplastic-neoplastic lesions were observed. 
These changes further implicate tobacco smoke induced LDC changes in 
the pathogenesis of these pulmonary lesions and also highlights the 
significant relationship between cessation of further exposure to tobacco 
smoke and the consequent reversible pulmonary changes. 
7.4 Langerhans dendritic cells and tobacco smoke cutaneous 
carcinogenesis 
The observations that tobacco interacted with pulmonary LDC (Chapter 4) 
indicated further analysis was required to investigate further the direct 
effect of tobacco smoke on LDC. The effect of TSC on murine epidermal 
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skin during cutaneous carcinogenesis was analysed in this part of the 
study (Chapter 5). Treatment of the mice skin with TSC led to the increase 
in the number of epidermal LDC, altered their morphology and impaired 
their function. This was associated with the development of squamous 
hyperplasia, dysplasia and consequently the development of skin 
papilloma and squamous cell carcinoma tumours in all treated mice. 
This parallels the previous observations (Chapter 4) where tobacco smoke 
inhalation increased the density of pulmonary LDC and assumedly 
impaired their function and consequently this led to the development of 
the previously described pulmonary lesions e.g. pulmonary Langerhans 
granulomatosis , bronchial and alveogenic tumours. 
The functionally impaired LDC which was induced by tobacco smoke or 
its condensate in murine lung and skin most likely compromised the 
anti-tumour immunosurveillance role of LDC and consequently led to 
the development of the described lesions in lung and skin of the treated 
mice. This may be related to the suppression of the cellular cutaneous 
immunity induced by the carcinogen induced prostaglandin release. 
The observations on TSC, epidermal LDC and the development of skin 
tumours in mice is in agreement with simillar observations reported by 
Muller et al., 1985; Ruby et al., 1989; Andrews et al., 1991, investigating the 
cutaneous carcinogenesis induced by the tobacco derived carcinogen BP. 
The suppression of the cellular cutaneous immunity induced by the 
carcinogen BP induced prostaglandin release was demonstrated elegantly 
by Andrews et al., (1991) when they implanted prostaglandins synthetase 
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inhibitor, indomethacin, beneath mice skin before treatment with 
benzo(a)pyrene and observed delay in the onset of tumour development 
and reduction in size of the developed skin tumour. 
Ten weeks after stopping the TSC treatment, LDC number in skin 
tumours and in skin around these lesions had not decreased, but 
significantly increased (p <0.0001). At this stage epidermal LDC became 
fully dendritic and this was correlated with lymphocytic infiltration into 
tumours, tumour necrosis, reduction in tumour size and/or tumour 
regression. It is concluded that the influx of normal LDC into the skin 
tumours allowed the development of an immune response and 
consequently tumour necrosis which was followed by reduction in 
tumour size and/or tumour regression. 
In this study it was clearly demonstrated that squamous cell carcinoma of 
the skin contains a high number of LDC. This parallels the previously 
reported observations in human well and moderately differentiated 
squamous cell carcinoma of human lung (Chapter 3) and supported other 
workers reporting similar findings in human squamous cell carcinomas 
of other human organs e.g. skin, cervix and oesophagus (Morris et al., 
1983; Caorsi and Figueroa, 1984, 1986; McArdle and Muller, 1986; Bonilla-
Musoles et al., 1987; Korenberg et al., 1988; Xie, 1990; Matsuda, etal., 1990). 
Epidermal LDC recognised TAA (Kato et al., 1977; 1979; Yagi et al., 1987) 
expressed by the squamous cell carcinoma leading to the increase in the 
number of fully dendritic epidermal LDC in and around these lesions. 
The TAA processed by the fully dendritic epidermal LDC, resulted in T- 
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lymphocyte activation, tumour necrosis, reduction in tumour size 
and/or tumour regression. These changes presumably reflect an effective 
immunological anti-tumour response initiated by the expression of TAA 
in these tumours. Other workers have proposed that tumours may 
release factors which are chemotactic for Langerhans dendritic cells, 
hence drawing them into the tumour environment (Halliday, et al., 
1992). Cytokines among other chemotactic factors may represent 
additional factors needed to stimulate the antigen processing and T 
lymphocytes stimulation by LDC. 
7. 5 Precursor of Langerhans dendritic cells 
S100+ LDC were identified in normal bone marrow, spleen and in lymph 
nodes. Their size and morphology varied within these tissues between 
small, intermediate and large, with or without obvious dendrites on their 
surfaces. The variation in size and morphology of LDC in tissues is 
consistent with the previous observations on the S100+ LDC in various 
lung tumours (Chapter 3) and in agreement with similar observations 
reported by both Watanabe et al., (1983) and Uccini et al., (1987). 
The S100+ cells in the blood and the isolated metrizamide enriched LDC 
were always small and did not have obvious dendrites extending from 
their cell membrane. These cells were significantly larger than 
lymphocytes (p<0.001) but smaller than monocytes. The findings in this 
study support the observations of Watanabe et al., (1983) and Uccini et al., 
(1987) as they reported the small S100+ lymphocyte-like cells in the blood, 
lymph nodes and spleen and proposed a lineage relationship between the 
Chapter 7 
	
General Discussion 	 Page 125 
S100+ LDC found the these tissues and the small S100+ cells observed in 
the blood. 
When the ultrastructure of the S100+ cells in the blood was examined 
(Fig. 6.6a&b), the results dearly supported the concept that these blood 
S100+ cells are in fact related to the S100+ LDC, but different from 
lymphocytes and monocytes.. S100+ cells in the blood had a few short 
dendrites, S100+ protein granules in the cytoplasm and around the 
indented nuclear membrane. Their cytoplasm contained numerous and 
large mitochondria, tubular cytoplasmic structures, single or 
multivesicular bodies, but no classical BG were seen. This description is 
totally consistent with the ultrastructure of LDC previously described 
(Steinman and Cohn, 1973; Van-Voorhis et al., 1982; Dezutter-
Dambuyant, 1988; Romani and Schuler, 1989; Steinman, 1991). The 
cytoplasm of these S100+ LDC did not contain the azurophilic granules 
found in monocytes (Zucker-Franklin, 1975), and was not granular as in 
lymphocytes and granulocytes (Zicca et al., 1981; Monahan et al. 1981). 
Based on these observations it is proposed that these S100+ cells in the 
blood represent the precursor of the S100+ LDC found in human bone 
marrow, spleen and lymphoid tissue. 
It is most likely that the S100+ lymphocytes described in the blood by 
Takahashi and co-workers, 1984, 1985, 1987; De Panfilis et al., (1988); 
Sansoni et al., (1987); Ferari et al._, (1988) and Hanson et al., 1991 were in fact 
the blood S100+ LDC. This is supported by the observations of other 
workers investigated the S100+ LDC and other lymphoid cells in various 
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human tissues (Timens, et al., 1988; Temenia et al., 1990; Gallo et al., 1991; 
Huang, 1990; Giannini et al., 1991; Cribier, 1992; Shin and Co-workers, 1992, 
Yamaguchi et al., 1992; Gaillard et al., 1993; Colasante et al., 1993; Paschke et 
al., 1993; Chaux's group, 1993; Hart and Co-workers, 1993). There has not 
been a single report describing 1-lymphocytes coexpressing S100 protein in 
their cytoplasm . 
Based on the evidence presented in this study, it is proposed that the small 
S100+ cells found in the peripheral blood, represent the precursors of LDC 
found in human skin, bone marrow, spleen, lymph nodes and some 
pathological conditions such as tumours. While they co-express the 
common leukocyte surface marker CD45 and occasionally weak T cell 
surface markers, there is no obvious lineage relationship with either T-
lymphocytes or monocytes. 
7.6 General conclusion 
This thesis demonstrated clearly that the density of the antigen 
presenting Langerhans dendritic cells in tobacco smoke induced human 
lung cancer is related to tumour type and differentiation. Their highest 
density in bronchioalveolar carcinoma, well and moderately 
differentiated SCC was associated with marked TIL in and around these 
tumours. This was associated with tumour necrosis and longer patients 
survival. 
Why bronchioalveolar, well and moderately differentiated squamous cell 
carcinomas attracted more LDC than SCLC and poorly differentiated 
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squamous cell carcinoma is an important question yet to be answered. 
The relationship between LDC and TAA in certain human tumours 
deserves further investigation. 
It was also demonstrated that tobacco smoke and/or its condensate 
increased the number of LDC in murine lungs and skin. This was 
associated with the development of pulmonary Langerhans dendritic cell 
granulomatosis and other tobacco smoke induced bronchial and alveolar 
lesions. The increase in number of morphologically altered and 
functionally compromised LDC induced by TS was associated with the 
development of pulmonary Langerhans cell granulomatosis, lung and 
skin tumours. This experiment demonstrated a clear relationship 
between tobacco smoke exposure and the development of pulmonary 
Langerhans cell granulomatosis, bronchial and alveolar lesions. This is 
the first experimental observation of this relationship and implicates 
pulmonary Langerhans dendritic cells in the pathogenesis of these 
lesions. 
The role of these antigen presenting LDC during tumour development 
warrants further investigation with special emphasis on their functional 
status. 
While stopping tobacco smoke inhalation was associated with decrease in 
pulmonary LDC number, their number increased significantly in murine 
SCC of the skin after ceasing further treatment with TSC. The decrease in 
their number in murine lungs was associated with reversible changes of 
all tobacco smoke induced pulmonary lesions with the exception of 
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bronchial squamous metaplasia which persisted. The continuous increase 
in their number in skin SCC after stopping further TSC treatment was 
associated with marked TIL causing tumour necrosis, spontaneous 
regression of these tumours and/or decrease in tumours size. 
It is concluded that tobacco smoke and its condensate increased the 
number of the functionally compromised LDC. This decreased the 
cellular immunity and resulted in the development of pulmonary and 
skin lesions. This implicates the tobacco smoke induced LDC changes in 
the pathogenesis of tobacco smoke induced lesions. 
The increase in their number in well, moderately differentiated SCC of 
human lungs and in murine SCC of the skin and the associations with 
longer survival in human and spontaneous regression of murine SCC of 
the skin indicates an effective anti-tumour response. 
The ani-tumour activity of tumour infiltrating LDC, their interaction 
with tumour cells and TIL is an excellent direction for future research in 
the field of tumour immunology. 
Based on the evidence presented in this study, it is concluded that the 
small S100+ cells found in the peripheral blood, most likely represent the 
precursors of LDC found in skin, lymphoid tissue and some pathological 
conditions such as tumours. While they co-express the common 
leukocyte surface marker CD45 and weak T cells markers, there is no 
obvious lineage relationship with either T-lymphocytes or monocytes. 
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The diagnostic and prognostic values of S100+ LDC in the peripheral 
blood of patients with malignant diseases, various types of atopic allergy, 
autoimmune diseases and in patients had organ transplant are yet to be 
investigated. The pharmacological control of the function of LDC in such 
conditions warrents study as it may provide an approach to control these 
conditions. 
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S100 POSITIVE DENDRITIC CELLS IN HUMAN LUNG 
TUMORS ASSOCIATED WITH CELL DIFFERENTIATION 
AND ENHANCED SURVIVAL 
NAIEM A. ZEID AND H. KONRAD MULLER 
Department of Pathology, University of Tasmania, Hobart 
Summary 
Antigen presenting S100 positive dendritic cells have been 
quantified in normal trachea, lung, bronchial lymph nodes, 130 
lung tumors and in 100 lymph nodes regional to tumor. Dendritic 
cells are rarely seen as intraepithelial components of the normal 
bronchial mucosa, but are more commonly observed in the pen -
vascular lymphoid l i  tissue of the submucosa and in the alveolar 
septae of normal lung parenchyma (6 ± 4.85 cells/HPF). The 
density of these dendritic cells is marked in histologically normal 
bronchial lymph nodes. Bronchioalveolar (Alveolar II), well and 
moderately differentiated squamous cell carcinomas contain the 
highest density of S100 positive dendritic cells, while small cell 
lung cancer and poorly differentiated squamous cell carcinoma 
show the lowest density. Regional lymph nodes to lung tumors 
with lymphocytic predominance and active germinal centres show 
the highest density of dendritic cells, while unstimulated lymph 
nodes contain the lowest number of S100 positive dendritic cells. 
Tumor infiltrating lymphocytes are marked in and around lung 
tumors with the higher density of dendritic cells. Survival of 
patients whose tumors contain high density of S100 positive 
dendritic cells is more favourable compared to tumors with low 
density of these cells. It is concluded that the density of the 
antigen presenting S100 dendritic cells in lung tumors is related 
to subtype, and tumor differentiation. A high dendritic cell density 
is associated with enhanced patient survival. 
Key words: Langerhans cells, S100 positive dendritic cells, human lung 
tumors, enhanced survival and S100 dendritic cells. 
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INTRODUCTION 
Langerhans cells (LC) were the first dendritic cell to be 
described in the epidermis. The unique ultrastructural 
marker of this cell is the cytoplasmic organelle, the 
Birbeck granule. The bone marrow origin of LC was first 
reported by Frelinger et al.' and demonstrated by the 
elegant experiments of Katz and colleagues. 2 
LC are widely distributed in human skin, esophagus, 
cervix, ocular and buccal epithelia. 3 Other related 
dendritic cells have been reported in the dermis of the 
skin (indeterminate dendritic cells), in the afferent lymph 
(veiled dendritic cells), in spleen and lymph nodes (inter-
digitating dendritic cells) and interstitial dendritic cells 
in the connective tissue of all organs but the brain. 4 Little 
is known about the precursor of LC in the bone marrow. 
The Primary function of LC and other related dendritic 
cells is to process and present antigen to T lympho- 
cytes in the regional lymph nodes to initiate an immune 
response." 
LC were first reported in human tumors (cervix) by 
Younes et al.' Since then LC have been reported in other 
tumors: bronchioalveolar tumor of lung,' laryngeal carci-
noma,' pleomorphic adenoma of salivary gland,' skin 
tumors, 11,12 lung, 8,21,22 breast and thymoma, 3 esopha-
geal" and gastric tumors," papillary thyroid carcinoma,' 
colorectal carcinoma,' nasopharyngeal carcinoma,' and 
prostatic carcinoma." S100 protein was used as a marker 
for LC in most of the above reports. Hammar et al. 3 
reported Birbeck granules in all the S100 positive dendritic 
cells in lung bronchioalveolar cell carcinoma and adeno-
carcinoma, nasopharyngeal, ovarian, breast carcinomas, 
thymoma and in malignant histiocytosis. 
Basset and colleagues8 first reported dendritic cells in 
the bronchio-alveolar lavage fluid of patients with primary 
alveolar carcinoma of the lung similar in ultrastructural 
features to LC. Since then Kawanami et al. 17 and Richard 
et al.' have described LC with characteristic features in 
normal human lung. Sertl et al." and Holt and Schon-
Hograd, 2° have also reported Ia positive dendritic cells in 
the bronchial epithelium and in the alveolar septum of 
normal lungs of mice, humans and rats. 
In human lung tumors there are conflicting reports on 
dendritic cells and prognosis. While Furukawa et al. 21 
associated longer survival with marked infiltration of LC 
in stage la adenocarcinomas of the lung, Fox et al. 22 
suggested that a high number of LC in lung tumors is 
associated with a worse prognosis. They also reported 
CD1 positive LC mainly in squamous cell carcinoma and 
adenocarcinoma of the lung. 
In the present study S100 positive dendritic cells have 
been quantified in normal trachea, lung, 130 lung tumors 
and in regional lymph nodes draining lung tumors. 
MATERIALS AND METHODS 
Specimens 
Paraffin blocks of 130 lung tumors, 100 regional lymph nodes, 13 
normal lung and 7 normal bronchial lymph nodes were obtained from 
the files of the Department of Anatomical Pathology, Royal Hobart 
Hospital. Three 3-4 micron sections were cut from each block, one for 
S100 staining, a second for antibody control and a third for hematoxylin 
and eosin staining. 
Clinical data 
All data related to patients involved in this study were obtained from 
the files of the Medical Record Department, Royal Hobart Hospital. 
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Preparation of tracheal and bronchial mucosa! sheets 
Four segments, 2 x I cm each of unfixed trachea and major bronchus 
from 2 autopsies were incubated in 20 mm solution of EDTA, pH 7.2 
(ethylene diamine tetraacetic acid-Na4-salt, Serva 11282). The incuba-
tion time and temperature were modifications of those suggested by 
Scaletta and MacCallum. 23 The mucosal segments were incubated for 
3 hrs at 37°C and overnight at 4°C. The tracheal and bronchial segments 
were treated with 50 per cent ethanol alcohol for 30 mins. The mucosal 
sheets were separated gently from the underlying cartilage, flattened 
on filter paper and processed for routine paraffin embedding; mucosal 
segments were blocked in paraffin as a flat mucosal sheet. The whole 
tracheal and bronchial mucosa were tangentially and serially sectioned 
at 3 micron. A total of 159 sections were prepared for immunohistology 
and routine staining. 
Immunohistology 
Rabbit antibody to bovine S100 protein (Dakopatts, Denmark, Z 311) 
was used to identify the dendritic cells in paraffin sections. The paraffin 
wax of sections was first melted at 56°C for 2 hrs, dried overnight at 
37°C and then the paraffin wax remelted at 56°C for 5 mins before 
dewaxing in 2 changes of xylene, 5 mins each. Sections were hydrated 
in descending concentration of ethanol alcohol to water. Dewaxed 
sections were placed in pre-warmed phosphate buffer saline (PBS), pH 
7.4 at 37°C for 5 mins. Enzyme digestion was then carried out by placing 
the sections in pre-warmed 360 mL PBS, pH 7.4, containing 0.02 gm 
of protease (Sigma No. 8038) and incubated at 37°C for 6 mins. After 
washing the sections in running water for 5 mins they were rinsed in 
0.05 M TRIS-HCL saline, pH 7.6, for 5 mins. After drying, S100 anti-
body diluted 1:400 in diluent (1% bovine serum albumin, Sigma A 7030 
and human serum group AB, CSL 1121001) was applied to the sections 
and incubated for 90 mins at room temperature. Sections were washed 
in 0.05 TRIS-HCL, pH 7.6, for 5 mins. Sections were then incubated 
for 50 mins at room temperature with the secondary antibody 
(biotinylated anti-rabbit immunoglobulin, Biogenex HK 326-UR) diluted 
1:500 as for S100 antibody. After washing sections in 0.05 M TRIS-
HCL saline, they were incubated with label streptavidine alkaline phos-
phatase (Biogenex UK 321 UK) diluted 1:50 in TRIS-HCL 0.05 M pH 
7.6 and incubated at room temperature for 50 mins. Sections were rinsed 
in 0.1 M TRIS-HCL pH 8.2 after washing in 0.05 M TRIS-HCL pH 
7.6. The substrate (naphthol phosphate in Tris buffer) and the chro-
magen, Fast Red (fast red TR salt and levamisole, Biogenex, USA, HK 
182-5K) were applied to the sections and incubated at room tempera-
ture for 20 mins and then counterstained in Mayers hematoxylin for 
3 mins after washing in de-ionised water for 5 mins. Following washing 
in de-ionized water sections were mounted in crystal/mount (Biomeda, 
USA, MO2), cleaned in xylene and finally mounted in Eukitt (Carl Zeiss, 
West Germany, 00 20 02). 
Identification and counting of S100 positive dendritic cells 
The S100 positive dendritic cells were identified by their red cytoplasm, 
indented nuclear membrane and prominent nucleolus (Fig. I). Chondro-
cytes of bronchial cartilage, myoepithelial cells of the serous glands in 
the lamina propria and nerve fibres are S100 positive in lung sections, 
but these cells were readily distinguished from the S100 positive dendritic 
cells. 
S100 positive dendritic cells (DC) were counted in 4 high power fields 
( x 400) for each section. These fields covered the tumor itself and zonal 
junction between the tumor and the surrounding lung parenchyma. The 
mean of the dendritic cells number in the 4 high power fields and the 
standard deviation were calculated for each case. 
The relationship between the S100 positive DC in each type of lung 
tumor and the density of tumor infiltrating lymphocytes (TIL) in and 
around tumors was recorded. The density of TIL have been evaluated 
as mild, moderate and marked. 
Counting the S100 positive DC in lymph nodes was done following 
the same methodology applied to lung sections. 
Fig. 1 S100 posito, e denciritic cell (DC) shows red cytoplasm and 
indented nucleus (Immunoperoxidase Technique x 250). 
RESULTS 
Normal tracheal, bronchial mucosa and lung 
S100 positive DC were rarely found in the intraepithelial 
component of the bronchial tree (Fig. 2). They were 
commonly observed in the lamina propria of the tracheal 
and bronchial mucosa close to the perivascular lymphoid 
tissue. An average of 2 S100 positive DC were present 
in both tracheal and bronchial sections in every 3 HPF. 
DC were observed in the alveolar septum of all sections 
of normal lung, but in various densities. Occasionally DC 
were found in the alveolar spaces (Fig. 3). The mean of 
S100 positive DC count in 4 high power fields was 6 ± 4.85 
cells in normal lung. 
Dendritic cells in lung tumors 
S100 positive DC were found in direct contact with TIL 
and tumor cells in all varieties of lung tumors, but with 
various densities. Bronchioalveolar (Fig. 4) and well and 
moderately differentiated squamous cell carcinomas 
(Fig. 5) showed the highest number of these cells within 
tumors. Small cell lung cancer, mucus producing 
Fig. 2 S100 positive DC in the bronchial epithelium and in the 
bronchial lymphoid tissue (Immunoperoxidase Technique x 400). 
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Fig. 3 S100 positive DC in the alveolar spaces. Al‘colar macro-
phages (arrow) are negative for SIO0 protein (Immunoperoxidase 
Technique x 400). 
Fig. 4 S100 positive DC in bronchioalveolar carcinoma 
(Immunoperoxidase Technique x 250). 
Fig. 5 S100 positive DC in well differentiated squamous cell 
carcinoma (Immunoperoxidase Technique x 100). 
adenocarcinomas and poorly differentiated squamous cell 
carcinomas contained the lowest number of S100 posi-
tive DC. Table 1 summarizes these results. 
Dendritic cells morphology in lung tumors 
The number of DC dendrites in relation to the histological 
variety of the lung tumors were examined. DC were 
divided into 2 groups according to the number of 
dendrites extending from the cell body, first DC with 
more than 3 dendrites and secondly DC with less than 
3 dendrites. DC with more than 3 dendrites were found 
in 77.8% of bronchioalveolar carcinomas, 67.4% of well 
and moderately differentiated squamous cell carcinomas, 
34.7% of all varieties of adenocarcinomas and in 32.6% 
of poorly differentiated squamous cell carcinomas. 
Dendritic cells with less than 3 dendrites were more 
commonly seen in the majority of small cell lung cancer 
and poorly differentiated squamous cell carcinoma. 
Contact between DC and lung tumor cells 
Direct contact between S100 positive DC and tumor cells 
(Fig. 6) was consistently present in all bronchioalveolar 
(alveolar II) carcinomas, in all well and moderately 
differentiated squamous cell carcinomas and in 81.3% 
of all varieties of adenocarcinomas. Contact between DC 
and tumor cells was rarely observed in poorly differen-
tiated squamous cell carcinomas and small cell lung 
cancers, although LC were present in these lesions. 
Contact between DC and TIL in lung tumors 
Direct contact between DC and TIL were found in all 
varieties of lung tumors (Fig. 7). In general there was a 
proportional relationship between the number of DC and 
the density of TIL in and around various lung tumors. 
The density of TIL was marked in bronchioalveolar, and 
in well and moderately differentiated squamous cell carci-
nomas. The density of TIL was moderate in other 
varieties of adenocarcinomas and mild in both poorly 
differentiated squamous cell and small cell lung cancer. 
Central tumor necrosis, DC number and 
TIL density in lung tumors 
Central tumor necrosis was evident in lung tumors with 
high number of DC and marked density of TIL. Marked 
TABLE 1 S100 positive DC in lung tumors 
H istology No. of cases 
Mean of 
S100+ DC SD 
I. Bronchioalveolar 16 57.8 26.5 
2. Well differentiated squamous 
cell carcinoma 
16 42.6 21.2 
3. Moderately differentiated 
squamous cell carcinoma 
14 37.4 10.8 
4. Poorly differentiated squamous 
cell carcinoma 
38 13.2 10.8 
5. Nonciliated and Clara cell 
adenocarcinomas 
18 25.06 11.4 
6. Ciliated and mucous producing 
adenocarcinomas 
14 12.35 5.7 
7. Adenosquamous carcinoma 4 24.25 8.2 
8. Small cell lung cancer 10 4.7 3.8 
Normal lung 13 6 4.85 
(Using the non-parametric, Wilcoxon test,  1 verse 4, 5, 6, and 8 was 
significantly different, p <0.0005). (2 verse  4, 5, 6, and 8 also signifi- 
cantly different, p <0.0001, 0.0125, 0.0001 and 0.0003 respectively). 
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Fig. 6 Direct ,ontact between S100 positive DC and tumor cells, 
adenocarcinoma (Immunoperoxidase Technique x100). 
Fig. 7 Contact between S100 positive DC and tumor infiltrating 
lymphocytes (TIL) (Immunoperoxidase Technique x400). 
central tumor necrosis was found in 70% of well and 
moderately differentiated squamous cell carcinomas as 
well as in 30 07o of the small number of cases with 
bronchioalveolar carcinomas. 
Dendritic cells in lymph nodes regional to lung tumors 
Based on the histological evidences of immunological 
activity, 24 lymph nodes regional to the lung tumors 
examined in this study have been divided into 3 groups. 
Firstly lymph nodes with lymphocytic predominance, 
secondly lymph nodes with active germinal centres and 
thirdly an unstimulated group of lymph nodes. S100 posi-
tive DC were found in the paracortical T lymphocyte area 
(Fig. 8). The density of S100 positive DC in various 
groups of lymph nodes are shown in Table 2. The density 
of S100 positive DC was high in lymph nodes showing 
lymphocytic predominance and in lymph nodes with 
active germinal centres. The unstimulated lymph nodes 
showed the lowest density of DC. The density of the S100 
positive DC in bronchial lymph nodes regional to normal 
lung was higher than unstimulated lymph nodes. 
Fig. 8 S100 positive DC in the T-zone of lymph nodes 
(Immunoperoxidase Technique x 250). 
The dendritic nature of DC was recorded in all vari-
eties of lymph nodes examined. About 93% of DC in 
lymph nodes with lymphocytic predominance show 
more than 3 dendrites, compared to 89% in lymph nodes 
with active germinal centres and to less than 50% in 
unstimulated lymph nodes. The number of dendrites 
reflected the state of immunological activity of these 
lymph nodes. 
S100 positive DC and patients' survival with lung cancer 
When patients were divided into those with the highest 
number of S100 positive DC in their tumors and a second 
group with the lowest number of DC (see Table 3), impor-
tant comparisons were evident. 
The density of TIL was marked in tumors with the 
highest number of DC and it was scanty in tumors with 
the lowest number of DC. The overall survival of patients 
in the former group was almost twice that of the second 
group. About 92.6% of the cases in the better surviving 
group are well, moderately differentiated squamous cell 
and bronchioalveolar lung carcinomas, while small cell 
lung cancer, poorly differentiated squamous cell and 
other varieties of adenocarcinomas formed about 85.2 
per cent of cases in the second group. 
The M:F ratio in the 2 groups was 3:1. Patients in 
both groups smoked an average of 28 cigarettes a day 
for some 37 yrs. There was no difference in tumor size 
or in the incidence of lymph node metastasis in both 
groups. 
TABLE 2 S100 positive DC in regional lymph nodes 
Histology of lymph nodes No' 
Mean of 
SI0O+DC SD 
Lymphocytic predominance (A) 27 69.26 28.88 
Active germinal centre (A) 46 69.67 28.42 
With metastasis (A) 16 69.95 43.92 
Unstimulated (B) 33 24.82 13.43 
Normal lymph nodes (B) 7 35 10.23 
411 )\ 
411411 " 	• 
Based on the Bonferroni multiple-comparison test, lymph nodes with 
(A) were not significantly different at the 5% level, while groups (A) 
and (B) were significantly different. 
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TABLE 3 Lung tumors with the highest and lowest number of S100 
positive DC 
Highest No. of DC Lowest No. of DC 
1. No. of cases 27 41 
2. S100+ DC/HPF 69.8 ± 19.40 6.55±3.53 
3. Density of TIL Marked Scanty 
4. Average tumor 3.53± 1.43 4.7±3.26 
size (cm) 
5. LN metastasis 33.3% 34.3% 
6. M:F ratio 3:1 3:1 
7. Cigarettes/day 28.69 ±15.39 27.62±17.18 
8. Smoking years 37.23 ±10.32 36.27 ±13.3 
9. No. of dead 8 (29.6%) 28 (68.6%) 
10. Survival (months) 68.46±32.87 8.3±7.72 
since diagnosis 
11. Histological D.SCC 59.3% PDSCC 55.17% 
typing BA 	33.3% ADENO 31.03% 
ADENO 7.4% SCLC 	13.79% 
D.SCC = well and moderately differentiated squamous cell carcinoma. 
PDSCC= poorly differentiated squamous cell carcinoma. 
BA =bronchioalveolar carcinoma. ADENO =adenocarcinoma. 
SCLC = small cell lung carcinoma. 
DISCUSSION 
This study demonstrates that in lung tumors the density 
of antigen presenting S100 positive dendritic cells varies 
according to cellular subtype and differentiation of lung 
carcinomas. Bronchioalveolar (alveolar II), well and 
moderately differentiated squamous cell carcinomas 
contain the highest number of dendritic cells. The density 
of TIL is in direct proportional relationship with the 
number of S100 positive dendritic cells. Patients with high 
number of dendritic cells in their lung tumors, e.g. 
bronchioalveolar, well and moderately differentiated 
squamous cell carcinomas, survived longer than patients 
with a low number of dendritic cells, e.g. poorly differ-
entiated squamous and small cell lung cancer, i.e. 68.46 ± 
32.87 mths compared to 8.3 7.72 mths. 
S100 positive DC with more than 3 dendrites were the 
majority in bronchioalveolar, well, and moderately 
differentiated squamous cell carcinomas of the lung and 
in lymph nodes with lymphocytic predominance and 
active germinal centres. These findings favour the hypo-
thesis that the increase in number of LC dendrites in 
certain tumors may reflect an active immunological state. 
Contact between S100 positive DC, tumor cells and T 
lymphocytes were investigated in the varieties of lung 
tumors and in lymph nodes. Direct contact between these 
antigen presenting cells and tumor cells was observed in 
all bronchioalveolar, well differentiated, moderately 
differentiated carcinomas and in the majority of 
adenocarcinomas. Direct contact was also observed 
between T lymphocytes and DC in lung tumors and in 
the T-zone of lymph nodes. This contact may reflect the 
immune interaction between DC, tumor cells and T 
lymphocytes. This has also been reported in human skin 
tumors. 11 
Central tumor necrosis in the investigated lung neo-
plasms was related to high density of S100 positive DC 
and marked infiltration of TIL. This was observed in 
well, moderately differentiated squamous cell and in 
bronchioalveolar carcinomas. This may result from the 
effect of sensitized T lymphocytes acting specifically 
against the target tumor cells. 4 ' 6 
The current study shows that the density of dendritic 
cells in lymph nodes regional to lung tumors is directly 
related to the immun °histological activity of these lymph 
nodes. Lymph nodes showing active germinal centres or 
lymphocytic predominance contained higher numbers of 
S100 positive dendritic cells than the unstimulated 
nodes." 
Kitaichi et al." reported that the 3 yr survival of 
patients in stage 2 and 3 of lung cancer in which the 
regional lymph nodes showed lymphocytic predominance 
or active germinal centres was better than in patients with 
unstimulated lymph nodes. 
Furukawa et al."- also reported that patients with a 
marked number of S 100 positive DC in and around their 
lung adenocarcinomas survived longer than patients 
without or with minimal infiltration of these cells. 
Temeck et al. 25 found 65.25°70 of patients with carcino-
mas of the lung alive 10 yrs after diagnosis and treatment 
were epidermoid carcinomas. Patients with adeno-
carcinoma represented 33.05%, while there was only one 
patient with small cell lung cancer and one patient with 
large cell lung cancer alive. A similar study by Kern et 
al. 28 reported 46.36 070 of patients with carcinomas of the 
lung who survived an average of 15.5 yrs after diagnosis 
and treatment had epidermoid carcinomas, 25.45% 
adenocarcinomas and 11.81% bronchioalveolar carcino-
mas. In a recent study of 9090 patients with carcinomas 
of the lung, Watkin et a1. 27 reported a longer survival 
for squamous cell carcinomas than small cell lung cancer. 
A relationship between the increased density of dendritic 
cells in other human tumors and longer patient survival 
has been reported during the last 5 yrs, e.g. nasopharyn-
geal tumors, 28 gastric tumors," papillary thyroid carcin-
omas," colorectal adenocarcinomas 16 and squamous cell 
carcinomas of the esophagus." 
This study also demonstrated that S100 positive 
dendritic cells are present in normal trachea and 
bronchus, normal lung parenchyma and normal bronchial 
lymph nodes. These dendritic cells were more commonly 
observed in the alveolar septum of normal lung but 
occasionally were seen in the normal tracheal or 
bronchial mucosa. T'hese observations are in agreement 
with Sertl et al.,' Richard et al." and Holt and 
Schon-Hegrad." 
The primary function of dendritic cells is the presenta-
tion of antigen to T lymphocytes in the regional lymph 
nodes." The selective increase in the number of DC 
in bronchioalveolar,  , well and moderately differenti-
ated squamous cell carcinomas may be related to specific 
tumor associated antigen. 4 . 19 Alternatively, tumors 
may release factors which are chemotactic for den-
dritic cells, hence drawing them into the tumor 
environment . 30 
In conclusion this study has clearly demonstrated that 
the density of S100 positive DC in lung tumors was related 
to cellular subtype and differentiation of tumor cells. 
Bronchioalveolar, well and moderately differentiated 
squamous cell carcinomas attracted the highest number 
of DC, and this was associated with marked density . of 
TIL and better survival. The mechanism by which the 
increased number of antigen presenting cells accumulate 
in tumors -warrants detailed investigation. 
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TOBACCO SMOKE INDUCED LUNG GRANULOMAS AND TUMORS: 
ASSOCIATION WITH PULMONARY LANGERHANS CELLS 
NAIEM A. ZEID AND H. KONRAD MULLER 
Department of Pathology, University of Tasmania, Hobart 
Summary 
The density of zinc-iodide-osmium (Z10) positive pulmonary 
Langerhans dendritic cells (LC) was increased about 20-fold in 
mice after passive exposure to tobacco smoke. This was 
associated with pulmonary changes consistent with the cigarette 
smoking-related clinical syndrome in humans, pulmonary Lange-
rhans cell granulomatosis. The major feature was an interstitial 
peribronchial granuloma. The cellular infiltrate of the granuloma 
(lymphocytes, plasma cells, eosinophils, clusters of large 
histiocyte-like cells and macrophages) extended into the adjacent 
alveolar septum forming a star-shaped lesion. The histiocyte-like 
cells were large with pale acidophilic cytoplasm and many ill-
defined short dendrites extending from the cell membrane. Bron-
chial epithelial metaplasia also developed. The interstitial 
changes were followed by the development of proliferative 
alveolar and bronchial lesions in 2 mice. The zinc-iodide-osmium 
positive cells were consistent with la positive pulmonary dendritic 
cells and their ultrastructure was similar to that of pulmonary 
Langerhans cells. After ceasing exposure to tobacco smoke the 
density of pulmonary Langerhans cells returned to that of the 
control level; interstitial granulomatous lesions disappeared, but 
the bronchial epithelial metaplasia did not reverse. Tobacco 
smoke exposure of mice produces interstitial granulomatous 
inflammation similar to Langerhans cell granulomatosis in 
humans. The elevated level of pulmonary Langerhans cells impli-
cate these cells in the pathogenesis of these lesions. 
Key words: Langerhans cell, tobacco smoke, pulmonary histiocytosis X, 
Langerhans cell granulomatosis. 
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INTRODUCTION 
Histopathological changes in the lungs induced by 
cigarette smoking have been documented in humans," 
and experimental animals." Auerbach et al., 2 reported 
tobacco smoke induced histologic changes in human 
tracheobronchial epithelium. These included basal cell 
hyperplasia, stratification and squamous cell metaplasia 
of the bronchial epithelium. The epithelial changes were 
more frequent in patients with lung cancer than in cancer-
free smokers. 
The carcinogenic effects of tobacco smoke on the lungs 
of laboratory animals have been investigated by many 
workers. 3-7 These studies have concentrated on tobacco 
smoke induced precancerous changes and tumor develop-
ment. In mice, the pulmonary changes induced by 
tobacco smoke include bronchitis, atypical bronchial 
epithelial proliferation and occasional adenomatous lung 
tumors. 3 
Casolaro, 8 reported an increase in the number of CD1 
positive dendritic cells in the bronchio-alveolar lavage 
fluid of smokers, while Soler et al., 9 described an increase 
in both T6 + LC and M241 + dendritic cells in smokers' 
lung. A relationship between tobacco smoke inhalation 
and pulmonary interstitial granulomas has been reported 
in humans — 90% of patients with pulmonary histiocy-
tosis X were smokers.'" 
Basset and Turiaf," together with Nezelof et al.," 
established that the pulmonary histiocytosis X cell is a 
Langerhans cell. These cells were isolated from bronchio-
alveolar lavage fluid and characterized ultrastructurally. 
An excellent review of LC granulomatosis (histiocytosis 
X) was published by Hance et al.') The 3 clinical 
syndromes, Letterer-Siwe disease, Hand-Schiiller-
Christian syndrome and eosinophilic granuloma were 
grouped together and called histiocytosis X, based on the 
similarities of the lesions." . " Pulmonary Langerhans cell 
granulomatosis (pulmonary histiocytosis X) is slightly 
different from the other varieties of histiocytosis X. The 
former is commonly seen in young male adults," but not 
in children as are the other forms of histiocytosis X. 
Katzenstein and Askin," described the detailed histo-
logic features of pulmonary eosinophilic granuloma which 
included bronchiocentric, patchy and nodular lesions due 
to interstitial infiltration with a mixture of histiocyte-like 
cells and variable numbers of eosinophils, plasma cells and 
lymphocytes. The nodular interstitial lesions may appear 
"star-like" due to cell infiltration and fibrosis along the 
alveolar septum. A DIP-like reaction (desquamative inter-
stitial pneumonia-DIP), with accumulation of alveolar 
macrophages in the surrounding alveolar spaces may be 
seen but is not specific for pulmonary LC granulomatosis. 
Bronchiolitis is frequently observed and spontaneous 
healing of pulmonary LC granulomatosis may take place 
leaving a star-shaped scar." 
The diagnostic cell in this lesion is the Langerhans 
dendritic cell or histiocytosis X cell. It is a large cell with 
an ill-defined border, abundant eosinophilic cytoplasm, 
and a folded or indented nucleus with an inconspicuous 
nucleolus. There are many of these cells in active lesions, 
but they become rare in older fibrotic lesions." Birbeck 
granules (BG) in both epidermal LC and histiocytosis X 
cells show the same affinity for zinc-iodide-osmium (ZIO) 
staining," both cells are S100," and OKT6 positive." 
The ultrastructural features of histiocytosis X cells are 
consistent with those of LC. 18 ' 2° However, the BG in the 
histiocytosis X cell appear to be more often attached to 
the cell membrane than those in epidermal LC. 
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Fig. 1 Tobacco smoke chamber consisting of smoke generating unit with a cigarette holder (1) connected by plastic tube (2) to a central continuous 
source of air. This was connected by plastic tube (3) to the smoke exposure tent (4) which covered the mouse cage (5). The air outflow unit was 
composed of a safety smoke outlet (6) and adjustable central suction (7). 
The aim of this study was to investigate experimentally 
the effect of tobacco smoke on pulmonary LC in mice. 
The associated pulmonary lesions which developed are 
described. 
MATERIALS AND METHODS 
Animals 
BALB/c female mice 6-8 wks old Were obtained from the Central Animal 
House at the University of Tasmania after Animal Ethics Committee 
approval. The 108 mice used for the tobacco smoke inhalation experi-
ment were divided into 2 groups — experimental and controls, each 
of 54 mice. Control mice were kept separately in groups of 12 during 
the experiment, while the experimental mice were kept in groups of 6 
mice. 
Experimental design 
Experimental mice were exposed to the tobacco smoke of 8 cigarettes 
every day including weekends. Each cigarette needed 2 mins to burn 
completely, so the mice were exposed for a maximum of 16 mins each 
day. The smoke:air ratio used in this study was 1:12; other researchers 
have used ratios of 1:7. 21-23 An appropriate smoke:air ratio is vital 
to protect the mice from acute smoke toxicity and death. 
During the first week of the experiment, mice were exposed to the 
smoke of only one cigarette a day to acclimatize them to the much higher 
dose of 8 cigarettes during the second week. Six test and 6 control mice 
were killed by cervical dislocation at wks 1 and 2 and then every 4 wks. 
One lung from each mouse was snap-frozen in liquid nitrogen and stored 
in a – 80 °C freezer for ZIO and anti-la immunoperoxidase staining. 
The other lung together with the trachea and bronchi was perfused over-
night in 10 0/o formalin in PBS (pH 7.3), and processed for histological 
examination. At 28 wks histological examination of the lungs of the test  
group showed positive tobacco induced changes. The remaining mice 
ceased to be exposed to further tobacco smoke and were kept for another 
6 wks to study the reversibility of the tobacco induced changes in the 
lung. 
Tobacco smoke chamber 
The tobacco smoking chamber (Fig. 1) was designed by one of the 
authors (N. A. Z). It consisted of 3 units, a smoke generating unit, a 
smoke exposure tent and an air outflow unit. 
The smoke generating unit was a 500 mL filter (Buchner flask, Selbys, 
Cat No 414644, FB500/3) connected by plastic tube to a central 
continuous source of air. The rate of air flow can be adjusted by a valve 
switch. A cigarette holder was fitted in the centre of the cover of the 
flask. The mouthpiece of the cigarette holder was connected by plastic 
tube to the smoke exposure tent. The central air flow was switched on 
before lighting the cigarette and firmly closing the flask. The air flow 
to the flask was adjusted to ensure the 2 mins' time needed for complete 
burning of the cigarette. The air in the flask together with the gener-
ated tobacco smoke flowed through the cigarette holder and plastic tube 
to the smoking tent. The amount of smoke generated from burning 
one untipped cigarette was about 350 mL. 
The smoke exposure tent was designed to provide the mice in the tent 
with an environmental air similar to that of any enclosed place in the 
human situation. It consisted of the plastic tent and the mouse cage. 
The tent was constructed from transparent plastic and supported by 
a steel frame. The tent was not sealed at the lower margin in order to 
provide continuity and similarity between the tent and the room environ-
mental air. The tent was provided with a smoke inlet and safety smoke 
outlet connected to a central adjustable air suction. A standard animal 
cage was used provided with 74 holes at all sides, each hole about 1 cm 
in diameter. The cage measured 50 x 33 x 13 cm. 
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The air outflow unit consisted of a safety smoke outlet connecting 
the tent to the adjustable central suction. 
Tissue preparation 
Representative sections from the lung and bronchial lymph nodes of 
both control and test groups were processed and vacuum embedded 
in wax. Four pm sections were cut and stained with Haematoxylin and 
eosin for light microscopy examination. 
ZIO procedure to visualize Langerhans dendritic cells 
A modified ZIO procedure, 24.25 was developed because of the nature 
of the lung. The ideal size and thickness of the lung tissue were 
5 x 5 x 2 mm to ensure complete penetration of the fixative and staining 
solution. The frozen lung sections were fixed in V-7.4-ZIO (veronal 
sodium-HC1 buffer solution — pH 7.4-Z10) at 4°C for 19 hrs and then 
processed for routine paraffin embedding after washing in running tap 
water for 5 mins. Five pm sections were cut, dewaxed in 2 changes of 
xylene, 5 mins each and mounted directly in Eukitt mounting media 
(Carl Zeiss, West Germany, 00 20 02). 
Preparation of V-7.4-ZIO solution 
A mixture of 2.4 gm zinc powder (BDH Australia, Prod No 30596) and 
1 gm of iodine bisublimate (Ajax, Sydney-Melbourne, 267, 70516) was 
added to 40 mL of 0.2 M 7.4 veronal sodium-HC1 buffer. After shaking 
the mixture for 10 mins the solution was immediately filtered. The 
filtered solution was mixed with 2% osmium tetroxide (0s0., BDH 
Australia, Prod No 29422) in a ratio of 3:1. This solution was prepared 
fresh for each experiment. 
V-7.4-ZI0 staining for electron microscopy examination 
Modifications of the procedure of Rodriguez and Caorsi, 25 were used. 
Lung sections 25 pm thick were cut from paraffin blocks of lung tissue 
which had been already incubated with V-7.4-ZIO solution. They were 
dehydrated in ascending concentration of ethanol alcohol, 20 mins each 
and embedded in Epon resin. 
Immunoperoxidase staining to visualize Langerhans cells 
Five pm acetone-fixed frozen sections of lung tissue were mounted on 
potassium-dichromate-gelatine coated slides, dried for 2 hrs, incubated 
with mouse monoclonal anti-la (MKD6) for 90 mins at room tempera-
ture, washed 3 times in phosphate-buffered saline (PBS, pH 7.4) over 
20 mins, and incubated with horse radish peroxidase-conjugated rabbit 
anti-mouse immunoglobulin (HRPO-anti-Ig, 1:80; Dakopatts, 
Denmark). Sections were washed in PBS 3 times over 20 mins. The la 
positive cells were identified by incubating the sections with 0.5 mg/mL 
diaminobenzidine (DAB, Sigma) in PBS containing 0.02% H 20 2 , pH 
7.4 for 10 mins. Sections were washed in running water over 10 mins 
and counterstained with Mayers Haematoxylin. The washed sections 
were mounted in glycerol gelatine (Sigma, 86F-6098) for microscopic 
examination. 
Enumeration of ZIO positive LC in lung sections 
The number of ZIO positive LC in 4 high power fields (HPF x 400) 
was calculated using standard fields and the same microscope and objec-
tives throughout the study. The mean and the standard deviation were 
statistically analyzed for groups of mice assessed. 
RESULTS 
Pulmonary changes induced by tobacco smoke 
Bronchial epithelial hyperplasia, focal alveolar cell hyper-
plasia, mononuclear and eosinophil infiltration of the 
alveolar septum, together with alveolar macrophages in 
the alveolar spaces were observed in lungs of mice after 
4 wks of exposure to tobacco smoke. By the end of week 
8, multifocal interstitial lung lesions were present 
Fig. 2 Increase in thickness of the alveolar septum due to 
increased numbers of mononuclear cells. (Haematoxylin and eosin, 
original magnification x 100). 
composed of monocytes and lymphocytes (Fig. 2). This 
was observed in the lungs of 6 mice examined at this time. 
After 12 wks of tobacco smoke exposure, interstitial 
granulomas without central necrosis or cavitation were 
observed in lungs of 3 of 6 mice. Cholesterol-like crystals 
(Fig. 3) were present between the cells forming these 
granulomas as well as histiocyte-like cells, foamy macro-
phages, lymphocytes, plasma cells and eosinophils. The 
alveolar spaces around the granulomas showed alveolar 
epithelial hyperplasia with marked accumulation of 
macrophages. 
By 16 wks, bronchial epithelial hyperplasia and occa-
sional focal bronchial squamous metaplasia were 
observed (5 of 6 mice). The lung of one mouse at this 
stage showed a complex of histopathological changes. 
The basic lesion was peribronchial chronic inflammation 
(Fig. 4). Some lesions contained granulomas and there 
was a central cavity (Fig. 5). The cellular infiltrate of the 
granuloma extended in the adjacent alveolar septum 
Fig. 3 Interstitial granuloma showing cholesterol crystals, mononuclear 
cells and foamy alveolar macrophages. (Haematoxylin and eosin, 
original magnification x 200). 
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Fig. 4 Multiple peribronchial interstitial granulomatous inflammation. 
(Haematoxylin and eosin, original magnification x 100). 
forming a star-shaped lesion (Fig. 6). The cells forming 
the granuloma included clusters of large histiocyte-like 
cells and macrophages containing PAS positive material 
and hemosiderin. The histiocyte-like cells (Fig. 7) were 
large with irregular and indented nuclei with occasional 
prominent nucleoli. The cytoplasm appeared pale and 
acidophilic with ill-defined short dendrites extending from 
the cell membrane. 
Some bronchioles adjacent to the inflammatory lesions 
were filled with acute inflammatory exudate (Fig. 5) and 
the alveolar spaces contained a marked number of 
alveolar macrophages (DIP-like reaction, Fig. 8). The 
alveolar epithelium was hyperplastic and the subpleural 
airspaces showed focal emphysematous changes. 
By the end of 20 wks, 2 of 6 mice showed marked bron-
chial epithelial hyperplasia together with squamous 
metaplasia with occasional atypical epithelium. Multi-
focal interstitial granulomatous lesions were observed in 
the lungs of 2 of 6 mice similar to that found after 16 
Fig. 5 Interstitial pulmonary granuloma with a central cavity. 
Polymorphs are present in the bronchial lumen. (Haematoxylin 
and eosin, original magnification x200). 
Fig. 6 Star-shaped lesion of the interstitial pulmonary granuloma. 
(Gomori's reticulum stain, original magnification x400). 
wks. Older interstitial lesions demonstrate typical satel-
lite or star-shaped fibrosis. 
Neoplastic-like lesions were found in the lungs of 2 
mice. One lesion consisted of proliferating alveolar 
epithelial cells bounded by chronic inflammation (Fig. 
9). These histopathologic features are similar to so called 
alveogenic lung tumors, although the nature of these 
lesions is in question, ie reactive or neoplastic. 
The lesion in the lung of the second mouse was a single 
microscopic lesion consisting of multiple papillary struc-
tures (Fig. 10), filling what appeared to be a bronchiolar 
lumen. The cells of this lesion were cuboidal to columnar 
in shape and the nuclei hyperchromatic, rounded and 
eccentrically located. There were no cilia extending from 
the free borders of these cells. The histologic features of 
this lesion were consistent with a Clara cell bronchial 
adenoma. 
Fig. 7 Langerhans dendritic cells (arrow) in peribronchial interstitial 
granuloma. (Haematoxylin and eosin, original magnification x400). 
Fig. 10 Papillary Clara cell adenoma. (Haematoxylin and eosin, 
original magnification x400). 
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Fig. 8 Desquamative interstitial pneumonia (DIP) in the lung 
parenchyma. (Haematoxylin and eosin, original magnification x 100). 
At week 20, tobacco smoke exposure ceased and the 
remaining mice (6) were kept for a further 6 wks. The 
alveolar epithelial hyperplasia, the interstitial cellular 
accumulation, interstitial granulomas, features of bron-
chiolitis, DIP and the emphysematous changes resolved 
in 83 olo of the mice (5/6). A mild degree of these changes 
were observed in the remaining mouse. Only bronchial 
epithelial metaplasia persisted. 
Control animals did not show any of the changes 
observed in the test group during the time course of the 
study. 
Pulmonary ZIO positive Langerhans cells 
The ZIO positive dendiitic cells were smaller than alveolar 
macrophages and most were oval or triangular in shape. 
Black granules (Fig. 11) were observed scattered in the 
cytoplasm. The dendritic nature of these cells was demon-
strated in serial sections. The nuclear:cytoplasmic ratio 
Fig. 9 Focal alveolar proliferative lesion bounded by inflammatory 
reaction. (Haematoxylin and eosin, original magnification x 200). 
was always low around 1:2 and the nucleus appeared 
irregular. Most of the ZIO positive LC were found in the 
alveolar septum, and infrequent in alveolar spaces and 
were rarely found in the bronchial epithelium. The mean 
number of ZIO positive LC in normal lung was 1.3 
LC ± 0.4/HPF. 
There was a steady increase in the number of ZIO 
positive LC mainly in the thickened alveolar septa of the 
tobacco smoke exposed mice (Fig. 12) starting from the 
end of the first week (test = 2.3 ± 1; control = 0.8 ± 0.3). 
After 8 wks of tobacco smoke exposure, the number of 
pulmonary LC peaked (test =16.5 ± 3.6; control = 
0.67 ± 0.4, p <0.0001) and remained high with continuous 
exposure to tobacco smoke (test= 14.3 ± 4.3; control = 
0.5 ± 0.2, p <0.0001). When exposure to tobacco smoke 
ceased at the end of the 20 wks, the number of ZIO posi-
tive LC in the lungs of the remaining mice decreased to 
the level of the control group (test = 0.5 ± 0.3; control = 
0.7 ±0.6) after a further 6 wks. 
On ultrastructure the pulmonary dendritic cells with 
positive ZIO staining showed all the ultrastructural 
features of LC; the indented large irregular nucleus and 
Fig. 11 ZIO positive dendritic cells in  lung granulomatous 
inflammation after exposure to tobacco smoke. (ZIO staining, 
original magnification x 200). 
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Fig. 12 Pulmonary murine LC after exposure to tobacco smoke. 
Analysis of variance between test and control group showed a 
statistically significant difference in LC number (p <0.0001) between 
4-20 wks. 
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Fig. 14 ZIO positive pulmonary dendritic cell showing branched 
and unbranched labelled (arrow) Birbeck granules. (V-7.4-ZIO 
staining, original magnification x 34,000). 
black BG were easily identifiable (Figs. 13 and 14). Some 
branched BG were observed near the nuclear membrane. 
Many tubular structures were identified in the cytoplasm 
and the mitochondria were numerous. 
la positive pulmonary LC 
The morphology and size of the la positive dendritic cells 
were consistent with that of ZIO positive LC. Ia positive 
cells were mainly found in the alveolar septum and were 
occasionally seen with a few dendrites. Their numbers 
were similar to that of the ZIO positive LC. 
DISCUSSION 
The number of dendritic LC in the lungs of mice exposed 
to tobacco smoke for 20 wks increased approximately 25 
fold. Although the increase in the pulmonary LC was 
observed within one wk, the highest level was obtained 
Fig. 13 ZIO positive pulmonary dendritic cell showing labelled 
(arrow) Birbeck granules. (V-7.4-ZIO staining, original magnification 
x 34,000). 
after 8 wks and remained elevated until smoke inhala-
tion treatment ceased at 20 wks. This is in agreement with 
Casolaro et al., 8 and Soler,' who reported an increase 
in LC in smokers' lungs in humans. 
In this study ZIO positive pulmonary LC were always 
observed in control lungs in the alveolar septum and 
rarely in the bronchial epithelium.  The mean of ZIO posi-
tive pulmonary LC in normal murine lung was 0.9 ± 0.4 
cells/HPF. This parallels our previous findings on the low 
density of pulmonary LC in normal human lung.' 
The increase in the ZIO positive pulmonary LC after 
tobacco smoke exposure was associated with the develop-
ment of interstitial granulomas and inflammation. The 
alveolar spaces around the granulomas showed alveolar 
epithelial hyperplasia with marked accumulation of 
alveolar macrophages. By 16 wks, the basic lesion was 
the interstitial granuloma with a central cavity together 
with an inflammatory reaction  of the lung parenchyma 
around the granuloma. The  cellular infiltrate of the 
granuloma extended into the adjacent alveolar septum 
forming star-shaped lesions. 
The cytological features of the histiocyte-like cell were 
consistent with those of the histiocytosis X cell." They 
were irregular, with an indented or lobulated nucleus, pale 
acidophilic cytoplasm with ill-defined short dendrites 
extending from the cell membrane. While there were 
many of these cells in active  lesions, they become rare 
in older fibrotic lesions. 
In this study, on ultrastructural examination of the ZIO 
positive pulmonary dendritic cells, BG (Figs. 13 and 14) 
were observed in the cytoplasm. This confirmed the 
lineage relationship between histiocytosis X cell and LC. 
The bronchioles associated with the granulomas were 
filled with acute inflammatory exudate and the alveolar 
spaces contained many alveolar macrophages (DIP-like 
reaction). The alveolar epithelium was hyperplastic. By 
the end of 20 wks, some older interstitial granulomas 
progressed into typical fibrotic satellite or star-shaped 
lesions. These histopathological features are consistent 
with the human clinical syndrome related to tobacco 
smoke, pulmonary histiocytosis X, th. " now called 
pulmonary LC granulomatosis.' 
Although the pathogenesis of pulmonary LC 
granulomatosis is not clear, 90% of patients are 
smokers. 10-13 Carcinogens of tobacco smoke, eg 
benzo[a]pyrene and catechols may cause alveolar 
epithelial damage leading to proliferative, hyperplastic 
and neoplastic alveolar epithelial cells. 10,20.27.28 The 
damaged alveolar epithelium may express neoantigens 
which trigger the LC response and T-lymphocyte activa-
tion leading to necrosis of the target cells. Activated 
macrophages secreting collagenase, elastase, prosta-
glandins and other factors are also central to granuloma 
formation."'" 
Benzo[a]pyrene (BP) while increasing the number of 
pulmonary LC, may alter cellular immunity via prosta-
glandins. 2" Ruby et al., 29 and Andrews et al.," 
reported BP and co-carcinogen catechols increased the 
number of la positive LC, changed their morphology and 
impaired their function. This was associated with the 
development of skin tumors after 24 wks of treatment. 
Andrews and colleagues, 3° implanted the prostaglandin 
synthetase inhibitor, indomethacin beneath mouse skin 
before treatment with BP. This restored contact hyper-
sensitivity; delayed the, onset and reduced the size of skin 
tumors induced by BP: In a separate study we also inves-
tigated tobacco smoke condensate (TSC) induced 
cutaneous carcinogenesis and changes in epidermal LC. 
TSC increased the LC density, altered their morphology 
and impaired their function. This was associated with skin 
tumor development. 28 
Studies on the carcinogenic effects of tobacco smoke 
on the lungs of laboratory animals have concentrated on 
precancerous changes and tumor development."'" 
Interstitial granulomas have been observed only in one 
previous study, ie that by Mostofi and Larsen." They 
were investigating the histopathogenesis of urethane 
induced pulmonary tumors in mice when they observed 
the formation of interstitial granulomas between 3-12 wks 
prior to tumor development. They also observed large 
acidophilic cells in these granulomas. While Mostofi and 
Larsen,' did not investigate their observation further, 
their description of the interstitial granuloma is consistent 
with that of pulmonary LC granulomatosis (histiocytosis 
X). The large acidophilic cells are atypical LC. 32 
In this study we observed that the development of 
tumor-like lesions followed the formation of the inter-
stitial granuloma after 20 wks exposure to tobacco smoke. 
The histopathologic features of these lesions were consis-
tent with bronchial Clara cell adenoma and so called 
alveogenic tumors. This was associated with a high 
density of ZIO positive pulmonary LC. Shimkin and 
Stoner, 32 reported 95% of lung tumors in mice originate 
from the alveolar epithelium. We have previously 
described high density of S100 positive LC in tobacco 
smoke related human bronchioalveolar carcinoma and 
well differentiated squamous cell carcinoma. 26 
While tobacco smoke increased the ZIO positive pul-
monary LC density, the impaired function of these cells 
induced by benzo[a]pyrene in the inhaled tobacco smoke 
may have resulted in disordered alveolar epithelial growth 
in a setting of compromized immunological function. 
TOBACCO SMOKE AND PULMONARY LANGERHANS CELLS 253 
After tobacco smoke exposure ceased the fiistopatho-
logical changes resolved and the density of pulmonary 
LC returned to that of control levels. Only the bronchial 
epithelial metaplasia did not show reversible change. 
Bronchial epithelial metaplasia may require a longer time 
to resolve. 
In conclusion, this study has demonstrated that tobacco 
smoke increased the density of ZIO positive pulmonary 
dendritic cells and this was associated with the develop-
ment of bronchial squamous metaplasia, interstitial 
granulomatous lesions (pulmonary LC granulomatosis) 
and alveolar cell proliferation. The density of pulmonary 
LC returned to that of the control level after ceasing 
tobacco smoke exposure and the interstitial granulo-
matous lesions, but not the metaplasia resolved. The 
mechanism by which tobacco smoke increased the density 
of pulmonary LC may be related to benzo[a]pyrene, while 
functional changes in these antigen presenting cells may 
have a role both in chronic granulomatous inflammation 
and tumor development. 
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Summary. Tobacco smoke condensate was painted on the skin of BALB/c 
mice. It increased the density and changed the morphology of Langerhans' 
cells (LC). LC number in epidermal sheets of treated mice was significantly 
higher (1793 LC/mm 2) than in controls (946 LC/mm 2) (P<0.0001) and 
remained elevated for 35 weeks. LC became less dendritic, or even rounded 
in shape, and smaller in size. The function of the morphologically altered LC 
was impaired when assessed by the contact hypersensitivity response. 
These changes were associated with skin tumour development in all treated 
mice. 
Ten weeks after stopping the TSC treatment, LC number in skin tumours 
and in skin around these lesions had not decreased, but significantly 
increased (P < 0.0001). During this period tumour regression occurred in 
23% of tumours; the remaining tumours showed a 50% reduction in size. 
At 45 weeks, the LC number in epidermal sheets around skin papillomas 
was 2274 ± 14.14/mm 2 and in invasive squamous cell carcinomas was 
2088 183/mm 2. This was associated with reversible changes in LC 
morphology, where cells became fully dendritic. This also correlated with 
lymphocytic infiltration into tumours, tumour necrosis, reduction in tumour 
size and/or tumour regression. It is concluded that the influx of normal LC 
into the skin tumours allowed the development of an immune response with 
tumour regression. 
Keywords: Langerhans' cells, tobacco smoke condensate, carcinogens, 
squamous cell carcinoma, tumour regression 
Benzo[a]pyrene and catechols are the most important of 
the 71 carcinogens in tobacco smoke condensate (TSC) 
(Dube & Green 1982). Skin papillomas and squamous 
cell carcinomas of the skin have been reported in 
various animals, e.g. guinea-pigs, Swiss mice, C57 
black mice, after treatment with TSC (Wynder et al. 
1953; Wynder 1961; Druckrey 1961; Day 1966). 
Correspondence: Professor H.K. Muller, Department of Pathol-
ogy, University of Tasmania, 43 Collins Street, Hobart, Australia 
7000. 
Ruby etal. (1989) and Andrews etal. (1991) studied the 
effect of the tobacco derived benzo[a]pyrene (BP) and 
co-carcinogen catechols on the number, morphology 
and function of epidermal Langerhans' cells (LC). They 
reported a significant increase in number of the la 
positive LC, changes in their morphology and impair-
ment of their function. This was associated with the 
development of skin tumours after 24 weeks of treat-
ment (58% were squamous cell papilloma and 42% 
squamous cell carcinoma). 
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The various reports on the density of LC in squamous 
cell carcinomas of human skin are conflicting. Gatter 
etal. (1984) used NA1/34 monoclonal antibody to identify 
- 7 
LC in human skin tumours and reported changes in LC 
morphology and depletion in their number in squamous 
cell carcinomas. Smolle etal. (1986) used OKT-6 to study 
LC in human skin tumours and reported a low density of 
LC in squamous cell carcinomas compared to normal 
skin. McArdle and co-workers (1986) used an antibody 
to S100 protein to study LC in various skin lesions 
and reported a high LC density in keratoacanthoma, 
squamous cell carcinomas and basal cell carcinomas 
compared to the normal epidermis. Korenberg and his 
colleagues (1988) also used an antibody to S100 protein 
to study LC and supported McArdle et al. (1986) in 
regard to the high density of LC in keratoacanthoma 
but found a low density of S100 positive LC in squamous 
cell carcinomas. Alcalay et a/. (1989) used adenosine 
triphosphate to study LC and reported changes in LC 
morphology but no increase in LC number in squamous 
cell carcinomas. 
Analyses of LC in cervical intraepithelial neoplasia 
likewise are conflicting. The majority of reports indicate 
high LC number in cervical intraepithelial neoplasia 
(Morris et al. 1983, Caorsi & Figueroa 1984; 1986; 
Bonilla-Musoles et a/. 1987; Xie X. 1990) but Tay et al. 
(1987) reported low LC numbers in this lesion. The 
variation in the number of LC in squamous cell carcinoma 
in these reports may reflect the different methods used 
including counting techniques. 
The present investigation arose out of a previous 
study where we demonstrated an increase in LC 
density in well and moderately differentiated human 
lung squamous cell carcinomas in association with 
increased patient survival (Zeid & Muller 1993). As 
tobacco smoke is linked to the cause of these tumours 
(Auerbach et al. 1957), the present investigation was 
designed to examine the effect of TSC on LC during 
carcinogenesis in murine skin, a well established 
model to analyse the sequential development of 
squamous tumours. 
Materials and methods 
Animals 
Two hundred and four BALB/c male mice 6-8 weeks old 
were obtained from the central animal house at the 
University of Tasmania after ethical approval. A group 
of mice (48) were used to assess the function of LC, 
while the remaining 156 mice were divided into two 
groups of 78 mice each, experimental and control. 
Control mice were treated with olive oil and acetone, 
while the experimental mice were treated with TSC in 
acetone and olive oil. 
Experimental design 
After shaving the dorsal skin of control mice, this group 
was treated with 200 pi of olive oil and acetone (1: 1). 
The skin of the experimental mice was prepared as for 
the control and treated with 100 pl of olive oil and 100 AI 
of tobacco smoke condensate in acetone (1: 1). The 
treatment was applied every second day including the 
weekends. At 35 weeks TSC treatment was stopped, and 
the mice were kept for a further 10 weeks to observe 
changes in tumour size and relation to LC numbers. Six 
mice from the control and test group were killed by 
cervical dislocation at 3 days, 1, 2, 4, 8, 12, 16, 20, 24, 28, 
32, 36 and 45 weeks. Skin sections were stained with 
haematoxylin and eosin and irrimunoperoxidase anti-la 
staining to visualize and count LC in the prepared 
epidermal sheets. 
Preparation of tobacco smoke condensate 
The TSC was prepared by condensation of cigarette 
smoke by a cold trap (Bentley & burgan 1961). TSC 
was collected in jars and the water content evaporated 
by placing the jars, after gradual warming, in a water 
bath maintained at 100°C. TSC was then dissolved in , 
an equal volume of acetone. Each 550 cigarettes gave 
55g (35 ml) of condensate. After dilution with an equal 
volume of acetone, the total amount of diluted conden-, 
sate was 70 ml. 
Preparation of epidermal sheets 
A modification of the method of Scaletta and MacCallum 
(1972) was used to prepare epidermal sheets. The 
dorsal skin was shaved using electrical clippers and 
then depilated with a thioglycolate cream (Veet, Reckitt 
& Colman, UK). Adhesive cellophane tape was then 
applied to the dry skin, the skin was removed and 
incubated at 37°C for 3 hours in tetra-sodium i ethylene-
diamine tetraacetic acid solution (0.38g EDTA in 50 ml 
PBS, pH 7.4; Serva, 11282). Using fine forceps the 
epidermis was separated from the dermis and stained 
with anti-la to demonstrate epidermal LC. • 
lmmunoperoxidase anti-la staining of LC in epidermal 
sheets 
Epidermal sheets were fixed in acetone at MOM 
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temperature for 20-30 minutes and then incubated 
overnight at 4°C with mouse monoclonal anti-la 
(MK-D6). After the sheets had been washed in PBS for 
20-30 minutes, they were incubated at room 
temperature for 2 hours with horse-radish peroxidase-
conjugated rabbit anti-mouse immunoglobulin (HRPO-
anti-Ig, Dakopatts, Denmark), diluted 1:80 in PBS, 
pH 7.4. Epidermal sheets were washed again in 
PBS for 30 minutes and incubated for 10 minutes with 
diaminobenzidine (DAB; Sigma; 0.5 mg/ml of PBS 
containing 0.02% hydrogen peroxide, pH 7.4). The 
epidermal sheets were mounted in glycerine gel 
after washing in tap water. 
The la positive LC were identified in the epidermal 
sheets as brown dendritic cells with various numbers of 
dendrites extending from the cell body (Ruby etal. 1989). 
lmmunoperoxidase anti-la staining of LC in tumour 
sections 
Frozen sections (8 pm thick) of skin tumours were fixed 
in acetone for 20-30 minutes, washed three times in 
PBS over 20-30 minutes, incubated with.anti-la for 30 
minutes at room temperature, washed in PBS as before 
and incubated with HRPO-anti-Ig for 30 minutes at room 
temperature. Sections were washed again in PBS 
before incubation with DAB at room temperature (Ruby 
etal. 1989) for 10 minutes and counterstained in Mayer's 
haematoxylin after washing in running tap water for 5 
minutes. Finally, sections were mounted in glycerine 
gel. 
Enumeration of la positive LC in epidermal sheets 
LC were assessed as the number of la positive LC/mm 2 . 
The mean and the standard deviation were calculated. 
Histology 
Skin sections of mouse tumours and normal control 
skin were processed for routine haematoxylin and 
eosin staining. 
Contact hypersensitivity assessment 
The functions of LC were assessed by inducing a 
contact hypersensitivity reaction at the 2nd and the 6th 
weeks, after either treatment with TSC in a 1: 1 solution 
of acetone:olive oil or, in the control mice, acetone:olive 
oil alone. The dorsal skin of the test mice was initially 
sensitized with 10 Al of a 1% solution of 2,4,6-trinitro-
chlorobenzene (TNCB; Tokyo-Kasei Lot FCV61, 0.01 g/ml). 
Figure 1. Skin lesions and changes in LC number induced by 
TSC. a, Epidermal hyperplasia; b, dysplastic changes; c, skin 
papilloma; d, early invasive squamous cell carcinoma; 
e, treatment with TSC stopped; f, 10 weeks post ceasing TSC 
treatment. Difference in LC number in epidermal sheets of 
both — — —, test and —, control groups is significant 
(P < 0.0001). The increase in LC number in the test mice, 10 
weeks after stopping TSC treatment (2) is significant 
compared with LC number at 35 weeks (1), P <0.0001. 
The right ears of both control and test mice were 
challenged with 10l of a 1% TNCB solution 5 days 
after sensitization. The thickness of the right and the left 
(unchallenged) ear was measured 24 and 48 hours 
later using a spring-loaded engineers' micrometer. The 
percentage increase in ear swelling was calculated 
according to the following formula: 
% increase = 
thickness of right ear — thickness of left ear 
 x 100 
thickness of left ear 
The average percentage increase and the standard 
deviation were calculated for each group of mice. 
- Results 
Skin pathology induced by tobacco smoke condensate 
(TSC) 
The histopathological changes induced by the TSC in the 
skin of the treated mice are summarized in Figure 1. 
Epidermal hyperplasia was observed 2 weeks after 
treatment; the epidermis was composed of 6-8 cell 
layers compared to 2-3 layers of control epidermis. 
Dysplastic changes in the hyperplastic epidermis 
were observed in 25% of mice after 10 weeks of TSC 
treatment. The cells had enlarged hyperchromatic 
nuclei, and a high nuclear : cytoplasmic ratio. By 18 
weeks, about one-third of the treated mice developed 
macroscopic skin tumours, small wart-like papillomas, 
up to 2 mm in diameter. 
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Figure 2. Nest of invasive squamous 
cell carcinoma with mononuclear cell 
reaction around tumour; 10 weeks after 
ceasing TSC treatment. H&E. x200. 
Figure 3. la positive LC in frozen 
section of skin tumour. 
lmmunoperoxidase anti-la staining. 
x200. 
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After 26 weeks of treatment, the skin of the remaining 
50 mice showed skin tumours of various sizes, between 
1 and 6 mm in diameter. The histology of the largest 
skin tumour showed early invasive squamous cell 
carcinoma. By 35 weeks, the sizes of the skin tumours 
of all treated mice were between 0.2 and 1.3 cm in 
diameter and one-third of the mice had developed 
multiple tumours. The histology of skin tumours of the 
six mice killed at this stage showed invasive squamous 
cell carcinoma. 
Application of TSC was stopped at 35 weeks and 48 
mice were kept under observation for a further 10 
weeks. Macroscopically, 23% of tumours sponta-
neously disappeared and the remaining tumours 
showed about 50% reduction in their size. Histopatho-
logic examination of these lesions revealed invasive 
squamous cell carcinomas of the skin in 50% of lesions 
with varying degrees of tumour necrosis and lympho-
cytic infiltration (Figure 2). Skin papillomas were 
observed in 27% of skin lesions; the remaining 23% 
showed various degrees of hyperplasia and dysplasia. 
Epidermal LC enumeration in tobacco smoke 
condensate treated mice 
During the first two weeks there was an increase in the 
density of the la positive LC in the skin of mice treated 
with TSC and the highest LC level was achieved 28 
weeks after treatment. The number of LC in the skin of 
the treated mice during this period was significantly 
higher (1793 LC/mm 2) than in the controls (946 LC/mm 2 ) 
(P < 0.0001) (Figure 1). 
At 45 weeks, almost 10 weeks after stopping the 
treatment with TSC, the number of LC in frozen skin 
tumours (Figure 3) and in epidermal sheets from 
skin around the lesions (Table 1) had not decreased 
and in general remained elevated (Figure 1). The 
exceptions were hyperplastic and dysplastic lesions. 
The difference in LC number before and after stopping 
TSC treatment was significant (P < 0.0001). 
Table 1. LC in epidermal sheets around skin lesions 10 weeks 
after ceasing TSC treatment 
Skin lesion No. Mean of LC/mm2 s.d. 
(1)Skin papilloma 13 2274 14.14 
(2)Invasive SCC 13 2088 183 
(3)SCC with necrosis 11 1960 61.25 
(4)Hyperplasia and dysplasia 11 1650 153.53 
Using Scheffe's test at the 0.05 level, 2 vs 1,3 vs 1, 1 vs 2 and 1 vs 3 no 
significant difference; 4 vs 1, 2 and 3 all significant. 
Table 2. Cutaneous contact hypersensitivity response to TNCP 
of mice treated with TSC 
Group No. Time 
Mean increase in ear thickness 
(%) 
After two weeks 
Control 6 24HR 110 ± 19.96 
TSC 6 24HR 54±9.95 
Control 6 48 HR 81 ± 6.96 
TSC 48HR 42±8.06 
-After 6 weeks 
Control 6 24 HR 105 ± 6.59 
TSC 6 24HR 54 ± 9.95 
Control 6 48HR 76 ± 7.07 
TSC 6 48HR 50±7 
Differences between the percentage increase in ear thickness of test 
and control group is significant (P < 0.0001) at all times. 
Epidermal LC morphology in tobacco smoke treated 
mice 
After 2 weeks of TSC treatment, 25% of LC in epidermal 
sheets became smaller in size and the dendrites were 
blunt and short when compared with normal LC (Figure 
4a). By 6 weeks many of the LC cells were rounded or 
oval in shape (Figure 4b). 
Ten weeks following cessation of application of TSC 
the morphological changes reversed and the LC 
became more dendritic with more than 3 branched 
dendrites (Figure 5). 
Contact hypersensitivity response after TSC treatment 
Table 2 summarizes the percentage increase in ear 
thickness of both TSC treated and control mice at 2 
and 6 weeks following sensitization and challenge 
with TNCB. 
The percentage increase in thickness of the right 
ear of the TSC treated mice when challenged after 
sensitization with TNCB was significantly less than 
that of the control group (P < 0.0001), at both 24 and 
48 hours. This suggests an impairment in the contact 
hypersensitivity response in the TSC treated mice and 
indicates a compromised function of the morpho-
logically altered LC. 
Discussion 
TSC increased the density of the epidermal LC assessed 
in epidermal sheets; the highest LC level was achieved 
28 weeks after treatment. The density of the epidermal 
LC in the treated skin was double the control value; the 
high level of the epidermal LC around lesions remained 
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Figure 4. a, Normal fully dendritic LC in 
epidermal sheet of control mice. 
Immunoperoxidase anti-la staining. 
x 1000. b, Rounded LC 6 weeks after 
TSC treatment. lmmunoperoxidase 
anti-la staining. x400. 
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Figure 5. LC returned to their dendritic 
morphology, with more than 3 branched 
dendrites 10 weeks after stopping TSC 
treatment. Some LC still abnormal in 
shape. Immunoperoxidase anti-la 
staining. x400. 
elevated even after stopping TSC treatment. The 
morphology of epidermal LC in the treated skin was 
altered. Cells became smaller and the dendrites 
became shorter and blunt. The functions of the morpho-
logically altered LC were impaired when assessed 
by the contact hypersensitivity response. The initial 
increase in epidermal LC number, the morpho-
logical changes and the impairment in their function 
observed during TSC treatment were also associated 
with tumour development. 
These findings support similar observations reported 
by Ruby et al. (1989) and Andrews etal. (1991) when they 
investigated the effect of benzo[a]pyrene on murine 
epidermal LC. Andrews et a/. (1991) demonstrated that 
implantation of the prostaglandin synthetase inhibitor, 
indomethacin, beneath mouse skin before treatment 
with the tobacco derived carcinogen, benzo[a]pyrene, 
delayed the onset of tumour development and reduced 
tumour size. Andrews and co-workers (1991) proposed 
that the cutaneous carcinogenesis induced by 
benzo[a]pyrene may be related to the suppression of 
cellular cutaneous immunity by prostaglandins. 
It is of interest that while the density of epidermal LC 
decreased (1650 154 cells/mm 2 ) in the skin of mice 
with hyperplastic and dysplastic lesions 10 weeks after 
stopping treatment with TSC, the density increased 
(P < 0.0001) in epidermal sheets around both squamous 
cell papillomas (2274 ± 14 cells/mm 2 ) and squamous 
cell carcinomas (2088 + 183 cells/mm 2 ). The LC at this 
stage appeared fully dendritic. This was associated with 
spontaneous regression of 23% of skin tumours and 50% 
reduction in tumour size of the remaining lesions. The 
high density of the fully dendritic epidermal LC after 
stopping TSC application was accompanied by 
increased LC number in frozen sections of skin 
tumours. This was associated with marked lymphocytic 
infiltration and necrosis of these lesions. 
Muller et al. (1985) also reported skin tumour regres-
sion after cessation of application of the chemical 
carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA). 
DMBA depletes epidermal LC and this is associated 
with impaired skin immune function and skin tumour 
development (Muller et al. 1992). Repopulation of 
epidermal LC was associated with tumour regression 
(Muller etal. 1985). 
The increase in LC density in epidermal sheets 
around tobacco smoke induced squamous cell skin 
carcinomas (Table 1) supports our previous report on 
the increase in S100 positive LC in squamous cell 
carcinomas of the lung (Zeid & Muller 1993). This is 
in agreement with the results of previous workers. 
McArdle et a/. (1986) and Korenberg et a/. (1988) 
82 N.A. Zeid and H.K. Muller 
reported an increase in LC density in squamous cell 
carcinomas of the skin. Caorsi and Figueroa (1984), 
together  with Bonilla-Musoles et al. (1987), reported a 
similar LC elevation in cervical squamous cell carci-
noma, and Matsuda et al. (1990) in squamous cell 
carcinoma of the oesophagus. 
LC are the best known antigen presenting cells. Their 
increase in certain tumours may follow recognition by 
the LC of antigen expressed by tumour cells. Grabbe 
et al. (1991; 1992) reported la positive LC are capable 
of presenting tumour associated antigen derived 
from a murine spindle cell tumour inducing an anti-
tumour immune response manifested by tumour 
rejection and induction of delayed-type hypersensitivity 
in immunized animals. 
While the extent of LC infiltration of cutaneous 
and other tumours may be linked to tumour antigens, 
how LC arrive in the skin lesions remains unclear. One 
possibility is that skin tumour derived cytokines attract 
LC into the skin lesions (Halliday et al. 1992). Once 
functionally normal LC are in lesions, they could trigger 
an immune response leading to tumour regression as in 
the present experiment. 
It was concluded that TSC increased LC number, 
altered their morphology and impaired LC function; 
this was associated with tumour development. These 
events may be related to suppression of cellular 
cutaneous immunity by prostaglandins as related to 
the effects of benzo[a]pyrene already described. The 
further increase in epidermal LC number after stopping 
TSC treatment was associated with reversible changes 
in LC morphology; the cells became fully dendritic. 
These changes correlated with lymphocytic infiltration, 
tumour necrosis, reduction in tumour size and/or 
tumour regression, presumably due to an effective 
anti-tumour response. 
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